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CHAPTER I 
 
INTRODUCTION 
 
 The liver is the largest gland in the body, and second largest organ (preceded only 
by the skin).  Proper liver function to regulate physiological processes, such as 
detoxification, metabolism (glycogen storage, decomposition of red blood cells, protein 
synthesis, and hormone production), and digestion, is indispensible to support life in 
vertebrates.  Indeed, liver disease is the 4th leading cause of death among middle-aged 
adults in the United States, and ranks 12th in death rate for all ages (Courtesy of the Center 
for Disease Control). Liver disease includes a wide-range of disorders from drug or alcohol-
induced damage to genetic disorders, infection and cancer. In the United States, the leading 
cause of liver-related death is due to cirrhosis of the liver. Conversely, in low-income 
nations, cirrhosis of the liver ranks as the 16th overall cause of death, and liver cancer is the 
19th (Courtesy of the World Health Organization). An additional, yet less prevalent type of 
liver disease is hepatobiliary disease with estimates of the prevalence ranging from 1:500 to 
1:2500 for cholestatic hepatobiliary disease. (Mushtaq et al., 1999). Our understanding of 
how liver development proceeds and liver disease initiates and progresses is limited. In this 
dissertation, I will use a model of a genetic hepatobiliary disease to help elucidate how 
proper development contributes to normal function and initiation of disease. I will first 
summarize what is currently known and the questions that remain with regards to liver 
development and hepatobiliary disease. 
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Hepatobiliary Disease 
 Hepatobiliary diseases are a subset of liver diseases that include a highly 
heterogenous group of diseases of the hepatocytes and biliary system, which can be 
caused by a variety of insults. Grossly, hepatobiliary disease can be divided into two major 
categories, acute and chronic. Sub-categories of liver disease include viral hepatitis, 
inflammatory liver disease, alcoholic liver disease and cholangiopathies. Often the same 
insults can lead to acute or chronic depending on the dose and length of exposure (Carton 
et al., 2007).  
 
Cholangiopathies 
 A specific sub-type of hepatobiliary diseases are termed cholangiopathies, and refer 
to any disorder that affects the cholangiocytes (bile duct epithelial cells). This disease 
classification includes both acute and chronic disorders that affect both adult and pediatric 
populations. Cholangiopathies share a number of pathological characteristics, including 
inflammation, cholestasis, fibrosis, and apoptosis (Strazzabosco et al., 2005). However, 
three subcategories of cholangiopathies have been defined: 1. genetic or inherited 
disorders, 2. immune-mediated disorders, 3. idiopathic, drug-induced, ischemic and 
malignant disorders. All currently identified cholangiopathies and their associated 
phenotypes are listed in Table 1.1. The specific pathogenesis of most cholangiopathies 
remains largely unknown, however all cholangiopathies progress to ductopenia, defined as 
the loss of >50% of intrahepatic bile ducts (Bogert and LaRusso, 2007). Further, the 
diagnosis of a cholangiopathy is a strong indicator for the progression to liver transplant, 
accounting for 10-20% of total transplants in adult, and ~80% in pediatric (Strazzabosco et 
al., 2005).  
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Subcategory Disease Pathology/Pathogenesis 
Genetic and  Alagille Syndrome (AGS) JAGGED1 – Bile duct paucity  
Inherited Cystic Fibrosis (CF) CFTR – Ductal cholestasis; focal 
biliary cirrhosis 
 Progressive Familial Intrahepatic 
Cholestasis – Type 3 (PFIC-3) 
MDR3 – Ductular reaction; early 
fibrosis 
 Autosomal Dominant Polycystic Kidney 
Disease (ADPKD) ** 
PDK1 & PDK2 – Ductal plate 
malformations; biliary 
microhamartomas; cysts 
 Autosomal Recessive Polycystic Kidney 
Disease (ARPKD) ** 
PKHD1 – Ductal plate malformations; 
biliary microhamartomas; cysts 
 Autosomal Dominant Polycystic Liver 
Disease (ADPLD) ** 
PRKCSH & SEC63 – Ductal plate 
malformations; biliary 
microhamartomas; cysts 
 Caroli’s Syndrome ** PKHD1 (some cases) – Ductal plate 
malformations; cystic dilation of 
intrahepatic bile ducts 
 Congenital Hepatic Fibrosis (CHF) ** MPI – Ductal plate malformations; 
biliary microhamartomas, fibrous 
stroma 
Immune-mediated Primary Biliary Cirrhosis (PBC) Immune response towards 
cholangiocytes; biliary cirrhosis; end-
stage liver disease 
 Primary Sclerosing Cholangitis (PSC) Immune-mediated association with 
Inflammatory Bowel Disease; recurrent 
cholangitis, biliary cirrhosis, 
cholangiocarcinoma  
 Autoimmune cholangitis (AMA-negative 
PBC) 
Immune response towards 
cholangiocytes; ductopenia 
 Acute allograft rejection Alloimmune T cell-mediated damage 
of bile duct epithelium 
 Chronic allograft rejection Ductopenic cholestatic syndrome; 
allograft failure 
 Graft-versus-host disease (GVHD) Ductopenia;cirrhosis 
Idiopathic, Drug-
Induced, Ischemic and 
Malignant 
Biliary atresia (BA) Embronic (10-20%) – ductal plate 
malformations; Perinatal (80-90%) – 
immune mediated bile duct destruction 
 Sarcoidosis (Rare liver involvement) 
Granulomatous cholangitis; ductopenia 
 Idiopathic adulthood ductopenia Ductopenia of unknown causes 
 Drug-induced cholangitis Variable from mild cholestasis to 
chronic cholestasis to ductopenia 
 Ischemic Segmental strictures to impair bile flow 
 Malignant cholangiocarcinoma Chronic biliary inflammation; bile duct 
lithiasis; fibropolycystic diseases; PSC 
 
Table 1.1 Cholangiopathies. Cholangiopathies are diseases that affect the cholangiocytes, 
or bile duct epithelia. Three different disease sub-categories have been defined: genetic and 
inherited, immune-mediated, and idiopathic, drug-induced, ischemic and malignant. These 
sub-categories and the cholangiopathies that belong to these categories are listed in this 
table along with the pathological findings associated. For genetic and inherited diseases, the 
known gene mutation is underlined. ** - Diseases that are also classified as ciliopathies. 
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 A major clinical finding of cholangiopathies is the presence of cholestasis. 
Cholestasis is the general term for loss or reduction of bile flow. The origin of cholestasis in 
cholangiopathies varies from loss of bile ducts to obstruction of the intra- or extra-hepatic  
bile ducts. Cholestasis is the dominant clinical concern in cholangiopathies, as cholestasis 
may initiate or worsen the progression of disease (Strazzabosco, 1997). Cholestasis is 
initially suspected when alkaline phosphate (ALP) is elevated. ALP is an enzyme that 
catalyzes the hydrolysis of phosphate esters at an alkaline pH, however it’s function has 
little to do with cholestasis. ALP is expressed in all tissues of the body, but is concentrated 
in the liver and bone. In the liver, ALP expression is highest in bile canaliculi, the channel by 
which bile drains from hepatocytes into the biliary system. It is proposed that obstruction or 
damage of the bile ducts leads to the release of ALP into the blood stream (Lindor and 
Talwalker, 2008). Current therapy for cholestasis ranges from surgical intervention to 
administration of bile acid binding resins or secondary bile acids (Strazzabosco et al., 2005). 
Bile acid binding resins, such as cholestyramine were originally described as a treatment for 
xanthomas. Xanthomas are deposits of cholesterol-rich material in the skin, which results in 
severe pruritus or itching and is often associated with cholestatic liver disease (Visintine et 
al., 1961).  Thus cholestyramine treats the symptoms of cholestasis, but does not address 
the root cause. Conversely, administration of a secondary bile acid, ursodeoxycholic acid 
(UDCA) is the only FDA-approved medical treatment for a specific cholangiopathy, Primary 
Biliary Cirrhosis (PBC). PBC is a disease in which immune cells attack cholangiocytes 
resulting in biliary cirrhosis (Table 1.1). While a treatment has been identified, approximately 
one-third of PBC patients do not respond to UDCA treatment and still require liver transplant 
(Nguyen et al., 2010). Further, the mode of action of UDCA is still unclear; some studies 
have demonstrated that UDCA stimulates hepatocyte transporters and thus hepatocyte 
function (Trauner et al., 2005). While some cholangiopathies have cholestasis as a result of 
improper hepatocyte function, others are due to the lack of bile ducts. Thus if the latter were 
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indeed the mode of UDCA action, it would seem an ineffective treatment option for 
cholestasis due to a lack of bile ducts. Understanding the mechanisms involved in the 
initiation and progression of cholangiopathies is critical for future therapeutics, which would 
circumvent the need for liver transplant. 
  
A Genetic Cholangiopathy:  Alagille Syndrome 
 Genetic or inherited cholangiopathies are among the more rare types of 
cholangiopathies. However, understanding how the liver develops, and how development is 
disrupted in these genetic disorders, will further understanding of cholangiopathies as a 
whole. In particular, Alagille syndrome (AGS; OMIM: 118450 and 610205) is a pleiotropic 
developmental disorder affecting, among other things, the liver intrahepatic bile ducts 
(IHBDs).  The diagnosis of AGS is based on the paucity of IHBDs, and three to five other 
major features:  chronic cholestasis, cardiac disease, skeletal abnormalities, ocular 
abnormalities, and characteristic craniofacial features (Alagille, 1996). Over 96% of AGS 
patients present with chronic cholestasis, which is attributed to the paucity of bile ducts 
(Emerick et al., 1999). 
 Mutations in the Notch signaling pathway are highly causative of AGS, with greater 
than 94% of patients having a mutation in JAGGED1, a ligand of the Notch pathway, and an 
additional two families, with mutations in NOTCH2, a receptor of the Notch pathway 
(McDaniell et al., 2006; Warthen et al., 2006). Despite a well-characterized genetic link, the 
pathogenesis of AGS is very poorly understood. Indeed, the mechanism by which bile duct 
paucity arises in AGS individuals remains unknown; whether paucity is a result of improper 
development, an inability to maintain ductal structures or a lack of post-natal branching and 
elongation remains to be determined (Emerick et al., 1999; Libbrecht et al., 2005). Further, 
there is no discernable correlation between the specific genetic mutation and clinical 
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phenotype (Krantz et al., 1998; Kamath et al., 2009). At this juncture, there are no molecular 
or pathological predictors to intimate the outcome of AGS patients.  
The heterogeneous clinical course is highlighted by the following examples. First, 
cholestasis in AGS patients generally worsens until school age, and then in a subset of 
patients cholestasis stabilizes or resolves (Lykavieris et al., 2001). The features that 
distinguish patients who will stabilize or resolve the cholestasis have not been identified. 
Another example is a subset of patients who fail to excrete a biliary tracer upon hepatobiliary 
scintigraphy (Emerick et al., 1999). These patients are often misdiagnosed as biliary atresia 
patients. Biliary atresia is an idiopathic cholangiopathy characterized by the immune-
mediate destruction of bile ducts, and mainly affects extrahepatic bile ducts (Table 1.1).  The 
diagnosis of biliary atresia results in patients undergoing a hepatoportoenterostomy (Kasai 
procedure or Roux-en-Y procedure), a procedure that replaces the extrahepatic common 
bile duct with a segment of intestine to bypass blockage. Kaye and colleagues determined 
that AGS patients, who underwent a Kasai procedure after improper diagnosis, had more 
severe liver disease and thus progressed to liver transplant more often than AGS patient 
who did not undergo a Kasai procedure (Kaye et al., 2010). The authors suggest that the 
Kasai procedure itself was detrimental to liver function and resulted in liver failure, however 
it remains unclear whether these patients would have progressed to liver failure, regardless 
of the surgery, as a result of biliary obstruction. The last example of AGS clinical 
heterogeneity is that only 21-31% of AGS patients proceed to liver transplant, which is 
usually due to complications of chronic cholestasis (Kamath et al., 2010), however what 
makes these patients unique is unknown. Thus determining how a genetic mutation can 
lead to variable clinical outcomes is critical for patient stratification and future therapeutics of 
not only Alagille syndrome, but also cholangiopathies as a whole. To understand how 
developmental processes go awry in human diseases, it is important to first understand how 
liver architecture is normally acquired. 
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Hepatic Microarchitecture 
 In mammals, as specifically described here in mice, the liver is composed of seven 
lobes and contributes to approximately 5% of the body weight.  The basic structural unit of 
the liver is the liver lobule (Figure 1.1).  The lobule is composed of cords of hepatocytes 
radiating away from portal veins towards a central vein.  Sinusoidal endothelial cells line the 
cords of hepatocytes, generating a capillary network from the afferent portal vein to the 
efferent central vein. The lobule is roughly hexagonal, with a central vein in the center, and 
portal veins at the six corners.  Portal veins contribute to a microstructural feature called a 
portal triad.  In addition to the portal vein, this triad contains an IHBD and a hepatic artery.   
The IHBD acts as a conduit to mediate the transport of bile from the liver into the 
gallbladder for storage or into the duodenum for aid in digestion. Hepatocytes, which 
produce the bile, secrete bile into channels on their apical surface called canaliculi (Figure 
1.2). Bile drains through the canaliculi into the canals of Hering, which are classically 
defined as lined by hepatocytes on one side, and cholangiocytes on the other. The canals of 
Hering represent the transition between the hepatocyte canaliculi and ductal system. After 
bile passage through the canals of Hering, bile enters the ductal system where it proceeds 
through an intricate IHBD network (Figure 1.2). Proper development of this microarchitecture 
is critical for liver function and homeostasis, however there are still gaps in the field of liver 
biology as it relates to the molecular, temporal and spatial cues required to generate hepatic 
microarchitecture. An overview of our current understanding of mammalian liver 
development, as studied in mice, is described below. 
 
Murine Liver Development 
The liver primordium is first identifiable at embryonic day (E) 8.5-9.0 in mice.  The 
ventral foregut endoderm responds to mesenchymal signals to initiate the liver gene  
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Figure 1.1 The hepatic lobule. The hepatic lobule is roughly hexagonal, with portal veins at 
the apexes and a central vein in the middle.  Blood flow proceeds from the afferent portal 
veins through the hepatic sinusoids and to the efferent central vein.  The portal vein a 
component of a microanatomical feature called the portal triad, consisting of a portal vein, a 
bile duct and a hepatic artery.  Vessels – red, Hepatocytes – green, Bile Ducts – blue, 
Hepatic Artery – dark red, Mesenchyme – grey. CV – Central Vein, PV – Portal Vein. 
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Figure 1.2 Bile conduits. Bile, produced by the hepatocytes, is first excreted into a 
canalicular space, then flows through the canaliculi into the canals of Hering, which are 
surrounded on one side by small hepatocytes, and on the other by cholangiocytes. Bile then 
enters into the intrahepatic bile ducts at the smallest branches, and continues to be 
transported out into the extrahepatic bile ducts. Red arrows indicate bile flow. Hepatocytes – 
green, Small Hepatocytes – blue-green, Cholangiocytes – blue. 
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regulatory network and formation of the liver diverticulum. The precise tissue source of 
these cues, whether septum transversum mesenchyme (STM), cardiac mesoderm, lateral 
plate mesoderm or vascular precursors, remains to be elucidated.  It is however, well 
established that Fibroblast Growth Factor (FGF) and Bone Morphogenetic Protein (BMP) 
are required inductive cues, though the specific ligands and receptors involved are unclear  
(Reviewed in (Tremblay, 2010)).  The liver diverticulum is composed of bi-potential 
progenitor cells termed hepatoblasts. Around E9.5, hepatoblasts delaminate, with the 
assistance of matrix metalloproteases, and migrate in cords into the surrounding STM.  I will 
highlight cell lineages that orchestrate and define the hepatic microarchitecture. 
 
Vascular Lineage 
 In the adult liver, the major blood vessels are the aforementioned portal vein, central 
vein, hepatic sinusoidal capillaries and hepatic artery.  The precise patterning of these 
vessels is equally important for proper liver development and homeostasis as epithelial 
development.  The majority of our understanding of hepatic vascular development is 
extrapolated from anatomical human studies of cadavers, however even then our 
understanding is limited.  
The first vessels to form during development are the sinusoidal capillaries, which 
arise via angiogenesis of existing vessels in the STM during hepatoblast migration.  In the 
adult, one major afferent vessel, the portal vein, transports blood from the intestine, 
pancreas and spleen into the liver.  On the contrary, during development, two major afferent 
vessels, the umbilical vein and vitelline vein feed the liver.  Segments of the vitelline vein 
form the portal vein, but it does not become the major afferent vessel until the umbilical vein 
collapses, which is after birth in humans.  One major efferent vessel, the central vein, exists 
in the adult and egresses via the caudal (inferior) vena cava.  Developmentally, the vitelline 
vein participates in the formation of the central vein. Whether murine afferent vessel 
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development occurs in a similar manner remains to be investigated.  My thesis work 
describes a mouse model in which the number of portal veins per millimeter of tissue is 
reduced as a result of deleting Notch signaling within the hepatoblast population (Please 
refer to Chapter IV, Figure 4.11).  This result suggests that the liver epithelial cell lineages is 
required to provide cues for venous remodeling.  Further support of this hypothesis is a 
study by Masyuk et al., in which the authors fed α-Naphthylisothiocyanate (ANIT), a drug 
that induces cholangiocyte proliferation with chronic administration, to rats.  In this study, the 
portal vein branching increases in concert with increased biliary branches (Masyuk et al., 
2003).  The molecular cues involved in a potential feedback loop between the biliary and 
portal vein system have yet to be elucidated.  
The fourth and final vascular system within the liver is the hepatic artery, which 
develops substantially later in development than the venous and capillary systems.  The 
hepatic artery originates from the celiac artery and it thought to respond to cues from ductal 
epithelium.  In particular, one study showed that human and mouse cholangiocytes express 
angiogenic growth factors consistent with a model of hepatic artery recruitment.  Further, 
this group and others used a mouse model in which bile ducts do not form properly and 
demonstrated that arterial development is also disrupted (Clotman et al., 2003; Fabris et al., 
2008).  Despite this seminal study, further experiments are needed to define the 
mechanisms of arterial recruitment by biliary epithelial cells and migration of endothelial 
cells to form the hepatic artery. 
 
Hematopoietic Lineage 
 During mammalian development, the liver serves as the major hematopoietic organ 
beginning shortly after hepatoblast migration into the STM. Hematopoietic precursor cells 
first arise in the yolk salk and aorta-gonad-mesenepheros region where they are maintained 
until E11 (Moore and Metcalf, 1970). Beginning at E11, hematopoietic precursors appear 
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within the fetal liver and increase exponentially; the homing cues required for this transition 
have not been identified. For approximately the next 6 days of development the liver 
remains the primary hematopoietic organ (Ema and Nakauchi, 2000). While hematopoiesis 
continues in the liver until after birth, at E16 hematopoietic stem cells (HSCs) begin to take 
up residence in the spleen and bone marrow, the major sites of adult hematopoiesis. The 
homing and colonization of HSCs from the liver to the spleen and bone marrow is not well 
understood. Originally it was thought that HSCs, responding to a homing cue, left the fetal 
liver and homed to the sites of adult hematopoiesis. Yet work from Christensen et al. 
demonstrated that fetal HSCs are constitutively found in the circulation, and the seeding of 
the spleen and bone marrow is a gradual process (Christensen et al., 2004). These results 
suggest a progressive transition that involves homing and niche factor establishment within 
the spleen and bone marrow to define the adult HSC niche, and loss of fetal liver HSC niche 
factors. However, while the factors that establish and maintain the adult HSC niche have 
been investigated, it is currently unknown what maintains an HSC niche in the fetal liver and 
how these signals are lost during development. One in vitro study suggests that Wnt 
signaling within the fetal microenvironment maintains actively cycling HSCs, while Notch 
signaling within the adult microenvironment maintains quiescent HSCs, but this model 
remains to be substantiated (Martin and Bhatia, 2005). The contribution of HSCs to the 
formation and maintenance of hepatic microarchitecture is not well understood. On the other 
hand, it has been hypothesized that proper hepatic microarchitecture is required to define a 
HSC niche and improper liver epithelial development would disrupt embryonic 
hematopoiesis. 
 
Mesenchymal Lineage 
 Mesenchymal cells termed hepatic stellate cells are found within the space of Disse 
between hepatocytes and the sinusoidal endothelial cells. The role of stellate cells in normal 
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and diseased liver has been well described (Friedman, 2008). Specifically, stellate cells 
have been suggested to facilitate bile duct development in humans (Libbrecht et al., 2002), 
although a mechanism has not been proposed. Vitamin A storage is an important function of 
stellate cells in quiescent liver (Hendriks et al., 1985). Further, stellate cells have been 
defined as an important mediator of the immune response by amplifying chemokines that 
recruit immune cells (Maher, 2001). Upon liver injury, stellate cells are activated into a 
myofibroblastic cell, which proliferates and contributes to fibrosis (Friedman, 2008).  
 The origin of the hepatic stellate cell had remained a mystery for many years. 
Originally it was proposed that stellate cells were of neural crest origin due to the expression 
of both mesenchymal and neural markers (GFAP, nestin, N-cam, NGF, BDNF, etc) (Geerts, 
2001). However, lineage tracing studies using Wnt1-Cre, which is expressed in neural crest 
cells, and ROSA26 reporter mice, demonstrated that the neural crest is not the origin of 
hepatic stellate cells (Cassiman et al., 2006). Instead, a recent study using lineage tracing 
demonstrated that the origin of the hepatic stellate cells is mesodermal (Asahina et al., 
2009). Thus, hepatic stellate cells are a unique and highly diverse population of cells within 
the liver that contribute to the hepatic microarchitecture. However, the breadth of their 
function and diversity remains to be fully understood. 
 
Epithelial Lineage 
Bi-potential hepatoblast progenitor cells have the potential to become either 
hepatocytes or cholangiocytes.  Hepatocytes represent the preponderant population of the 
liver at approximately 70% of total liver cells in mice, while cholangiocytes represent only 
approximately 3% (Si-Tayeb et al., 2010). Hepatoblast cell fate decisions occur in a subset 
of cells adjacent to the portal vein in a wave from the hilum, or base of the liver, to the 
periphery. Whether all hepatoblasts are competent to become cholangiocytes remains 
controversial. Work from my thesis using a mouse model which constitutively activates 
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Notch signaling in hepatoblasts, resulting in excess cholangiocyte differentiation, suggests a 
zone of competence in proximity to the portal vein possibly due to unique inductive cues 
residing within that environment (Please see Chapter III, Discussion: Notch signaling acts 
permissively with the hepatoblast population for cholangiocyte specification). In contrast, 
another study, using an inducible system to constitutively activate Notch in adult 
hepatocytes suggests that all cells remain competent to become biliary cells (Zong et al., 
2009). However, the authors of the later study define adult as post-natal (P) 4, when naïve 
hepatoblasts are still present and do not provide a global view to address where in the 
lobule the induced cholangiocytes are located. Thus their results remain controversial and a 
definitive answer as to the spatial and temporal cues regulating hepatoblast competence 
remains to be determined.  Regardless, this decision of the bi-potential hepatoblast to 
become a cholangiocyte is the initiation of the process of biliary epithelial morphogenesis 
(Figure 1.3).  
In contrast to other epithelial branching organs, such as the lung, the epithelial liver 
primordium and the bile duct network does not form via morphogenesis of a single epithelial 
sheet. Instead, the liver diverticulum delaminates, as described earlier, and the biliary 
epithelium begins to form by the differentiation of hepatoblasts into cholangiocytes directly 
adjacent to the portal vein.  The sleeve of differentiating cells up-regulates cytokeratin19 to 
form a “ductal plate” surrounding the portal vein (Figure 1.3). In humans, a series of 
cytokeratins have been identified to mark the lineage restriction of hepatoblasts into the 
cholangiocyte cell fate (Crawford, 2002), however a lack of cross-reacting antibodies has 
prevented the translation of this information into murine models. Early mouse 
cholangiocytes are reactive to a pan-cytokeratin antibody, which recognizes a wide range of 
cytokeratins (56-64 kD molecular weight), and cytokeratin19. Unfortunately, cytokeratin19 is 
expressed early in the ductal plate and remains on throughout the lineage restriction. Thus,  
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Figure 1.3 Bile duct morphogenesis. Bile duct development occurs in a wave from the 
hilum, or base of the lobe, towards the periphery tracking along the portal vein. The 
process of morphogenesis begins when (1) a ductal plate, composed of cells that up-
regulate cytokeratin, is specified from hepatoblasts directly adjacent to the portal vein 
mesenchyme. Subsequently, (2) a subset of ductal plate cells form a luminal duct, and 
(3) the ductal plate cells not contributing to the bile duct regress, thus leaving the mature 
structure of a bile duct associated with a portal vein. Portal Vein/Endothelial Cells – red, 
Bile Ducts/Cholangiocytes – blue, Mesenchyme – grey, Early Hepatoblasts – light 
brown, Late Hepatoblasts – dark brown, Hepatocytes – green. PV – Portal Vein. 
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a lack of specific cholangiocyte markers in mouse has made it impossible to define the 
maturity and heterogeneity of early cholangiocytes. Subsequent to ductal plate formation, 
cholangiocytes at focal points within the ductal plate remodel to form a luminal ductal 
structure (Figure 1.3).  What dictates the initial focal location of duct formation is not clear; 
however it is well established that hilar regions form first, with differentiation and remodeling 
occurring in a temporal fashion towards the periphery. Further, there is controversy within 
the field as to whether the luminal structure forms due to migration of cells from the ductal 
plate or a second wave of differentiation.  In vitro evidence from Tanimizu et al., using 
collagen sandwich cultures of mouse hepatoblasts, demonstrated that a single epithelial 
sheet contained cells that delaminated and migrated to form luminal structures (Tanimizu et 
al., 2009).  In contrast, a recent in vivo study of the expression of an early ductal marker, 
Sox9, suggests a model of transient asymmetry in which hepatoblasts nearest the portal 
vein differentiate foremost, followed by a second wave of differentiation of the remaining 
hepatoblasts (Antoniou et al., 2009). However, without the establishment of live cell imaging 
in mouse liver, neither model has yet to be conclusively demonstrated in vivo. 
Cells of the ductal plate that do not contribute to the mature bile ducts undergo 
“regression”.  However, the mechanism of regression remains to be determined. The 
unincorporated cytokeratin19-positive cells are hypothesized to undergo apoptosis or de-
differentiate to become hepatocytes. One study suggests that, in human development, these 
cells undergo apoptosis (Terada and Nakanuma, 1995), however I have been unable to 
demonstrate apoptosis in regressing ductal plate cells in the mouse, suggesting a de-
differentiation program is more likely. Whether regression occurs differentially in human and 
mouse development remains to be definitely shown.  
An additional consideration is that the adult biliary network is heterogeneous with 
regards to type of epithelium, whether cuboidal or columnar, normal function and response 
to injury (Glaser et al., 2009). While specific differences in cholangiocyte function will be 
	   17	   	  
discussed later in this Introduction (Please refer to Adult Cholangiocytes: Cholangiocyte 
Heterogeneity), it is important to consider that it is currently unknown how hilar (branches 
originating at the hilum) and peripheral (branches originating from hilar branches) ducts are 
differentiated during development, and whether regionally different ducts arise by the same 
or different mechanisms. Currently, all models are based on the earliest duct formation, 
which originates at the hilar region. Therefore, it remains to be definitively described whether 
branches of the IHBD that form subsequent to and originate from hilar ducts form by the 
remodeling of a ductal plate, or a different mechanism. Additionally, while the basic 
morphology of biliary morphogenesis for hilar ducts has been elucidated, our understanding 
of the molecular cues, which initiate differentiation and remodeling, is in its infancy.   
 
Molecular Cues for Bile Duct Development 
 Identification of signaling pathways that regulate cholangiocyte lineage restriction 
and morphogenesis has been limited. The two pathways that have been irrefutably identified 
to be required for biliary development are TGF-beta and Notch signaling. Interestingly, only 
Notch signaling has been linked to a human disease state (Please refer to Hepatobiliary 
Disease: Alagille Syndrome). 
 
1. Overview of Transforming Growth Factor (TGF)-beta Signaling 
 The Transforming Growth Factor (TGF)-beta superfamily consists of sub-categories 
of signaling factors: TGF-beta, bone morphogenic proteins (BMPs), activin, nodal, myostatin 
and anti-Muellerian hormone (AMH). All ligands signal through a heterodimeric 
serine/threonine kinase receptor complex. Ligands bind the type II receptors (5 different 
types), which initiates association with the type I receptors (7 different types) and 
phosphorylation of the serine and threonine residues. Receptor activation then leads to a 
variety of downstream signals, with the canonical pathway signaling via Smads.  TGF-beta, 
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activin, nodal and myostatin signal via receptors that phosphorylate Smad2 and 3, whereas 
BMP and AMH signal via receptors that phosphorylate Smad1, 5 and 8. Upon Smad 
phosphorylation, a common Smad, Smad4, associates with the complex to facilitate gene 
transcription (Massague and Gomis, 2006).  
 
1A. TBF-beta in Cholangiocyte Development 
 The role of TGF-beta in in vivo cholangiocyte specification has been inferred by 
analysis of hepatocyte nuclear factor (HNF)-6 (part of the Onecut transcription factor family 
of proteins, OC1) knockout mice.  HNF6 is highly expressed in biliary epithelial cells at the 
onset of the hepatoblast cell fate decision, and thus provided a potential target as an 
important transcription factor for biliary development (Clotman et al., 2002).  Indeed, global 
knockout of HNF6 results in an excess of cytokeratin-positive biliary structures, which were 
identified as hybrid cells expressing markers of both cholangiocytes and hepatocytes 
(Clotman et al., 2002; Clotman et al., 2005). The global knockout of HNF6 phenocopies a 
liver-specific knockout of HNF1beta (Coffinier et al., 2002), therefore the authors 
investigated the possibility that loss of HNF6 reduced HNF1beta expression. By semi-
quantitative reverse transcriptase PCR analysis, the authors demonstrated that HNF6 
knockout mice had a reduction in HNF1beta transcript levels, and further that HNF6 bound 
the HNF1beta promoter by chromatin IP (ChIP) (Clotman et al., 2002).  
 The same group of investigators went on to determine that some redundancy exists 
within the Onecut transcription factors, and that global deletion of both HNF6 and OC2 
resulted in a more severe expansion of the hybrid cells (Clotman et al., 2005). Interestingly, 
the authors demonstrated, when HNF6 knockout and HNF6/OC2 double knockout mice 
were crossed to a mouse line expressing a TGF-beta responsive promoter (12-Smad 
binding sites upstream of EGFP), that both knockout mice had an expansion in the domain 
of TGF-beta responsive cells (Clotman et al., 2005). It had been previously shown that TGF-
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beta promotes the differentiation of cultured hepatoblasts into cholangiocytes (Isfort et al., 
1997), thus the expansion of TGF-beta in HNF6 knockout and HNF6/OC2 double knockout 
would explain an increase in hybrid cells. Together these results suggest that HNF6 and 
OC2 are required to restrict the TGF-beta gradient required for biliary differentiation. 
 These studies suggest a direct role for HNF6 in the hepatoblast and/or early 
cholangiocyte cell fate decision. Therefore our laboratory undertook a project to test the cell 
autonomous requirement of HNF6 in liver development by deleting HNF6 specifically within 
the hepatoblast population. Surprisingly, we can detect no defects in the liver-specific HNF6 
knockout  (Vanderpool et al., In Preparation). These results suggest that while HNF6 is 
highly expressed in biliary epithelial cells (Clotman et al., 2002), it is not essential within this 
intrahepatic compartment. Instead the effects described in the global knockout suggest that 
the extrahepatic defects (i.e. an absent gallbladder and abnormal distended extrahepatic 
ducts) lead to secondary intrahepatic defects that resolve in 25% of HNF6 global null mice 
(Clotman et al., 2002). Interestingly though, when we cross our liver-specific HNF6 knockout 
with a liver-specific Notch signaling-deficient mouse, we find that loss of HNF6 exacerbates 
the cholestatic phenotype of the Notch deficient mice (Vanderpool et al., In Preparation).  
Thus suggesting in the background of cholestasis, HNF6 can synergize with Notch signaling 
to promote liver disease. In normal development, HNF6 protein is expressed exclusively in 
the liver epithelial lineage. However, it remains unknown what cells produce the TGF-beta to 
initiate a gradient and how this gradient is regulated. The mechanism by which HNF6 
restricts the TGF-beta signal is not clear, however one study suggested that in the absence 
of HNF6, TGF-beta receptor type II expression is increased (Plumb-Rudewiez et al., 2004).  
Thus much work remains to elucidate the mechanisms by which TGF-beta and HNF6 
contribute to biliary specification and morphogenesis. 
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2. Notch Signaling 
 Notch signaling is an evolutionarily conserved intercellular signaling pathway 
required for cell specification, lineage commitment and maintenance of stem and progenitor 
cells both during development and in adults (Chiba, 2006). Notch ligands, which are present 
on the cell surface, bind Notch receptors on the surface of an adjacent cell. Ligand and 
receptor interaction initiates a series of proteolytic cleavages (Figure 1.4). First, the receptor 
is cleaved in the extracellular domain by ADAM10 (a disintegrin and metalloprotease 
domain), a member of the ADAM family of metalloproteases (Bozkulak and Weinmaster, 
2009; van Tetering et al., 2009).  Directly following the ADAM10-mediated cleavage, the 
receptor is cleaved intramembranously by gamma-secretase, which releases the 
intracellular domain of the receptor (Notch Intracellular Domain – NICD) (De Strooper et al., 
1999). Upon release from the membrane, the NICD translocates to the nucleus where it 
interacts with a common DNA-binding partner, recombination signal binding protein for 
immunoglobulin kappa J (RBP-J).  
In the absence of the NICD, RBP-J acts as a co-repressor of gene transcription, 
however upon NICD association, RBP-J becomes a co-activator.  In RBP-J’s transcriptional 
repressive function, it has been shown to bind to promoter regions and perturb the 
interaction between the transcription factors TFIIA and TFIID (Olave et al., 1998). Further 
RBP-J has been shown to bind to other co-repressors such as SMRT (silencing mediator for 
retinoid and thyroid receptor) and MINT (Msx2-interacting nuclear target protein), which 
recruit histone deacetylases (Tanigaki and Honjo, 2010). Upon NICD translocation into the 
nucleus, the NICD binds RBP-J, displacing the co-repressor complex, and actively recruits 
co-activators, Matermind, PCAF and GCN5 to initiate gene transcription (Tanigaki and 
Honjo, 2010). 
In mammals there are two families of canonical Notch ligands (JAG1 and 2, Delta-
like-1, 3, and 4) which signal through four canonical Notch receptors (Notch1-4). Previously  
	   21	   	  
 
 
 
 
 
Figure 1.4 Notch signaling pathway. Notch signaling is initiated when a Ligand, present 
on the cell surface, interacts with a Receptor on the cell surface of an adjacent cell. Upon 
Ligand engagement, ADAM10 mediates cleavage of the extracellular portion of the 
Receptor. This cleavage allows for a second, gamma-secretase-dependent cleavage to 
occur intramembranously. These cleavages release the Notch Intracellular Domain (NICD) 
to translocate to the nucleus. In the nucleus, the NICD binds a common DNA-binding 
partner, RBP-J, displaces co-repressor proteins and recruits co-activators to facilitate gene 
transcription.  
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it has been shown that both Notch1 and Notch2 are essential for embryonic development, 
since mice with global loss of either receptor die embryonically (Swiatek et al., 1994; Conlon 
et al., 1995; Hamada et al., 1999). In contrast, Notch3 and Notch4 are dispensable for 
development as mice lacking these receptors are viable (Krebs et al., 2000; Krebs et al., 
2003). However, in the absence of Notch1 or Notch2, Notch3 and Notch4 exhibit various 
degrees of redundant function (Pan et al., 2004). 
 Dysregulation of Notch signaling is intimately related to AGS, a disorder highlighted 
by paucity of bile ducts, thus revealing a role for Notch signaling in bile duct regulation. As 
mentioned earlier in this Introduction, it is unclear as to how Notch signaling contributes to 
bile duct paucity in AGS patients; whether by improper development, inability to maintain 
ductal structures or a lack of post-natal branching and elongation (Please refer to 
Hepatobiliary Disease: Alagille Syndrome). Since Notch signaling is classically required 
developmentally for binary cell fate decisions, it was initially hypothesized that Notch 
signaling is required within the hepatoblast to mediate the bi-potential cell fate decision to 
become a cholangiocyte or hepatocyte.  
 
2A. Notch Signaling in Cholangiocyte Development: the Signal-Sending Cell 
 A number of mouse models have been generated to address this hypothesis. In an 
attempt to mimic the AGS clinical situation, Xue et al., generated mice homozygous and 
heterozygous for a targeted null mutation of the JAG1 gene (Xue et al., 1999). Mice 
homozygous for the Jag1 null mutation are embryonic lethal at E10 due to vascular defects. 
In contrast, mice that are heterozygous for the Jag1 null mutation, as observed in AGS 
patients, survive normally but exhibit mild eye defects (Xue et al., 1999). Thus this mouse 
model was not useful in understanding the role of Notch signaling in biliary development. 
 The next model generated was that of a hypomorphic allele of the Notch2 gene 
(McCright et al., 2001). Alternative splicing of the Notch2 mutant allele (Notch2del1) leads to 
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the production of two different in-frame shifts, which remove one or two of the extracellular 
EGF repeats required for ligand binding.  Homozoygous Notch2del1 mice demonstrate kidney 
glomerular development defects, heart and eye vascular abnormalities, as AGS, however 
still do not recapitulate the bile duct paucity observed in AGS patients (McCright et al., 
2001). 
 The first mouse model to recapitulate a majority of the defects observed in AGS 
patients was described in 2002 by generating mice double heterozygous for the Jag1 null 
mutation and the Notch2 hypomorphic allele (McCright et al., 2002). The double 
heterozygous mice demonstrate jaundice, growth retardation, IHBD paucity, kidney, heart 
and eye defects. However, the skeletal and craniofacial malformations observed in AGS 
patients are not represented in the mouse model (McCright et al., 2002). The partial 
recapitulation of AGS by a double heterozygous mouse emphasizes the importance of the 
threshold of Notch activity required in an organ and cellular specific context, and suggests 
an explanation for the variable phenotype of AGS patients. 
 While the aforementioned studies provided the groundwork for a mouse model of 
AGS, the next important goal became determining the cell types in which Notch intracellular 
signaling was required (signal receiving versus signal sending cell). The localization of 
Notch ligands and receptors during liver development and in the adult in human and mouse 
studies, as assessed by immunohistochemistry or immunofluoresecence, revealed 
conflicting results (Table 1.2).  
 Initial investigations focused on the role of Jag1 in biliary development. Loomes et al. 
determined that conditional deletion of Jag1 within the hepatoblast had no affect on liver 
development. Indeed, mice only exhibited bile duct paucity when placed on the background 
of a Jag1 null allele (Loomes et al., 2007). Therefore, Jag1 is not required in the liver 
epithelial compartment for proper biliary development.  Based on immunohistochemical  
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Table 1.2 Immunohistochemical expression of Notch pathway components in liver. 
This table summarizes currently published work which has suggested the cells, both 
developmentally and in the adult, that express different components of the Notch pathway 
(Ligands and Receptors). This data includes only immunohistochemical identification in 
tissue section in both human and mouse studies. Developmental studies are identified by 
Dev. Adult studies are identified by Ad. SEC – Sinusoidal Endothelial Cells. 
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analysis, Jag1 was consistently expressed in both the portal vein endothelium and 
mesenchyme (Table 1.2). A recent study examining the necessity of Jag1 within specific cell  
lineages demonstrated that the requirement of Jag1 resides within the portal vein 
mesenchyme (Hofmann et al., 2010). Hofmann et al. demonstrated that an endothelial-
mediated deletion of Jag1 had no effect on bile duct morphogenesis. In contrast, a smooth-
muscle-actin-mediated deletion of Jag1 recapitulated bile duct paucity as observed in AGS 
patients (Hofmann et al., 2010). These results are consistent with the mode of Notch action 
signaling between adjacent cells, as the portal hepatoblasts abut mesenchyme, not 
endothelium. Thus the signal-sending cell (expressing ligand) is considered to be the portal 
vein mesenchyme and the signal-receiving cell (expressing receptor), the hepatoblasts 
adjacent to the portal vein. 
 
2B. Notch Signaling in Cholangiocyte Development: the Signal-Receiving Cell 
 The majority of research investigating the role of Notch signaling in bile duct 
development has focused on the cell autonomous requirement of Notch signaling within the 
liver epithelium. At this point, it is important to make note of a deficiency of Cre lines with 
which to mediate deletion in the liver epithelium. For the purpose of my studies, I have 
utilized an Albumin-Cre transgene (Alb-Cre) (Postic and Magnuson, 2000). While this Cre 
line was originally reported to mediate deletion of the glucokinase locus at 6 weeks with 
90% efficiency in a C57/Bl6 background, as assessed by Southern blot, it has since been 
revealed that in a CD1 background Alb-Cre is expressed much earlier within the hepatoblast 
(Please refer to Appendix A for more information). Other Cre lines used to mediate 
hepatoblast deletion are: the albumin-enhancer and promoter plus alpha-fetoprotein-
enhancer driven Cre (Alfp-Cre; (Kellendonk et al., 2000)) and Forkhead box A3 driven Cre 
(FoxA3-Cre; (Lee et al., 2005)). Unfortunately, none of these Cre lines mediates gene 
deletion before the initial specification and diverticulum formation. Indeed, the earliest 
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documented Cre line is the FoxA3-Cre, and it has been reported to mediate recombination 
of the Rosa26 Reporter (R26R) in 81% of liver epithelial cells at E15.5 (Zong et al., 2009). 
Despite subtle differences in timing of deletion, little difference is observed in the resulting 
phenotype using Alb-Cre, FoxA3-Cre or Alfp-Cre, as assayed by cytokeratin-positive ductal 
morphology.  
The first study to investigate the cell-autonomous requirement of Notch signaling was 
Lozier and colleagues who used Alb-Cre to mediate deletion of a Notch2 floxed allele 
(Lozier et al., 2008). In parallel with this study, our laboratory was also examining the 
requirement of Notch2 in liver epithelial cells (Please refer to Chapter III, Results: 
Modulating Notch Signaling within the Hepatoblast Lineage Alters IHBD Development). Both 
my work and that of Lozier et al. determined that liver-specific loss of the Notch2 receptor 
results in the presence of un-remodeled cholangiocytes in peripheral liver tissue (Lozier et 
al., 2008). This phenotype is reminiscent of AGS patient biopsies. 
 While Notch2 is generally considered the primary receptor in the liver, it remains 
possible that the other receptors may partially compensate in the absence of Notch2. 
Therefore, Geisler et al., investigated the ductal defects as a consequence of Alb-Cre-
mediated deletion of Notch1 and Notch2 (Geisler et al., 2008). In concert with this study, our 
laboratory was also examining the liver-specific requirement of Notch1 and Notch2 (Please 
refer to Chapter III, Results: Modulating Notch Signaling within the Hepatoblast Lineage 
Alters IHBD Development). Both my work and that of Geisler et al. demonstrate that the loss 
of Notch1 and Notch2 is morphologically indistinguishable from that of Notch2 liver-specific 
knockout mice, and also displayed un-remodeled cytokeratin-positive cells in the periphery 
(Geisler et al., 2008). However, as these conclusions were drawn from observations in 
tissue section and the number of cytokeratin-positive cells not quantified, this does not 
preclude the possibility that the Notch2 liver-specific knockout and the Notch1/Notch2 liver-
specific double knockout have subtle but differential effects on the intact three-dimensional 
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(3D) biliary architecture. Indeed this is the case, as I have adapted a method of resin casting 
to reveal the 3D structure of the biliary system, and the Notch1/Notch2 liver-specific double 
knockout has more severe paucity of peripheral branch density than the Notch2 liver-
specific knockout alone (Please refer to Chapter III, Figure 3.10). Thus these results suggest 
that in the absence of Notch2, a level of compensation from other Notch receptors can 
occur. 
 While the major Notch receptors are considered to be the Notch1 and Notch2 
receptors, it is possible that in the absence of these receptors, the minor Notch receptors, 
Notch3 and Notch4, may compensate. Therefore to remove all signaling from Notch 
receptors, our laboratory and the Stanger laboratory independently examined the liver-
specific deletion of RBP-J, the common DNA binding partner for all four Notch receptors 
(Zong et al., 2009). Two caveats are noted regarding the use of RBP-J to delete Notch 
signaling; first in the absence of the NICD, RBP-J acts as a co-repressor, therefore loss of 
RBP-J has the potential to lead to de-repression of target genes. While de-repression upon 
loss of RBP-J is a possibility as demonstrated by a recent study in embryonic stem cell 
cultures (Meier-Stiegen et al., 2010), to date, no study has demonstrated that de-repression 
occurs in vivo. In fact, a recent study demonstrated that loss of RBP-J alone was not 
sufficient to mediate de-repression in developing thymocytes (Chari et al., 2010). The 
second caveat of note is that RBP-J has been proposed to have Notch-independent 
functions. This phenomenon has been described for the pancreas and spinal cord, in which 
RBP-J interacts with Ptf1a, a transcription factor expressed only in these two tissues (Obata 
et al., 2001; Hori et al., 2008). However, a Notch-independent role for RBP-J other than by 
Ptf1a interaction has not been described in mammals.  
 Therefore, our laboratory and others examined the effect of liver-specific deletion of 
RBP-J on bile duct development (Please refer to Chapter III, Results: Modulating Notch 
Signaling within the Hepatoblast Lineage Alters IHBD Development). Utilizing a FoxA3-
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mediated deletion of RBP-J, Zong et al. demonstrated a reduction in the number of cells 
specified within the ductal plate (Zong et al., 2009). Interestingly, despite using FoxA3-
mediated gene deletion, there are still cells specified and ducts formed, albeit fewer. My 
results using Alb-Cre mediated deletion of RBP-J demonstrate similar results; fewer cells 
specified in the ductal plate and fewer ducts formed. Using resin casting to visualize the 
effects on the 3D architecture as a consequence of deleting RBP-J demonstrates a drastic 
reduction in peripheral branch density (Please refer to Chapter III, Figure 3.10).  Thus, loss 
of RBP-J reveals a more severe phenotype than loss of both the Notch1 and Notch2 
receptors. The differential phenotypes with the liver-specific loss of RBP-J versus the liver-
specific loss of the Notch1 and Notch2 receptors further suggests that the threshold of 
Notch activity will be important to define the histopathology in AGS patients. These results 
suggest either a Notch-independent role of RBP-J, de-repression of gene targets or 
compensation by the Notch3 and/or Notch4 receptors in the absence of Notch1 and Notch2. 
Thus we examined the transcript levels of each of the Notch receptors in the Notch2, 
Notch1/Notch2 and RBP-J loss-of-function mice. Interestingly, in the Notch1/Notch2 double 
knockout, there is a significant increase in the transcription of the Notch3 and Notch4 
receptors at P15, suggesting the possibility of receptor compensation (Sparks et al., 2010). 
Further in the RBP-J loss-of-function mice, there is an increase in the transcription of all four 
receptors, suggesting a futile attempt to compensate for the lack of Notch signaling. 
Together studies of the cell-autonomous requirement of Notch signaling in the liver 
epithelium have suggested a threshold requirement for Notch signaling in bile duct 
development (Figure 1.7). Thus in the absence of all Notch signaling (loss of RBP-J), fewer 
ductal cells are specified during development. However, when signaling is removed via 
deletion of only two of the receptors (loss of Notch1 and Notch2), hepatoblasts specify the 
correct number of ductal cells, but they cannot remodel properly.  It is intriguing to note that 
in the absence of all Notch signaling, some ductal cells are still specified. This observation  
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Figure 1.5 A threshold requirement for Notch signaling in bile duct development. This 
graph represents the threshold requirement of Notch signaling during bile duct development. 
The Y-axis represents the level of Notch signaling, whereas the X-axis represents the ductal 
phenotype. In the presence of complete Notch signaling, specification and remodeling occur 
normally, however when signaling from two of the receptors is lost, only specification occurs 
and remodeling is deficient. Finally, when all Notch signaling is lost, via deletion of the 
common DNA-binding partner, both specification and remodeling are deficient. 
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leads to speculations as to whether Notch signaling acts permissively or instructively within 
the hepatoblast population. The specification of fewer ductal plate cells can be attributed to  
Notch signaling acting permissively, or to gene deletion occurring in a mosaic fashion during 
the process of the initial cell fate decision of the hepatoblast. As discussed earlier in this 
introduction, the Cre lines available for liver-specific deletion affect hepatoblasts at E15.5 at 
the earliest, and the initial hepatoblast cell fate decision occurs as early as E13 as observed 
by ductal plate formation. However, identical phenotypes in RBP-J knockout mice 
regardless of the timing of Cre deletion, suggests that this does not affect the amount of 
cells specified. Therefore, I hypothesize that Notch signaling is acting permissively within the 
hepatoblast to influence cholangiocyte cell fate decisions. Support of this hypothesis comes 
from an in vitro study where the NICD was expressed in cultured hepatoblasts (Tanimizu 
and Miyajima, 2004). Under these conditions, the expression of the NICD is not sufficient to 
drive the cholangiocyte fate in hepatoblasts. However, when hepatoblasts expressing the 
NICD were cultured on Matrigel containing growth factor stimulants, cholangiocyte markers 
were up-regulated (Tanimizu and Miyajima, 2004), thus suggesting that Notch maintains 
cells with the competency to become cholangiocytes, but additional cues are required to 
instruct the cell fate.  
The instructive or permissive role of Notch signaling in the hepatoblast population 
was further investigated in vivo using mouse models that constitutively express the NICD 
upon recombination of a STOP cassette in the ROSA26 locus (Murtaugh et al., 2003; 
Tchorz et al., 2009). Our laboratory has investigated the consequence of chronic Notch1 
ICD expression, via Alb-Cre-mediated recombination (NICD), on biliary development. NICD 
mice have an increase in the number of specified and remodeled biliary cells, suggesting 
Notch1 is both necessary and sufficient for bile duct development (Please refer to Chapter 
III, Results: Modulating Notch Signaling within the Hepatoblast Lineage Alters IHBD 
Development). However, the excess biliary cells are restricted to zones, which trace along 
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the tracts of the portal vein system (Please refer to Chapter III, Figure 3.7). These results 
support a permissive role for Notch signaling in biliary development, in which Notch 
maintains a competency zone of hepatoblasts with the potential to become cholangiocytes. 
Interestingly, when the Notch2 ICD (N2ICD) is expressed via Alb-Cre-mediated 
recombination, an excess of biliary cells are also specified and remodelled, but are 
restricted to regions directly adjacent to the portal vein (Tchorz et al., 2009), indicating the 
limited potential of Notch2 versus Notch1 in the ability to maintain hepatoblast competence. 
Unfortunately, the authors used the lectin Dolichos biflorus agglutinin (DBA) as a marker of 
ductal cells, which I have shown to be specific to hilar ducts (Please refer to Chapter III, 
Figure 3.8). Thus the precise effect of N2ICD expression on peripheral ducts remains to be 
fully understood. Zong and colleagues proposed a contrasting interpretation although they 
used a similar study. In their approach, they use the inducible Cre-mediated expression of 
the NICD within the liver epithelial population by Alb-CreER to make the assessment 
whether the expression of the NICD in mature hepatocytes can induce biliary 
transdifferentiation (Zong et al., 2009). The authors interpret the observation of excess 
cholangiocytes to suggest that Notch signaling acts instructively to specify the cholangiocyte 
cell fate in adult liver epithelia. However, some weaknesses in this experimental approach 
are the assumption that P4 is an adult and no naïve hepatoblasts remain. Also the authors 
do not examine if there is regional specificity of this potential transdifferentiation, which 
could be attributed to the known hilar to peripheral maturation of bile ducts. Thus the role of 
Notch signaling as an instructive or permissive cue in hepatoblast specification into 
cholangiocytes remains to be definitely determined, however the majority of evidence at this 
junction points towards a permissive role. 
 The cell-autonomous role of Notch signaling in hepatoblast specification has been 
extensively studied, however the precise requirement and regulation of signaling remains 
largely a mystery. In addition, the post-natal consequence of improper liver development 
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has not been extensively studied in a genetically defined model. The work described within 
this dissertation begins to address this question. The proper function of adult cholangiocytes 
is crucial for proper liver function, thus understanding how developmental modulations affect 
the adult function is critical for the generation of future therapeutics aimed to restore 
cholangiocyte function in cholangiopathies. 
 
Adult Cholangiocytes 
 
Cholangiocyte Function 
 Cholangiocytes provide not only the structure of the IHBD, but also provide many 
important physiological functions to maintain normal metabolic homeostasis. Cholangiocytes 
provide a conduit for bile to flow out of the liver, however the IHBD is not just a passive 
channel. Instead cholangiocytes modify the fluidity and alkalinity of bile, produced by 
hepatocytes, through coordinated secretory and absorptive processes. While cholangiocytes 
contribute to only a small percentage of total liver cells (~3%), their ability to effectively 
modulate bile production is evidenced by the fact that cholangiocytes contribute up to 30% 
of the bile volume in humans (Nathanson and Boyer, 1991). Cholangiocytes regulate bile 
volume by the secretion of osmolites such as Cl– and HCO3–, generating an osmotic 
gradient which drives water secretion into the luminal space (Roberts et al., 1994). While the 
function of cholangiocytes is generalized as the regulation of bile composition, the 
heterogeneity of the biliary epithelium, with respect to function and response to injury, has 
recently come to light (Glaser et al., 2004; Glaser et al., 2009). 
 
Cholangiocyte Heterogeneity 
Three categories of heterogeneity have been defined: morphological, secretory and 
proliferative. Morphological heterogeneity is defined by the size of cholangiocytes and the 
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type of epithelium they generate. For example, cholangiocytes that compose the hilar ducts 
are larger (mean cell size in mouse = 13.24+0.17µm), columnar and contribute to ducts >15 
µm in diameter; in contrast, peripheral cholangiocytes are smaller (mean cell size in mouse 
= 8.84+0.08 µm), cuboidal and contribute to ducts <15 µm in diameter (Glaser et al., 2009).  
Cholangiocyte secretory function is regulated by homone-responsive Ca2+- or cyclic 
adenosine 3’,5’-monophosphate (cAMP)-dependent events. However, only large 
cholangiocytes express the receptors and transporters required for ductal secretion, thus 
suggesting a secretory heterogeneity within the biliary system exists as well (Glaser et al., 
2004; Glaser et al., 2009). The functional role of small cholangiocytes in normal biliary 
homeostasis is unknown at this juncture. Further, it remains unclear whether all large 
cholangiocytes are equivalent in their ability to regulate ductal secretions, or another level of 
heterogeneity exists within the broader population.  
The final category of cholangiocyte heterogeneity was determined based on the 
ability of individual cell populations to respond to injury. Normal cholangiocytes are 
mitotically dormant, however in response to injury a limited range of cholangiocytes are able 
to respond by proliferating. Specifically, after bile duct ligation (BDL), a procedure used to 
model cholestatic liver disease, large bile ducts proliferate, whereas small bile ducts do not. 
Similarly, small bile ducts are resistant to carbon tetracholoride (CCL4)-induced damage, 
whereas large bile ducts lose their proliferative and secretory capacity. Interestingly, upon 
loss of large bile duct function, the small bile ducts begin to express the receptors and 
transporters required for ductal secretion (Kanno et al., 2000). The proliferation and 
functional quiescence of small bile ducts, and their ability to compensate for lost function in 
the large bile ducts has led to the hypothesis that small cholangiocytes represent the liver 
stem cell population (Alpini et al., 2002). 
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Cholangiocyte Cilia 
 As with most cells in the body (one exception being hepatocytes), cholangiocytes 
have a primary cilium located on their apical cell surface. While cholangiocyte cilia were 
described as early as 1963 (Grisham, 1963), the functional significance of the primary cilium 
was not appreciated until recently. Cholangiocyte cilia are now recognized as vital sensory 
organelles that detect changes in bile flow, composition and osmolality (Masyuk et al., 
2008). The importance of the primary cilia is highlighted by a number of cholangiopathies 
that arise due to defects in ciliogenesis (ciliopathies; Table 1.1). As with a heterogeneous 
cholangiocyte population, the length of primary cilia is also heterogeneous. Large bile ducts 
have longer cilia than small bile ducts (approximately two times) (Huang et al., 2006). Thus, 
cilia length has been proposed to correlate with the functional heterogeneity of biliary 
epithelium.  
 
Liver Regeneration 
 With the high prevalence of liver disease in the United States, understanding the 
mechanisms involved in liver regeneration is important for the development of new 
therapeutic options. The ability of the liver to regenerate after injury has intrigued 
researchers for centuries. It is generally accepted that two modes of liver regeneration 
occur: 1. proliferation of normally quiescent hepatocytes and 2. activation of a quiescent 
liver progenitor cell. Despite conjecture that a quiescent progenitor cell resides within the 
biliary epithelium, few studies have investigated the role of cholangiocytes in liver 
regeneration. 
 
Partial Hepatectomy 
 Liver regeneration, as classically described, is not achieved by the traditional 
mechanism of appendage replacement; instead when a portion of the liver is removed (i.e. 
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one or more lobes), the remaining lobes undergo a compensatory proliferation to recover 
the mass. The typical experiment to study liver regeneration is the 70% partial hepatectomy 
(PHx). Pioneering work, outlining the major physiological alterations after PHx in rats, was 
performed by Nancy Bucher (Bucher and Glinos, 1950; Bucher et al., 1951; Bucher, 1963; 
Bucher, 1967; Bucher et al., 1969; Bucher et al., 1977). More recently, genetic knockouts in 
mouse models have allowed a better understanding of the signaling pathways involved in 
regeneration. 
 The main cellular source of regeneration after PHx is proliferation of normally 
quiescent hepatocytes. Hepatocyte proliferation peaks at approximately 24 hours post-PHx 
in rat (approximately 36 hours for mice, (Miliutina, 1989)), with each hepatocyte undergoing 
one or two mitotic divisions to restore hepatic mass after 70% PHx (Stocker and Heine, 
1971). The cues that trigger hepatocyte proliferation and thus liver regeneration remain 
controversial. While many factors involved in hepatocyte replication have been shown to be 
up-regulated after PHx, knockout of any one of these is not sufficient to prevent liver 
regeneration, suggesting a redundancy within the signaling pathways (Michalopoulos, 
2007). Of further interest is that, while hepatic mass is recovered within five to seven days, 
the cues that regulate the precise control to stop growth remain a mystery (Michalopoulos, 
2007).  
 The majority of studies on liver regeneration have focused on the role of the 
hepatocyte, with cholangiocytes remaining largely ignored. In recent reviews, it is stated the 
proliferation of non-hepatocyte cells occurs approximately 24 hours after hepatocyte 
proliferation (i.e. 48 hours in the rat) (Michalopoulos and DeFrances, 1997). Interestingly, 
the reference cited, and the only study to investigate cholangiocyte proliferation post-PHx to 
my knowledge, states that proliferation is occurring between 20 and 24 hours post-PHx in 
the rat (Grisham, 1962). Thus suggesting that hepatocyte and cholangiocyte proliferation is 
occurring simultaneously. The source of this discrepancy in the timing of cholangiocyte 
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proliferation is not understood. Further, the time course of cholangiocyte proliferation after 
PHx in mice has not be determined. In Appendix E, I begin to investigate the mechanism of 
ductal regeneration after PHx and provide initial evidence that the ductal system expands in 
concert with the growth of the remaining lobes. 
 While many studies have investigated the role of individual signaling pathways and 
transcription factors on liver regeneration following PHx, to date no single factor can prevent 
the initiation or termination of liver regeneration (Riehle et al., 2011). A further unexplored 
question is what regulates the seemingly infinite regenerative ability of the liver. For 
example, a landmark study demonstrated that liver still regenerates after twelve successive 
surgeries on the same animal (Stocker et al., 1973). Further, it was shown more recently 
that cultured hepatocytes can undergo at least 80 doublings (Overturf et al., 1997). Thus, 
understanding the regenerative capacity of the liver and the factors that regulate each stage 
is critical for the next steps in liver therapeutics. 
  
Liver Progenitor Cells 
 Under normal circumstances, liver regeneration occurs via proliferation of 
hepatocytes. However, in the instance where hepatocytes are prevented from replicating, a 
facultative cell population arises in the vicinity of the portal vein, called “oval cells”, so 
termed based on their ovular shape (Farber, 1956). Experimental models of oval cell 
proliferation are achieved by the administration of hepatotoxic drugs. The origin and 
potential of oval cells has been the focus of many studies in recent years, however many 
key questions remain unanswered. 
 As oval cells are considered a transit amplifying population of cells, the question 
remains as to where the originating progenitor cell resides. Further, it is unknown whether a 
true progenitor cell exists in a latent form maintained from embryonic development, or if the 
plasticity of differentiated liver cells allows a mature cell type to dedifferentiate and act as a 
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stem cell. The origin of the oval cell has been purported to be many different cell types. 
Specifically, the functional heterogeneity of the ductal epithelium, as discussed early (Please 
refer to Adult Cholangiocytes: Cholangiocyte Heterogeneity) has lead to the hypothesis that 
small bile duct cells act as liver progenitors (Alpini et al., 2002). Thus far the most defining 
work to determine the origin of oval cells was published by Kuwahara and colleagues 
(Kuwahara et al., 2008). In this study, the authors used sub-lethal doses of acetaminophen 
in conjunction with label-retaining cell assays to define up to four potential protenitor cell 
niches. Specifically, label-retaining cells were found in the canals of Hering, intralobular bile 
ducts, periductular mononuclear cells and peribiliary hepatocytes (Kuwahara et al., 2008). 
Work from our laboratory using a cytokeratin19-CreER mouse to lineage label 
cytokeratin19-positive cells prior to injury and trace cells after induction of an oval cell 
response as a result of feeding 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC), suggests 
that oval cells do not arise from a cytokeratin19-positive population (Teagan Walter, 
unpublished observations). Thus, these lineage-tracing results rule out cytokeratin19-
positive cells as a potential source of progenitor cells. It remains possible that multiple 
progenitor cell sites exists within the liver, and that activation of the individual compartments 
may vary based on the type of injury, however this has not been investigated.  
 A second line of investigation is the contribution of oval cells to recovering cell 
populations during and after liver injury. Initially, it was shown that oval cells in culture had 
the potential to up-regulate markers of cholangiocytes and hepatocytes, thus suggesting the 
bi-potential nature of oval cells (Germain et al., 1988; Lazaro et al., 1998). The gold-
standard experiment to test the ability of oval cells to repopulate the liver in vivo was 
provided by Wang and colleagues (Grisham, 1962). In this study, the authors utilize a 
unique model of liver failure, the tyrosinema model, fumarylacetoacetate hydrolase (Fah)-
deficient mice (Grompe et al., 1993). With continuous administration of 2-(2-nitro-4-
trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), Fah-deficient mice survive normally, 
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however upon withdrawal of NTBC, Fah-deficient mice undergo mass hepatic failure via 
hepatocyte death (Grompe et al., 1995); thus these mice are ideal for addressing the 
reconstitution potential of various cell types. In the aforementioned study, a heterogeneous 
population of DDC-responsive oval cells were transplanted into Fah-deficient mice after 
withdrawal of NTBC to determine their repopulation potential in vivo. Indeed, the oval cells 
were able to repopulate and rescue the Fah-deficient metabolic liver failure (Wang et al., 
2003). Using the same Fah-deficient mice, in the same study the authors went on to 
demonstrate that oval cells do not arise from hepatocytes or bone marrow stem cells (Wang 
et al., 2003). 
 Despite the description of oval cells over 55 years ago, our understanding of their 
origin and how they contribute to alleviating liver disease remains poorly characterized. 
Further, the effect DDC has on the biliary architecture has not been investigated. Therefore 
in Appendix E, I begin to investigate the structural alterations induced by DDC treatment and 
discuss the discrepancies between cholestatic liver disease and drug-induced oval cell 
production. The identification of liver progenitor cells has very important clinical implications, 
and could provide an alternative therapy for the treatment of cholestatic liver disease; 
however much work remains to determine whether a liver progenitor cell exists or plasticity 
of differentiated cells contributes to this atypical liver regeneration. 
  
Aims of the Dissertation 
In my dissertation, I aim to first address the requirement of different levels of Notch 
signaling in bile duct development and describe the three-dimensional bile duct structure 
(Please refer to Chapter III). Next, I will investigate the hypothesis that Notch signaling is 
required for the post-natal maintenance of biliary structure (Please refer to Chapter IV). In 
the investigation of this hypothesis, I have revealed a previously unappreciated phenotype 
of progressive post-natal obstruction of the IHBD. The mechanisms contributing to this 
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obstruction and the acute requirement of Notch signaling in the adult are investigated in 
Chapter V. Thus, this dissertation will address the requirement of proper biliary development 
in the progression of cholestatic liver disease.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Mouse Lines 
 CD1 mice carrying the Albumin-Cre transgene (Alb-Cre) (Postic and Magnuson, 
2000) or the Cytokeratin19-CreER knockin allele (K19-CreERT2) (Means et al., 2008) were 
crossed with the conditional deletion allele for Notch1 (Notch1flox/flox) (Pan et al., 2004), 
Notch2 (Notch2flox/flox) (McCright et al., 2006), RBP-J (RBP-Jflox/flox) (Han et al., 2002), the 
conditional activation allele for Notch1 (ROSA26Notch1) (Murtaugh et al., 2003), and the 
ROSA26 reporter allele (R26R) expressing LacZ (Soriano, 1999) or enhanced yellow 
fluorescent protein (EYFP) (Srinivas et al., 2001). Further crosses were performed to obtain 
homozygous genotypes. Control genotypes are: Alb-Cre, K19-CreER, 
Notch1flox/flox;Notch2flox/flox, Notch1 flox/+;Notch2flox/+, Notch1flox/flox;Notch2flox/+, RBP-Jflox/flox, and 
ROSA26Notch. Genotyping was performed by polymerase chain reaction (PCR) analysis 
using previously published primer pairs. All breeding and experimental procedures were 
done with prior approval by the Vanderbilt Institutional Animal Care and Use Committee. 
Infection with Helicobacter hepaticus was ruled out by testing fecal samples for bacterial 
DNA by PCR. 
 
Serum Chemistry 
 Peripheral blood was collected post-mortem via a cardiac stick. Blood was 
centrifuged at 13,200 RPM for 5 minutes in a tabletop centrifuge to separate the serum. 
Serum was transferred into a new tube and sample analysis was completed within 7 days of 
collection. Alanine aminotransferase (ALT), total bilirubin (TB) and alkaline phosphatase 
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(ALP) were measured using colorimetric endpoint assays as per the manufacturer’s protocol 
(Teco Diagnostics). 
 
Bile Acid Isolation and Analysis 
 Bile acids were isolated from four different pools: the liver, gallbladder, serum and 
feces. Mice were fasted for 4 hours, with continual collection of feces. Upon sacrifice, blood 
was drawn via a cardiac stick, and set aside. Mice were weighed and the abdomen opened. 
The gallbladder was excised by first tying a ligature on the cystic duct just below to the 
gallbladder. The gallbladder was removed, and broken apart using #5 forceps in a tube to 
release the bile. Forceps were rinsed with methanol to maximize collection. The liver was 
extracted, and 110-115 mg from the center slice of the left lobe was maintained for analysis. 
Remaining fecal matter in the distal colon was removed and added to the previously 
collected feces. Internal standards (IS) for ultra performance liquid chromatography-tandem 
mass spectrometry (UPLC-MS/MS) analysis were: 40 µg/ml glycochenodeoxycholic-2,2,4,4-
d4 acid (d4-G-CDCA) and 20 µg/ml chenodeoxycholic-2,2,4,4-d4 acid (d4-CDCA) (C/D/N 
Isotopes, Inc.). 
 For the extraction of liver bile acids, 20 µ l of IS was added to tubes (one for each 
sample), and kept on ice. The liver sample was transferred into a dounce homogenizer with 
5 volumes of water (i.e. 500 µl for 100 mg and 550 µl for 110 mg). Liver was homogenized 
until clear and transferred into the 15 ml tubes with IS. Samples were vortexed and allowed 
to equilibrate for 5-10 min. For extraction, 3 ml of 5% ammonia hydroxide in acetonitrile was 
added to the samples, and vortexed immediately. Samples were then allowed to shake at 
room temperature for 1 hour, and then centrifuged at 12,000 x g for 15 min. The supernatant 
was retained and set aside. The pellet was resuspended in 1.5 ml of methanol, vortexed and 
allowed to shake for an additional 20 min, and then centrifuged at 12,000 x g for 20 min. The 
supernatants were combined and dried under a vacuum. Samples were reconstituted in 200 
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µl of 50% methanol, votexed and filtered through a 0.2 µm filter, by centrifuging at 12,000 g 
for 10 min.  Samples were stored at -20ºC until analysis. 
 For the extraction of gallbladder bile acids, 50 µ l of IS was added to the tubes with 
the collected gallbladder bile. Samples were vortexed and centrifuged at 15,000 x g for 10 
min. The supernatant was retained and set aside. The pellet was reconstituted in 2 ml of 
methanol, vortexed and allowed to shake for 30 min, and then centrifuged at 15,000 x g for 
10 min. The supernatant was retained and set aside. The pellet was reconstituted with 
another 2 ml of methanol, vortexed and then centrifuged at 15,000 x g for 10 min. 
Supernatants were combined and dried under a vacuum. Samples were reconstituted in 500 
µl of 50% methanol and stored at -20ºC until analysis. 
 For the extraction of serum bile acids, the collected blood was spun at 13,200 RPM 
for 5 min in a tabletop centrifuge. Serum was retained, and 100 µl was added to 5 µl of IS. 
Samples were vortexed, and equilibrated at room temperature for 5 min. After equilibration, 
1 ml of methanol was added to the samples, they were vortexed and allowed to equilibrate 
again for 10 min at room temperature. Samples were vortexed, and centrifuged at 12,000 x 
g for 10 min. The supernatant was retained and set aside. The pellet was resuspended in 
300 µ l of methanol, allowed to shake for 30 min at room temperature, and then centrifuged 
at 12,000 x g for 10 min. Supernatants were combined and dried under a vacuum. Samples 
were reconstituted in 50 µl of 50% methanol and stored at -20ºC until analysis. 
 For the extraction of fecal bile acids, feces was allowed to dry at room temperature, 
and then ground in liquid nitrogen. Ground feces was weighed out to between 49-51 mg. 
Feces was placed in a tube and 20 µl of IS and 2 ml of methanol was added. Samples were 
vortexed, allowed to shake for 30 min at room temperature, and centrifuged at 12,000 x g for 
10 min. The supernatant was retained and set aside. The pellet was resuspended in 2 ml of 
methanol, vortexed and allowed to shake for 30 min at room temperature. Samples were 
centrifuged at 12,000 x g for 10 min. Supernatants were combined and dried under a 
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vacuum. Samples were reconstituted in 200 µl of 50% methanol and stored at -20ºC until 
analysis. 
 UPLC-MS/MS analysis was performed at the University of Kansas Medical Center 
using techniques previously described (Zhang and Klaassen, 2010). A Waters ACQUITY 
ultra performance LC system was used for bile acid quantification. Chromatographic 
separations were performed on an ACQUITY UPLC BEH C18 column (1.7 µm, 100 x 2.1 
mm I.D.) heated to 45ºC in the column compartment, using a gradient elution of mobile 
phase A (10 mM ammonium acetate in 20% acetonitrile) and mobile phase B (10 mM 
ammonium acetate in 80% acetonitrile). The injection volume was 7.5 µ l and the flow rate 
set at 0.4 ml/min. The sample manager system temperature was maintained at 4ºC. The 
mass spectrometer was a Waters Quattro Premier XE triple quadrupole instrument with an 
ESI source. The entire LC-MS system was controlled by MassLynx 4.1 software. All bile 
acids were detected in the negative mode. The capillary, extractor, and RF voltages were 
set at 3 kV, 4 V and 0 V, respectively.  
Bile acid stock solutions were diluted with 50% methanol and spiked with 10 µl of IS 
to construct standard curves between 5 and 50,000 ng/ml. The assignment of target BAs in 
the UPLC profile was conducted by comparing their retention behavior and molecular mass 
spectra with the available bile acid reference standards. Quantification was performed via 
peak area rations (analyte versus IS) by linear-weighted (1/x2) least squares calibration 
curves within a range of working standard conditions.  
 
Immunohistochemistry and Immunofluorescence 
 Liver tissue was fixed at 4°C overnight in 4% paraformaldehyde. Tissue for frozen 
embedding was equilibrated in 30% sucrose, embedded in optimal cutting temperature 
compound (OCT), and sectioned at 10 µm. Tissue for paraffin embedding was processed by 
dehydration through alcohol and xylene, followed by paraffin infusion. Paraffin-embedded 
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tissue was sectioned at 6 µm, de-paraffinized, rehydrated, and subjected to antigen retrieval 
(antibody specifics in Table 2.1). For both frozen- and paraffin-embedded tissue, sections 
were incubated with primary antibody overnight at 4°C in 1% bovine serum albumin (BSA) in 
phosphate buffered saline (PBS) or 1% BSA, 0.2% nonfat dry milk, and 0.3% Triton X-100 
(Table 2.1). Sections were then incubated overnight at 4°C in the appropriate secondary 
antibody in 1% BSA or 1% BSA, 0.2% nonfat dry milk, and 0.3% Triton-X 100 in PBS (Table 
2.2). For immunohistochemical analysis, slides were incubated with R.T.U. Vectastain Elite 
Universal ABC kit for peroxidase or alkaline phosphatase, and developed with the substrate 
DAB and/or Vector Red. Slides were counterstained with Hematoxylin and Eosin or Mayer’s 
hematoxylin using standard histology techniques (Carson, 1990). For immunofluorescence, 
slides were incubated in bis-benzamide for DNA identification. Images were acquired using 
a Zeiss Axioplan2 microscope and QImaging RETIGA EXi camera. 
 
Histology 
 Identification of sulfated acid and acid mucins was achieved by staining with alcian 
blue pH 1.0 and 2.5 respective, using standard histological techniques (Carson, 1990). 
Sirius red staining was achieved by deparaffinization, incubation in sirus red (Newcomer 
Supply) for 1 hour, followed by two quick washes in acidified water (0.5% glacial acetic 
acid). Slides were then counterstained with methyl green for 5 min (stock is 5%, use at 0.5% 
in 0.1M sodium acetate buffer, pH 4.2), and washed in acidified water. Water was 
completely removed before placing the slides in three changes of 100% ethanol, clearing in 
xylene and mounting. 
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Antibody Company Species Concentration Antigen Retrieval 
Pan-cytokeratin Dako Rabbit 1:200 (no amp) 
1:2000 (amp) 
100 mM Tris, pH 10, 
ON, 60ºC, or Pro K, 5’ 
Cytokeratin19 
(Troma III) 
Developmental 
Studies 
Hybridoma 
Bank (DSHB) 
Rat 1:100 (no amp)  
1:1000 (amp) 
100 mM Tris, pH 10, 
ON, 60ºC, or Pro K, 5’, 
RT 
DBA-biotin Vector n/a 1:100 Pro K, 5’, RT 
BrdU Abcam Rat 1:400 (amp) 2N HCl, 20’, 37ºC, + 
Boric acid/Borate 
buffer, 1’, RT, + trypsin 
solution, 3’, 37ºC + Pro 
K, 5’, RT 
Beta-catenin Sigma Rabbit 1:500 (amp) 100 mM Tris, pH 10, 
ON at 60ºC 
Arl13b From Tamara 
Kaspary 
Rabbit 1:500 (no amp) Citrate Buffer, 
microwave, 10’ 
Apoptag Chemicon n/a n/a as per manufacturer’s 
instructions 
 
Table 2.1 Primary antibodies. Primary antibodies used within this dissertation and the 
conditions under which they were used. Pro K – Proteinase K (Dako). 
 
 
Antibody Company Concentration 
Anti-rabbit-
biotin 
Jackson 
Immunoresearch 
1:1000 
Anti-rat-biotin Jackson 
Immunoresearch 
1:1000 
Avidin-Cy2 Jackson 
Immunoresearch 
1:300 
Avidin-Cy3 Jackson 
Immunoresearch 
1:300 
Anti-rat-Cy2 Jackson 
Immunoresearch 
1:300 
Anti-rabbit-Cy3 Jackson 
Immunoresearch 
1:300 
 
Table 2.2 Secondary antibodies. Secondary antibodies used within this dissertation and 
the conditions under which they were used. 
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ARIOL Analysis 
 The percent of cytokeratin19-positive area was determined with the ARIOL SL-50 
automated image analysis system (Applied Imaging). Cell surface cytokeratin19 staining 
was processed and classified as positive or negative based on user-trained thresholds that 
evaluate color and intensity of staining. Three different mice were analyzed from each 
genotype (control, RBP KO and NICD) per time point. Total cytokeratin19-positive area in 
fields from hilar or peripheral regions was normalized to total nuclear area for analysis. 
 
Bile Ducts per Portal Vein and Portal Veins per millimeter Calculations 
 Mice of each genotype (control and RBP KO) were stained with cytokeratin19. A total 
of nine cross-sections from the left or medial lobe for each mouse were analyzed for 
independent cytokeratin19-positive luminal structures per portal vein in the periphery. A 
portal vein is defined as having a bile duct associated. The number of portal veins per 
millimeter was calculated by dividing the number of portal veins by the total peripheral tissue 
area as calculated by ImageJ software (Abramoff et al., 2004). 
 
Proliferation Analysis 
BrdU (5-bromo-2-deoxyuridine) was injected at 100 mg/kg body weight at 1 hour 
prior to sacrifice at P15. For proliferation analysis at P30, P60, P90 and P120 BrdU was 
administered at 1mg/ml in the drinking water for 4 days prior to sacrifice. Tissue sections 
from at least 2 different mice were examined for the number of BrdU and pan-cytokeratin 
double-positive cells at the hilum and periphery. At least 200 pan-cytokeratin-positive cells 
were counted from each region per mouse. The proliferation index was calculated by 
dividing the number of double-positive cells by the number of pan-cytokeratin-positive cells.  
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CFDA Dye Injections and Analysis 
 CFDA (Carboxyfluorescein diacetate succinimidyl ester; Vybrant CFDA SE Cell 
Tracer Kit, Invitrogen) was reconstituted in 90µl of DMSO (10mM stock solution), as per the 
manufacturer’s instructions. Aliquots were kept at -20ºC and used within two weeks.  For 
injection, 10 µl of the CFDA stock was added to 1 ml of PBS immediately prior to injection. 
The PBS/CFDA mixture was injected into either the common bile duct or portal vein. After 
injection, liver was left in the body for 1 hour at room temperature to facilitate dye uptake by 
cells. Tissue was fixed overnight in 4% paraformaldehyde and paraffin processed as usual. 
 For both analyses involving CFDA, paraffin sections were stained with cytokeratin19 
using a Cy3 secondary. Dual fluorescence was used to determine either the number of 
portal veins with bile ducts associated for portal vein injections or the number of double-
positive bile ducts for bile duct injections.  For the portal vein analysis, total dye-labeled 
vessels were also counted and the data represented as a ratio of portal veins with bile ducts 
associated to total portal veins. 
 
Resin Casts 
 
Resin Injection 
 Mice were sacrificed and the common bile duct was isolated and cannulated above 
the pancreas using stretched polyethylene-10 tubing. Cannulae were secured in the  
common bile duct by a ligature of 5.0 silk. PBS was manually flushed through the common 
bile duct to ensure proper cannulation. Liquid Mercox II resin (1ml; Ladd Industries) was 
mixed with 0.1 g of catalyst. Resin mixture was injected by manual, retrograde perfusion into 
the common bile duct until resistance was met. At this point, the cannula was removed and 
the common bile duct was ligated. Liver tissue was then either macerated or fixed for 
clearing. 
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Maceration 
 For maceration, the whole liver was resected from the abdominal cavity and floated 
in warm tap water for 10-30 minutes to allow the resin to cure. Then individual lobes were 
separated and placed in 15% potassium hydroxide overnight at room temperature to 
macerate the tissue. The following day, casts were rinsed with water and allowed to dry. 
 
Clearing 
 For clearing, the whole liver was resected from the abdominal cavity and floated in 
4% paraformaldehyde overnight at 4°C. After fixation, individual lobes were separated and 
transferred into 50% methanol in PBS for 4-12 hours at room temperature on a rocker. 
Lobes were then transferred to 100% methanol for an additional 4-12 hours at room 
temperature on a rocker. After equilibration in 100% methanol, lobes were incubated with a 
1:2 benzyl alcohol/benzyl benzoate (BABB) solution overnight at room temperature on a 
rocker.  
 
Nile Red 
 Nile red (BioReagent grade, Sigma) was dissolved at 1 mg/ml in acetone to generate 
a stock solution. Nile red was used at 0.05 mg/ml in resin (50 µl nile red stock + 1 ml resin) 
for analysis. Resin was mixed with the nile red solution before addition of catalyst to ensure 
good miscibility. 
 
Imaging 
 Macerated and cleared resin casts were imaged using a Leica MZ 16 FA 
stereoscope and QImaging RETIGA 4000R camera. Cleared resin casts were imaged in a 
solution of BABB to reduce glare. Nile red resin surface images were obtained using an 
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Axiophot/TE300 and MicroMax CCD camera. Cleared nile red resin cast images were 
obtained by acquiring a z-stack using a Nikon AZ100 and Nikon DS-QiMC black and 
white/DS-Ri1 color camera. Nile red fluorescence was visualized under all filters, but imaged 
under a Green/Red filter. 
 
MicroCT 
 
Scanning 
 Whole left lobe corrosion casts were scanned by microCT (model µCT40; Scanco 
Medical AG). Resin casts from control, RBP KO and NICD mice at P60, P90 and P120 were 
analyzed. Images were acquired with a 20 µm voxel size at 45 kV, 114 µA, 500 projections 
per 180º rotation, 300 ms integration, and 2X frame averaging to reduce noise. An optimized 
density threshold and Gaussian noise filter were applied to the 3D stack of images to 
segment the resin cast from air and generate a 3D reconstruction of the entire IHBD 
network. Analysis of ductal architecture was performed with the manufacturer’s software. 
The methods used to calculate the structural properties of the IHBD have been used to 
study analogous properties of trabecular bone (Muller, 2009). 
 
Volume and Thickness Determination 
 Total resin cast volume was calculated directly from the 3D reconstructions using 
total segmented voxel volume. Branch thickness was calculated by direct thickness 
determination, as described previously (Hildebrand and Rüegsegger, 1997). Briefly, a 
sphere is fitted within each point of the cast reconstruction, the diameter of the sphere is 
recorded, and the mean of all spheres represents the mean branch thickness. Use of 
distance ridge calculation allows for inclusion of local neighboring voxels; although this 
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method does not eliminate redundant points, it ensures that all points are included in the 
analysis. This calculation has no structural assumption.  
 
Segment Determination 
 The total number of segments, independent of the total analyzed volume, was 
calculated using the plate-model of Parfitt (Parfitt et al., 1983) to provide segment number 
per total analyzed volume (1/mm3). The total number of segments was determined by 
multiplying the segment number per total analyzed volume by the total cast volume (mm3). 
 
Main Branches 
 The determination of resin cast main branch patterning, and diameter of main 
branches was calculated visually by removing smaller diameter branches from the 3D 
reconstruction image. Control casts at P60, P90 and P120 were initially examined to 
determine a branch thickness that consistently incorporated the main branches, and a main 
branch pattern was defined from these reconstructions. Subsequently, these parameters 
were applied to RBP KO and NICD casts at P60, P90 and P120. 
 
RNA Preparation and Quantitative RT-PCR 
 Total RNA was isolated using TRIZOL and a Turbo DNA-Free kit. Total RNA (2.5 µg) 
was used in complementary DNA synthesis using the SuperScript III First-Strand kit. 
Quantiative real-time PCR was carried out using the ABI Prism 7900. Liver X receptor (LxR), 
farnesoid X receptor (FxR), multi-drug resistance-2 (MDR2), multi-drug resistance protein-2 
(MRP2), multi-drug resistance protein-3 (MRP3), bile salt export pump (BSEP), Cholesterol 
7 alpha-hydroxylase (Cyp7a1) and organic anion transporting polypeptide-1 (OatP1) 
messenger RNA was measured from three independent samples per genotype run in 
triplicate. Primer sequences are provided in Table 2.3.  
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Gene Forward (5’ to 3’) Reverse (5’ to 3’) 
MRP3 GCA GCA GAA CCA AGC ATC AAG GAC CGA CTC CTC ACC TGG 
MDR2 GCA GCG AGA AAC GGA ACA G GGT TGC TGA TGC TGC CTA GTT 
MRP2 GGA TGG TGA CTG TGG GCT GAT GGC TGT TCT CCC TTC TCA TGG 
FxR CGC TGA GAT GCT GAT GTC TTG CCA TCA CTG CAC ATC CCA GAT 
Cyp7a1 CAG GGA GAT GCT CTG TGT TCA AGG CAT ACA TCC CTT CCG TGA 
LxR CTG GTG AGC CTC CGT ACT TTG TCA GTC TGC TCC ACC CGT G 
OatP1 CAG TCT TAC GA GTG TGC TCC AGA T ATG AGG AAT ACT GCC TCT GAA GTG 
BSEP CTG CCA AGG ATG CTA ATG CA CGA TGG CTA CCC TTT GCT TCT 
GAPDH GAC ACC CAC TCC TCC ACC TTT G GTC CAC CAC CCT GTT GCT GTA G 
 
Table 2.3 Primers for quantitative RT-PCR. Primers used within this dissertation are 
described. 
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Statistical Analysis 
 Data was subject to either a two-tailed Student’s t-test or a one-way ANOVA with 
Dunnett’s post-test or Tukey’s multiple comparison post-test compared to control mice. A P-
value of less than 0.05 was considered statistically significant. 
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CHAPTER III 
 
THE ROLE OF NOTCH SIGNALING IN THE REGULATION OF INTRAHEPATIC BILE 
DUCT SPECIFICATION AND REMODELING  
 
Introduction 
 In humans, mutations in the Notch pathway are causative of Alagille syndrome 
(AGS) (McDaniell et al., 2006; Warthen et al., 2006).  AGS is a pleiotropic autosomal 
dominant disorder that is primarily characterized by neonatal jaundice, cholestasis and 
paucity of intrahepatic bile ducts (IHBDs). However, the underlying requirement for Notch 
signaling in liver development and in the adult is not well understood. For example, it 
remains controversial as to whether Notch regulates changes in cell fate decisions, 
proliferative status and/or maintenance of biliary structures.  It is also not well understood 
how two-dimensional alterations in bile duct formation correlate to three-dimensional 
architecture changes. 
 To analyze the cell-autonomous requirement of Notch signaling in the formation and 
patterning of the mouse biliary system, I used mouse models that modulate levels of Notch 
signaling specifically within the hepatoblast.  Further, I have adapted a resin casting method 
that allows visualization of the 3D architecture. With this approach, I have demonstrated a 
dose-dependent requirement for Notch signaling in the establishment of peripheral 
branches, suggesting a level of receptor redundancy.  Further, constitutive activation of the 
Notch pathway results in an excess of biliary branches, indicating that Notch is both 
necessary and sufficient for biliary morphogenesis. 
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Results 
 
Modulating Notch Signaling within the Hepatoblast Lineage Alters IHBD Development 
 To define the cell autonomous role of Notch signaling within early hepatoblast cell 
fate decisions, I used mouse models to modulate levels of Notch signaling within the 
hepatoblast lineage. Three mouse models were utilized to attain varying degrees of Notch 
loss: 1. Alb-Cre;Notch2flox/flox (N2 KO), 2. Alb-Cre;Notch1flox/flox (N1 KO), 3. Alb-
Cre;Notch1flox/flox;Notch2flox/flox (N1/N2 DKO), and 4. Alb-Cre;RBP-Jflox/flox (RBP KO).  Notch 
gain of function was achieved by utilizing Alb-Cre;ROSA26Notch1 (NICD).  To assess the 
affect each of these models has on bile duct development, liver tissues were examined 
histologically and immunohistochemically from embryonic day 16 (E16) to post-natal day 30 
(P30).   
 Bile duct development occurs in a temporal fashion beginning at the hilum and 
progressing to the periphery of liver lobes.  In the adult, the columnar epithelium composing 
hilar ducts has been shown to be functionally distinct from the cuboidal epithelium 
composing peripheral ducts (Glaser et al., 2009).  Therefore, for the purposes of these 
studies, I distinguish between hilar and peripheral regions (Figure 3.1). 
 As Notch2 was originally described as the predominant Notch receptor in the liver, 
both in humans and in mouse models (McCright et al., 2002; McDaniell et al., 2006), I first 
examined the histology of bile ducts in N2 KO liver sections.  Consistent with a concurrent 
publication (Lozier et al., 2008), I observed that ductal plates are able to form in N2 KO 
(Figure 3.2). However at P3, the structures are irregular, with cytokeratin-positive cells that 
are not closely associated with the portal vein (Figure 3.2 D-E). However, by P15, clear 
differences are observed in peripheral bile ducts.  An abundance of un-remodeled,  
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Figure 3.1 Hilum and periphery distinction. This schematic demonstrates how the hilar 
and peripheral ducts were consistently defined within the tissue section. (A) Left lobe of the 
mouse liver, with the hilar bile ducts running through (orange). The lobe was cut along the 
plane indicated by the dotted line for embedding and sectioning. (B) A section through the 
left lobe reveals the hilar bile ducts within the tissue section. The blue box indicates a hilar 
duct, and the red box indicates a representative region where peripheral ducts were 
analyzed. D – dorsal, V- ventral. 
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Figure 3.2 Hepatoblast-specific deletion of Notch1 and Notch2 does not disrupt ductal 
plate formation. Paraffin-embedded sections from control (A,D), N2 KO (B,E) and N1/N2 
DKO (C,F) tissue, at E16 and P3 was stained for pan-cytokeratin to mark ductal plate 
formation and counterstained with hematoxylin and eosin. (A-C) Control, N2 KO and N1/N2 
DKO livers have indistinguishable ductal plate formation at E16. (D-F) At P3, the N2 and 
N1/N2 DKO liver demonstrate normal ductal plate remodeling, with excess ductal plate 
remnants visible (arrows). Scale bar = 100 µm. 
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Figure 3.3 Morphologic defects of pan-cytokeratin-positive cells in hilar and 
peripheral liver tissue with hepatoblast-specific deletion of Notch1 and Notch2. 
Paraffin-embedded sections from control (A,D,G,J), N2 KO (B,E,H,K) and N1/N2 DKO 
(C,F,I,L) at P15 and p30 were stained for pan-cytokeratin to mark cholangiocytes and 
counterstained with hematoxylin and eosin. (A-F) Hilar ducts appear grossly normal in all 
genotypes at P15 and P30. (G-L) Peripheral bile ducts are un-remodeled in the N2 KO and 
N1/N2 DKO when compared with control. Un-remodeled cytokeratin-positive cells are 
observed at P15 and P30. Arrowheads – un-resolved ductal plate remnants. Asterisk – 
necrosis. PV – portal vein, BD – bile duct. Scale bar = 100 µm. 
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cytokeratin-positive ductal cells are noted specifically at the periphery (Figure 3.3 H,K). My 
work and that of others indicates that conditional loss of Notch2 via Alb-Cre deletion, results 
in failure of bile duct morphogenesis, but did not affect hepatoblast specification as indicated 
by indistinguishable ductal plate formation at E16 (Figure 3.2 B-C) (Lozier et al., 2008).  
 Despite the idea that Notch2 is the predominant receptor in liver, evidence that the 
Notch1 and Notch3 receptors are also expressed in liver, specifically in the bile ducts, has 
been demonstrated (Table 1.2). As the function of Notch3 is dispensable for life, I 
investigated the possibility that the Notch1 receptor can compensate in the absence of 
Notch2. When only the Notch1 receptor is lost within the hepatoblast populations (N1 KO), 
biliary development is morphologically indistinguishable from control tissue (data 
communicated by Melanie Brown). In N1/N2 DKO liver tissue, ductal plate formation was 
morphologically indistinguishable from the N2 KO (Figure 3.2 B-C, E-F).  Further N1/N2 
DKO liver demonstrated similar un-remodeled, cytokeratin-positive ductal cells at the 
periphery (Figure 3.2 E-F), which also persist until P30 (Figure 3.3 I,L). In N2 KO and N1N2 
DKO livers at P30, there is a wave of hepatic necrosis observed, however the significance of 
this remains to be understood (Figure 3.4 B and data not shown). In contrast to the 
observed peripheral defects, analysis of hilar bile ducts revealed normal ductal morphology 
with mild inflammation (Figure 3.3 F). My work and that of Geisler et al. concluded that bile 
duct morphology changes N2 KO and N1/N2 DKO were qualitatively indistinguishable from 
each other in two-dimensional (2D) analysis (Geisler et al., 2008).  
 At this juncture, my results and those of others suggest that Notch signaling is 
required for bile duct morphogenesis, but not specification.  However, two caveats are noted 
with this conclusion: The first is that signaling from the Notch3 and/or Notch4 receptor is still 
possible. The second is that my examination of Alb-Cre-mediated gene deletion suggests 
recombination of floxed alleles is occurring between E14 and E16.  Thus deletion is 
occurring at or after the initial hepatoblast cell fate decision, and therefore these mouse  
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Figure 3.4 Focal regions of necrosis are observed in N1/N2 DKO and RBP KO mice at 
P30. Paraffin-embedded sections from the left lob of P30 control (A), N1/N2 DKO (B) and 
RBP KO (C) mice were immunostained with pan-cytokeratin, and counterstained with 
hematoxylin and eosin. Images were obtained from the periphery as indicated in Figure 3.1. 
Arrows – pan-cytokeratin-positive cells. Asterisk – necrotic tissue. Scale bar = 100 µm. 
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models may only be affecting ducts that are formed later in development, i.e. peripheral 
ducts (Please refer to Appendix A).   
To investigate the possibility that the Notch3 and/or Notch4 receptors can 
compensate in the absence of Notch1 and Notch2, I used a mouse model that deletes RBP-
J, the common DNA-binding partner required for all four canonical Notch receptors to signal 
(RBP KO). In RBP KO peripheral liver tissue, ductal plates are able to form (Figure 3.5B). 
My observations suggest a reduction in the number of cells specified (Figure 3.5E), which is 
consistent with the data of Zong et al., using a FoxA3-Cre mediated deletion of RBP (Zong 
et al., 2009). Surprisingly, the reduction in cells within the ductal plate leads to the formation 
of patent ductal structures, albeit fewer, without the un-remodeled cytokeratin-positive ductal 
cells as observed in the N2 KO and N1/N2 DKO (Figure 3.5H,K). At P30, RBP KO livers 
also exhibit a wave of hepatocyte necrosis (Figure 3.4C), thus suggesting this is a common 
mechanism in mouse models of hepatobiliary disease. Similar to the N1N2 DKO results, 
hilar ducts in RBP KO demonstrated normal ductal morphology with mild inflammation 
(Figure 3.6 H,K). The different peripheral phenotypes between N1N2 DKO and RBP KO 
suggest a role for the Notch3 and/or Notch4 receptors in the absence of Notch1 and Notch2. 
To investigate this hypothesis, our laboratory investigated the mRNA expression of all four 
receptors in the various loss-of-function mouse models at P15.  These results confirmed an 
increase in the Notch3 and Notch4 receptor mRNA in the N1/N2 DKO liver (data courtesy of 
Kari Huppert, (Sparks et al., 2010)).  
Thus loss-of-function studies demonstrate a threshold requirement for Notch 
signaling in bile duct development. Subsequent to ductal plate establishment, Notch1 and 
Notch2 are necessary for bile duct morphogenesis, but Notch3 and Notch4 are sufficient to 
maintain the un-remodeled cytokeratin-positive cells. Further reduction of Notch signaling 
via loss of RBP-J results in ductal plate defects and fewer cytokeratin-positive cells.  
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Figure 3.5 Morphological defects in pan-cytokeratin-positive cells in peripheral liver 
tissue with Hepatoblast-Specific Deletion of RBP-J or Activation of Notch1. Paraffin-
embedded sections from control (A,D,G,J), RBP KO (B,E,H,K) and NICD (C,F,I,L) tissue 
over a developmental time course was immunostained for pan-cytokeratin to mark 
cholangiocytes and counterstained with hematoxylin and eosin. Images were obtained from 
the periphery as indicated in Figure 3.1. (A,B) At E16, control and RBP KO liver appear 
grossly identical with pan-cytokeratin-positive cells contributing to a ductal plate. (D,E) At 
P3, it becomes difficult to locate pan-cytokeratin-positive bile ducts in RBP KO mice. 
(G,H,J,K) Fewer bile ducts are observed in RBP KO mice compared to control mice at P15 
and P30. (C) At E16, NICD mice appear to have cords of pan-cytokeratin-positive cells 
radiating from the ductal plate. (F) By P3, these cells have begun to form tubules within the 
parenchyma. (I,L) The excess pan-cytokeratin-positive cells are maintained at P15 and P30. 
Arrowheads – ectopic pan-cytokeratin-positive cells. PV – portal vein, DP – ductal plate, BD 
– bile duct. Scale bar = 100 µm. 
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Figure 3.6 Morphological defects in pan-cytokeratin-positive cells in hilar liver tissue 
with hepatoblast-specific deletion of RBP-J or activation of Notch1. Paraffin-embedded 
sections from control (A,D,G,J), RBP KO (B,E,H,K) and NICD (C,F,I,L) tissue over a 
developmental time course was immunostained for pan-cytokeratin to mark cholangiocytes 
and counterstained with hematoxylin and eosin. Images were obtained from the hilum as 
indicated in Figure 3.1. (A-F) At E16 and P3, each genotype appears grossly identical, 
although NICD mice (C,F) have an increase in portal vein associated pan-cytokeratin-
positive cells at this time. (I) By P15, an excess of pan-cytokeratin-positive cells is apparent 
in the parenchyma of NICD mice, which persists at P30 (L). Conversely, in the hilum of RBP 
KO mice, at P15 (H) and P30 (K), there is mild to moderate inflammation and bile ducts 
appear tortuous and distorted. Arrowheads – un-resolved ductal plate remnants. PV- portal 
vein, DP – ductal plate, BD – bile duct. Scale bar = 100 µm. 
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However, morphological defects are limited to peripheral ducts, therefore suggesting that 
either gene deletion by Alb-Cre does not affect early hepatoblast decisions and thus hilar  
development, or Notch is differentially required for the development of peripheral versus 
hilar ducts. Since I am able to show that Alb-Cre has at least been expressed in the majority 
of hilar ducts (Please refer to Appendix A), I postulate that Notch is differentially required. 
To determine if Notch signaling is sufficient to induce cholangiocyte cell fate, I 
activated Notch signaling within the hepatoblast lineage by constitutive expression of the 
Notch1 intracellular domain (NICD mouse).  In both peripheral and hilar regions, ductal 
plates form normally, but with extra cytokeratin-positive cells present within the portal veins-
associated parenchyma (Figure 3.5-3.6 C,F,I,L, arrowheads). These excess cytokeratin-
positive cells persist throughout development and results in an increase in patent bile ducts 
(Figure 3.5-3.6 C,F,I,L).  Therefore, Notch signaling is sufficient although not necessary to 
promote biliary specification and morphogenesis. Interestingly, Notch1, independent of 
Notch2, is sufficient to induce cholangiocyte differentiation, further supporting a role of 
Notch1 in bile duct development.  
To understand the long-term consequences of improper bile duct development, and 
whether the phenotypes could be attributed to a developmental delay, I examined P120 liver 
tissue.  In both the N2 KO and N1/N2 DKO, the peripheral un-remodeled cells, which were 
present at P15, are maintained within the parenchyma (Figure 3.7 G-H). Further, the RBP 
KO mice demonstrate fewer bile ducts in the periphery as a consequence of the reduction in 
cytokeratin-positive cells contributing to the ductal plate (Figure 3.7 I). In the N2 KO, N1/N2 
DKO and RBP KO hilar regions patent bile ducts are maintained and morphologically 
indistinguishable from control (Figure 3.6 A-D, arrows). Additionally, in NICD liver tissues, 
the excess cytokeratin-positive cells are maintained and appear to be zonal (Figure 3.7 E,J).   
An important question remains as to the maturity status of the cholangiocytes in each 
of the aforementioned mouse models. Unfortunately, there is a deficit of markers to detail  
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Figure 3.7 Alterations in cytokeratin19-positive cholangiocytes at P120 as a 
consequence of chronic modulations of Notch signaling. Paraffin-embedded sections 
from control (A,F), N2 KO (B,G), N1/N2 DKO (C,H), RBP KO (D,I), and NICD (E,J) tissue 
was immunostained for cytokeratin19 to mark cholangiocytes and counterstained with 
Mayer’s hematoxylin. (A-E) Images obtained at the hilum. (F-J) Images obtained from the 
periphery. Arrows – bile ducts. Arrowheads – cytokeratin19-positive cells that have not 
formed patent bile ducts. Plus signs – regions void of cytokeratin19-positive cells. Scale bar 
= 100 µm. 
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the lineage restriction of cholangiocytes during development and to mark the heterogeneity 
of cholangiocytes within a patent bile duct. One marker purported to mark a more mature  
cholangiocyte, albeit with “patchy distribution”, is the lectin Dolichos biflorus agglutinin (DBA) 
(Shiojiri and Nagai, 1992). We were surprised to find that in control mice, the patchy 
distribution resulted from DBA marking only hilar ducts (Figure 3.8 A,F,A’,F’). Thus, DBA 
expression may not mark more mature ducts, but instead mark hilar ducts, further 
supporting the differential roles of hilar versus peripheral ducts in normal function.  When we 
analyzed DBA binding in the N2 KO, N1/N2 DKO and RBP KO mice, we found that these 
genetic manipulations only affected the non-DBA-positive set of peripheral ducts (Figure 3.8 
B-D, G-I, B’-D’, G’-I’).  Further, in NICD mice, we found that all of the excess cytokeratin-
positive cells were not DBA-positive (Figure 3.8 E, J, E’, J’); therefore suggesting again we 
are only affecting peripheral cholangiocyte development. 
 
Excess Cytokeratin-Positive Cells are Not Due to Changes in Proliferation 
 It was previously proposed that the un-remodeled cytokeratin-positive cells observed 
in the N2 KO and N1/N2 DKO, as well as in AGS patients, are a consequence of bile duct 
proliferation (Loomes et al., 2007). To investigate this possibility, I analyzed the 
incorporation of 5-bromo-2-deoxyuridine (BrdU), a thymidine analogue, into newly 
synthesized DNA.  Mice were administered BrdU via the drinking water at P26 and 
sacrificed at P30 for analysis.  In control mice, 15.4% of peripheral cytokeratin-positive cells 
proliferate over a 4-day period (Figure 3.9, A,F,L; Table 3.1).  N2 KO, N1/N2 KO and RBP 
KO mice demonstrated no significant difference in the amount of hilar or peripheral 
proliferation at this time, thus suggesting that proliferation does not play a role in the un-
remodeled cytokeratin-positive cells (Figure 3.9, B-D,G-I,L; Table 3.1).  Proliferation at P15 
after a 1-hour pulse of BrdU was assessed, but again no differences were detected (Figure  
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Figure 3.8 Modulations of Notch signaling only affect peripheral, non-DBA-positive, 
cholangiocytes. Paraffin-embedded sections from P120 control (A,F), N2 KO (B,G), N1/N2 
DKO (C,H), RBP KO (D,I) and NICD (E,J) tissue was immunostained for cytokeratin19 to 
visualize all bile ducts and counterstained with hematoxylin and eosin (A-E). An additional 
slide was stained for cytokeratin19, the lectin Dolichos biflorus agglutinin (DBA), and bis-
benzamide to mark DNA (F-J, Cytokeratin19 – red, DBA – green, bis-benzamide - blue). 
Hilar images (A-J) demonstrate that the majority of cells composing hilar ducts are double 
positive for DBA and cytokeratin19. All cytokeratin19-positive cells in hilar regions that are 
not incorporated into a ductal structure are DBA-negative. Peripheral images (A’-J’) 
demonstrate that all peripheral ducts regardless of genotype are cytokeratin19-positive and 
DBA-negative. Specifically, all excess ductal cells in NICD mice are not DBA-positive. 
Arrows – bile ducts. Arrowheads –un-remodeled ductal cells. Scale bar = 100 µm.  
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Figure 3.9 BrdU incorporation indicates that modulations in Notch signaling do not 
affect the proliferation index of cholangiocytes. (A-J) Representative sections from P30 
mice labeled for 4 days with BrdU administered via drinking water. Paraffin-embedded 
sections were stained for pan-cytokeratin to mark cholangiocytes, BrdU to mark DNA 
replication and bis-benzamide to mark DNA. The pan-cytokeratin-positive cells and double-
positive pan-cytokeratin and BrdU cells were counted from regions at the hilum (A-E) and 
periphery (F-J). (K-L) Ratio of double positive to total pan-cytokeratin-positive cells, absolute 
numbers in Table 1. (K) Peripheral analysis of P15 mice with 1-hour BrdU pulse. (L) 
Peripheral analysis of P26 administered BrdU for 4 days and sacrificed at P30. NICD mice 
have a significantly decreased percent proliferation as compared to control. Percent 
proliferation was calculated per region analyzed and averaged. Statistical analysis was 
performed using a one-way ANOVA with Dunnett’s post-test. Arrowheads – double positive 
cells. Error bars – standard error of the mean. *p<0.05. Scale bar = 100 µm. 
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P15 with one hour BrdU pulse 
 Hilar Peripheral TOTALS 
N Genotype Regions 
analyzed 
Total 
wsCK 
% Regions 
analyzed 
Total 
wsCK 
% Total 
wsCK 
% 
2 Control 7 306 2.1 11 222 2.6 528 2.3 
2 RBP KO 4 305 3.1 9 203 3.1 508 3.1 
3 NICD 7 677 2.7 7 986 2.1 1663 2.4 
 
 
P30 with four day BrdU label 
 Hilar Peripheral TOTALS 
N Genotype Regions 
analyzed 
Total 
wsCK 
% Regions 
analyzed 
Total 
wsCK 
% Total 
wsCK 
% 
2 Control 5 209 6.8 13 296 15.4 505 11.1 
2 N2 KO 7 284 17.4 7 305 7.9 589 12.7 
2 N1/N2 DKO 4 265 5.7 6 338 8.8 603 7.2 
2 RBP KO 5 243 4.7 5 210 8.6 453 6.6 
2 NICD 8 356 6.1 8 509 6.3 865 6.3 	  
 
Table 3.1 Proliferation of pan-cytokeratin-positive cells at P15 and P30.  BrdU was 
either injected 1-hour prior to sacrifice (P15, top) or administered in the drinking water, 4 
days prior to sacrifice (P30, bottom). N equals the number of mice analyzed by double-
immunofluorescence of paraffin sections for pan-cytokeratin and BrdU. Regions of analysis 
were as identified in Figure 3.1, and total indicates the combination of hilum and periphery. 
The number of fields counted at 40x is indicated as “Regions analyzed”. The number of 
double-positive BrdU/pan-cytokeratin cells was divided by the total number of pan-
cytokeratin-positive cells for each region to obtain the percent proliferation. These regional 
percentages were averaged to obtain a mean proliferation index (%). 
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3.9, K; Table 3.1). Interestingly, a significant decrease in cytokeratin-positive cell 
proliferation was observed at P30 in NICD mice (Figure 3.9, E,J,L; Table 3.1). Reduced  
cholangiocyte proliferation suggests, not only that the excess cytokeratin-positive cells arise 
due to increased specification, not proliferation, but also that the increased cholangiocytes 
compensate for the extra ductal mass by being less proliferative.   
 
Notch Signaling Dosage Regulates Three-Dimensional IHBD Architecture 
 Thus far, histological studies have given insight as to how Notch signaling regulates 
bile duct specification and remodeling, however it has not allowed interpretation as to what 
is functionally connected within the 3D architecture of the IHBD. It remains possible that the 
variable histological phenotypes result in indistinguishable 3D structures, however analysis 
of liver function suggests this is not the case (Table 3.2). While histological analysis of N2 
KO and N1/N2 DKO livers has not allowed me to distinguish a morphological difference, 
liver function tests suggest that N1/N2 DKO have more severe liver damage.  Further, liver 
function tests in RBP KO mice suggest the most severe damage, consistent with the idea 
that lack of bile ducts is the most severe phenotype.  Conversely, NICD mice have 
improved, but not statistically significant, liver function.  Therefore, I hypothesized that the 
three-dimensional IHBD architecture would support the severity observed in liver function 
tests.  
To date, three-dimensional imaging of the mouse liver has been limited due to the 
size and density of the organ.  To resolve the three-dimensional architecture of the IHBD, I 
utilized a method of resin casting via retrograde injection into the common bile duct.  Left 
lobe resin casts from control mice at P120 reveal an intricate branched structure, with fine 
resolution (Figure 3.10 A). In N2 KO resin casts, there is a minimal loss of peripheral branch 
density, but the majority of branches have formed (Figure 3.10 B). As predicted, N1 KO 
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Table 3.2 Serum chemistry analysis. Serum was obtained from 2-month old to 4-month 
old mice of the indicated genotypes and analyzed for alanine aminotransferase (ALT), total 
bilirubin (TB), and alkaline phosphatase (ALP). Values are mean (IU/L) + standard error of 
the mean. P values are calculated by a one-way ANOVA with Dunnett’s post-test comparing 
to control mice. Control values are pooled from littermate controls from all genetic 
backgrounds. *p<0.05, **p<0.01. 
 
Genotype n ALT n TB n ALP 
Control 40  57.5 + 5.5 37  1.2 + 0.1 29 8.421+1.197 
N2 KO 17  75.1 + 14.4 15  1.0 + 0.2 7 21.90+10.55 
N1N2 DKO 13  95.5 + 14.3     * 12  2.2 + 0.6 6 35.68+14.89 
RBP KO 24  123.6 + 14.4  ** 17  2.1 + 0.9 23 34.90+7.038 ** 
NICD 27  47.3 + 3.2 23  0.9 + 0.1 7 34.09+8.744 
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Figure 3.10 Three-dimensional resin casting of the biliary system reveals a role for 
Notch signaling in determining IHBD density. (A-E) Representative images of the ventral 
surface of left lobe resin casts are shown with red squares to designate the area in A’-E’ at 
P120. (A,A’) Control mice, 10 full casts from four different familial crosses were analyzed. 
(B,B’) N2 KO, six full casts from three different familial crosses were analyzed. (C,C’) N1/N2 
DKO cats, three full casts from three different familial crosses were analyzed. (D,D’) RBP 
KO, six full casts from three different familial crosses were analyzed. (E,E’) NICD, five full 
casts from four different familial crosses were analyzed. Loss of Notch signaling reveals 
dose-dependent loss of branch density, whereas activation of Notch signaling reveals an 
increase in branch density. Scale bar = 2 mm. 
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resin casts are indistinguishable from control (data communicated by Melanie Brown). 
However, in N1/N2 DKO resin casts, there is a more dramatic reduction in peripheral branch 
density (Figure 3.10 C), thus further confirming that the N1/N2 DKO is a more severe 
phenotype than N2 KO alone. The most severe of all is the RBP KO resin cast, which 
displays the greatest paucity of peripheral branches (Figure 3.10 D). Conversely, activation 
of Notch signaling results in an excess of formed branches (Figure 3.10 E). 
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Discussion 
 
There is a threshold requirement for Notch signaling at multiple stages during IHBD 
development 
 Modulating the levels of Notch deficiency within the hepatoblast leads to a variety of 
histological phenotypes. Specifically, loss of the Notch2 receptor (N2 KO) or the Notch1 and 
Notch2 receptors (N1/N2 DKO) results in un-remodeled cytokeratin-positive cells at the 
periphery (Figure 3.3), which are maintained until P120 (Figure 3.7). These cells could be 
due to a failure of ductal plate regression, or a proliferation of cholangiocytes, both options 
resulting in too many cholangiocytes, which are not incorporated into a duct.  Investigation 
of the proliferation index in N2 KO and N1/N2 DKO cholangiocytes demonstrate no change 
from control at the hilum or periphery (Figure 3.9, Table 3.1).  Thus my results suggest that 
the un-remodeled cytokeratin-positive cells can either not receive cues to regress or are 
unable to remodel into ductal structures.  Further reduction of Notch activity via loss of RBP 
(RPB KO) result in fewer cells contributing to the ductal plate, (Figure 3.5) which results in a 
post-natal reduction in the number of bile ducts formed (Figure 3.7).  Taken together, these 
results suggest that Notch activity is required at different levels for the specification of 
cholangiocytes and IHBD remodeling. 
 On the contrary, the constitutive activation of Notch signaling (NICD) results in an 
excess number of specified cholangiocytes (Figure 3.5), which remodel and are continuous 
with the ductal system (Figure 3.10). Surprisingly, the constitutive activation of Notch1, as 
demonstrated here, is able to maintain an excess of ductal cells until P120 (Figure 3.7), 
whereas a separate study, which constitutively activated Notch2 within the hepatoblasts 
demonstrated that Notch2 promotes ductal morphogenesis, but is not sufficient to maintain 
ductal structures outside the immediate portal environment (Tchorz et al., 2009). Thus we 
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suggest that while Notch1 maybe dispensable for normal biliary development, it may be 
critical to maintain tubular structures post-natally.  
 
Notch signaling affects peripheral, but not hilar duct development 
 In this study, I was careful to define hilar and peripheral duct development and 
architecture (Figure 3.1) due to functional differences previously described (Glaser et al., 
2009). My results demonstrate that modulations in Notch signaling only affect the peripheral 
ducts.  The differential affects could be due to either different mechanisms that determine 
the formation of hilar or peripheral branches, or it may be due to the timing of Alb-Cre 
mediated recombination.  Although I can demonstrate that Alb-Cre is expressed within the 
hepatoblasts using Rosa26 reporter expression as a readout, that DNA recombination of the 
Notch1 and Notch2 loci is equivalent in laser captured hilar and peripheral ducts, and that 
DNA recombination of the RBP locus is occurring as early as E14, I cannot speak to the 
latency of protein function and/or mRNA expression (Please refer to Appendix A).  
Therefore, it remains a possibility that hilar ducts, which develop first, are losing Notch 
expression after the initial requirement for hepatoblast specification and cholangiocyte 
remodeling.  To date, the earliest published deletion of Notch signaling via FoxA3-Cre 
results in a quantitative reduction of bile ducts, but not complete absence (Zong et al., 
2009).  Therefore, with currently available mouse models, hilar bile ducts are able to form in 
the absence of Notch signaling.  In support of different developmental mechanisms, I can 
demonstrate that activation of Notch signaling only increases peripheral, non-DBA-reacting, 
cholangiocytes (Figure 3.8). While loss-of-function studies depend on the half-life of mRNA 
and protein, gain-of-function studies can be correlated more directly with timing of locus 
recombination.  
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Notch signaling acts permissively within the hepatoblast population for cholangiocyte 
specification 
 Previous studies, in cultured hepatoblasts, have demonstrated that expression of the 
N1 intracellular domain (NICD) is sufficient to repress hepatocyte cell fate. Further, that 
NICD expression in hepatoblasts cultured in Martigel is able to induce the expression of 
cholangiocyte markers (Tanimizu and Miyajima, 2004). This in vitro data suggests that 
Notch is acting permissively, and additional factors are required to induce cholangiocyte cell 
fate. My data investigating the constitutive activation of the Notch pathway reveals that 
Notch promotes cholangiocyte differentiation, as observed by the excess cytokeratin-
positive cells. However, these excess cells are zonal as early as P3 (Figure 3.5) and this 
zonation becomes more obvious at P120 (Figure 3.7).  As not all hepatoblasts are fated to 
become cholangiocytes, I propose that Notch acts permissively in vivo to maintain a 
competence zone of hepatoblasts with the potential to respond to instructive cues to 
become cholangiocytes. 
 
Notch signaling regulates the formation of peripheral branches 
 In this work, I’ve described a resin casting technique, which allows visualization of 
the intact 3D IHBD architecture (Figure 3.10).  By reducing the amount of Notch signaling, I 
observe a progressive loss of peripheral branch density. While my results do not dispute 
that Notch2 is the predominant receptor in the liver, the resin casts highlight a previously 
unappreciated role for Notch1 in the absence of Notch2.  Further, RBP KO resin casts 
demonstrate the most severe paucity of branches, and NICD resin casts show an excess of 
branches. Consistent with these results, AGS patient biopsies demonstrate peripheral 
defects with normal hilar regions (Libbrecht et al., 2005), thus further supporting that Notch 
signaling is differentially required for hilar and peripheral bile duct development. 
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Notch signaling modulations provide mouse models of cholestatic liver disease 
 The hallmark of cholestatic liver disease is an elevated alkaline phosphate (ALP) 
level in the serum. In this chapter, the mouse models with deficient Notch signaling (N2 KO, 
N1/N2 DKO and RBP KO) all have significantly elevated ALP levels as compared to control 
(Table 3.2). Surprisingly, the gain-of-function Notch signaling mutant, NICD also had 
significantly elevated ALP levels as compared to control (Table 3.2). Thus while alanine 
aminotransferase (ALT) and total bilirubin (TB) levels in NICD mice are lower than control, 
suggesting that these mice do not have damaged hepatocytes or hepatocyte function. An 
experimental model of cholestasis, which induces cholangiocyte proliferation, is 
administration of the compound α-Naphthylisothiocyanate (ANIT). ANIT is used to produce a 
distinctive form of cholestasis and of acute and chronic bile duct injury (Zimmerman, 1999). 
ANIT has been shown to induce cholangiocyte proliferation and increase the number of 
connected ducts in rat models (Masyuk et al., 2001). Thus morphologically, ANIT 
cholestasis resembles the phenotype in the genetic NICD manipulations. However, ANIT 
does not specifically damage cholangiocytes; ANIT treated animals have an increase in ALP 
as well as ALT and TB (Zimmerman, 1999). Thus in this chapter, I have described a unique 
model of cholestasis in NICD mice, as defined by elevated ALP levels, but without 
hepatocyte damage and general liver dysfunction. 
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CHAPTER IV 
 
NOTCH SIGNALING IS REQUIRED TO MAINTAIN INTRAHEPATIC BILE DUCT 
COMMUNICATION IN ADULT MICE  
 
Introduction 
Alagille syndrome (AGS) is characterized primarily by a paucity of intrahepatic bile 
ducts (IHBDs).  However, whether paucity of IHBDs is due to a developmental defect in bile 
duct morphogenesis, a lack of post-natal branching and elongation or an inability to maintain 
formed ducts remains unclear (Perrault, 1981; Hadchouel, 1992; Libbrecht et al., 2005). 
Interestingly, AGS patients have progressive paucity upon serial biopsy (Dahms et al., 
1982), suggesting that, in addition to the developmental requirement of Notch signaling 
(Please refer to Chapter III), there maybe an additional requirement for Notch signaling in 
the post-natal maintenance of ductal structures. 
 To investigate the requirement of Notch signaling in bile duct maintenance, I used 
chronic alterations to reflect the changes in AGS patients, in which normal protein function is 
absent during development and in the adult. Activation of Notch signaling, via hepatoblast-
specific expression of the Notch1 intracellular domain (NICD), and loss of Notch signaling, 
via hepatoblast-specific loss of RBP-J (RBP KO), were used to assess post-natal alterations 
of the IHBDs. To analyze IHBD changes, I have once again undertaken resin casting to 
resolve the global 3D architecture of the mouse IHBD systems.  In this chapter, I have used 
resin casting in conjunction with microtomography (microCT) analysis to address the 
hypothesis that Notch signaling is required for the post-natal maintenance of intact IHBD 
structure.  
IHBD resin casts were examined at P60, P90 and P120 in NICD and RBP KO mice. 
NICD resin casts demonstrate increased peripheral branches that were maintained with 
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age, however these data do not achieve statistical significance most likely due to the 
resolution limit of the microCT. Conversely, RBP KO resin casts resulted in an age-
dependent loss of intact peripheral branches. Surprisingly, in 2D histological section, there 
were an initially reduced number of bile ducts per portal vein (BD/PV) and portal veins per 
millimeter (PV/mm), but no further reduction was observed at P120. Thus, chronic loss of 
Notch signaling in these mouse models does not mimic the 2D progressive paucity 
observed in AGS patients. Instead, I’ve defined a model that exhibits an acquired, post-natal 
disruption of the intact communicating IHBD system. I postulate that this model maybe used 
to understand a subset of AGS patients who fail biliary excretion tests, suggesting an 
obstruction. To my knowledge, this subset of patients has not been studied or well 
understood. 
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Results 
 
Peripheral resin cast branches are modulated with age  
 To visualize the macro-structural effect of gain or loss of Notch signing on 3D IHBD 
architecture, resin casts were obtained from control, RBP KO and NICD mice at P60, P90 
and P120 (Figure 4.1). Prior to P60, control mice are still rapidly growing (P30-P60 
slope=8.43 vs. P60-P120 slope=3.98; Figure 4.2); therefore, I selected time points that 
allowed me to specifically assay the maintenance subsequent to the post-natal branching 
and elongation period. Stereoscopic images of left lobe resin casts from control mice 
showed no noticeable changes with age (Figure 4.1 A-C), whereas casts from RBP KO mice 
appeared to lose peripheral IHBDs (Figure 4.1 D-F). Conversely, casts from NICD mice 
have increased peripheral branches early in development, which are maintained with age 
(Figure 4.1 G-I).  
 To quantify changes in the structure of the IHBD system, I quantified the volume, 
thickness and number of branches in left lobe resin casts using microCT analysis. A 
representative reconstruction of a microCT scanned control resin cast is depicted in Figure 
4.3 to demonstrate the level of resolution obtained by this approach (Figure 4.3A). Analysis 
of microCT scans was achieved by adapting trabecular bone analysis software from Scanco 
(Perrien et al., 2007). Left lobe casts of control, RBP KO and NICD mice were microCT 
scanned and analyzed at P60 (n=4, 5 and 3, respectively), P90 (n=4, 6 and 3, respectively) 
and P120 (n=4, 4 and 3, respectively).  The same casts were analyzed throughout this 
chapter.  As expected, based on growth curve analysis (Figure 4.2), the total volume of 
control IHBD casts did not change significantly with age (Figure 4.3B). However, the total 
volume of IHBD casts from RBP KO mice was reduced at P120, as compared to age-
matched control mice (P<0.01) and P60 RBP KO mice (P<0.05) (Figure 4.3B). Conversely,  
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Figure 4.1 Resin casts of adult mice reveal IHBD changes upon altered Notch 
signaling. Resin casting was performed by manual, retrograde injection of a modified 
acrylic into the common bile duct, followed by tissue maceration. (A-F) Representative 
stereoscopic images of the peripheral branches of left lobe resin casts. Casts from control 
(A,B), RBP KO (C,D) and NICD (E,F) mice were obtained at P60 and P120. RBP KO IHBD 
casts were unable to maintain intact IHBD structure with age, whereas NICD IHBD casts 
maintain an excess of branches. Scale bar = 2 mm. 
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Figure 4.2 Alterations in Notch signaling do not affect body weight or growth. Average 
body weight from P30, P60, P90 and P120 control (n=18, 15, 15 and 15, respectively), RBP 
KO (n=6, 16, 10 and 15, respectively) and NICD (n=6, 9, 7 and 11, respectively). Average 
body weight for control and RBP KO mice continually increases with age, but is not 
significantly different. NICD mice demonstrate an increased body weight in line with control 
mice until P90 when there is a significant increase as compared to control mice. The reason 
for this increase is not understood. Error bars – standard error of the mean. **p<0.01. 
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Figure 4.3 MicroCT analysis reveals that IHBD average volume is modulated with age 
upon deletion of RBP-J or activation of Notch1. Reconstruction of microCT scans 
provides a high-resolution global representation of resin casts. (A) Representative image 
from Scanco microCT 40 scanning of P120 control IHBD resin cast at 20 µm resolution. Red 
square demonstrates are in A’. (B) Total IHBD cast volume was calculated using software 
adapted from trabecular bone analysis. At P60, RBPK O cast volume is equivalent to 
control, however as age increases, the volume decreases when compared with control 
IHBD casts. This decrease is statistically significant at P120. The trend in NICD IHBD casts 
shows an increase in cast volume. For each genotype (control, RBP KO, NICD), casts at 
P60 (n=4, 5 and 3, respectively), P90 (n=4, 6 and 3, respectively) and P120 (n=4, 4 and 3, 
respectively) were scanned. Error bars – standard error of the mean. *p<0.05, **p<0.01. 
Scale bars = 1 mm. 
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NICD IHBD casts showed a consistent, but not significant, increase in cast volume with age 
compared with control (Figure 4.3B). 
 To further define the structural changes that are visually apparent in the resin casts, I 
calculated the distribution of branch thickness throughout the IHBD casts (Figures 4.4-4.6). 
Owing to variations in maximum thickness resulting from the imprecise method of individual 
lobe separation (i.e. separated manually), the analysis included only diameters less than 
520 um, which consistently incorporates the main branches regardless of genotype. Small 
branches, as defined by a diameter of <15 um (Glaser et al., 2009), are not resolved by this 
method due to detection limitations imposed by cast size; however, I define intermediate 
(20-220 um) and main (240-520 um) branches for the purpose of this analysis. As 
demonstrated in Figure 4.4 C-E, branches with a diameter between 240 and 520 um 
highlight main branches, whereas branches with a diameter between 20 and 220 um 
compose intermediate branches. Control IHBD resin casts demonstrate a high frequency of 
intermediate branches, and this frequency changes very little with age (Figure 4.4 A). By 
contrast, RBP KO casts showed a significant decrease in intermediate branch frequency at 
P120 compared with control and RBP KO casts at P60 and P90 (Figure 4.4 A). Intermediate 
branch diameter frequency in NICD IHBD casts did not significantly change with age (Figure 
4.4 A). 
 For all genotypes, the frequency of branches with a diameter of 240-520 um (main 
branches) was reduced compared with the frequency of intermediate branches (Figure 4.4 
A-B). Main branch frequency remained consistent in control and NICD IHBD casts with age, 
but was reduced in RBP KO IHBD casts at P90 and P120 compared with control (P<0.05 
and P<0.01, respectively), and at P120 compared with P60 RBP KO (P<0.001) (Figure 4.4 
B). Further dissection of the frequency of individual diameters revealed that 80 to 100 um 
diameters were the most frequent regardless of genotype or age (Figures 4.5-4.6 A-C). To 
visualize the relative contribution of each intermediate diameter branch to the total casts,  
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Figure 4.4 Alterations in Notch signaling affect the frequency of intermediate and 
main IHBD branches. (A,B) The frequency of intermediate branches (20-20 µm;A) and 
main branches (240-520µm;B) for each genotype are shown. The frequency of a diameter 
was ‘counted’ using the direct thickness determination model and summed for the indicated 
diameter range. (A) Control IHBD casts show a consistent frequency of intermediate 
branches with age. RBP KO IHBD casts demonstrate a significant reduction in intermediate 
branch frequency at P120 compared with control. Additionally, RBP KO cast demonstrate a 
progressive reduction in the frequency of intermediate branches within the genotype. NICD 
IHBD casts do not significantly change with this analysis. (B) Main branch frequency does 
not change significantly with age in control or NICD IHBD casts. However, there is a 
significant reduction in main branch frequency in RBP KO IHBD casts at P90 and P120 
compared with control. (C-E) A representative scan from control (C), RBP KO (D) and NICD 
(E) IHBD casts, with branch thicknesses from 240 µm to 520 µm highlighted. I have defined 
this thickness range as sufficient to incorporate all main branches. Colored bars indicate 
heat map thickness range; blue = 20 µm to red = 520 µm. Error bars – standard error of the 
mean. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 4.5 Notch signaling affects the frequency of different branch diameters in 
proportion to the original contribution. Individual diameter frequencies (A-C) represented 
as a percent contribution to the total structure (D-F). (A,D) In control IHBD casts, 80-100 µm 
branch diameters represent the greatest frequency and percent contribution. (B,E) RBP KO 
IHBD casts show decreased frequency of all diameters with age, but the percent 
contribution per branch diameter remains consistent with age. Therefore, all intermediate 
branches are lost in proportion to their original contribution. (C,F) NICD IHBD casts 
demonstrate consistent contribution of branch diameters at P60 and P90, however, at P120 
there is a shift towards the main branch contribution. Vertical dotted lines represent division 
between intermediate and main branches. Horizontal grey line represents 1 million (A-C) 
and 25% (D-F). Error bars – standard error of the mean.  
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Figure 4.6 Notch signaling affects the frequency of different branch diameters in 
proportion to the original contribution. Data from Figure 4.5 graphed by age instead of 
genotype. 
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frequency was represented as a percentage of all diameters (Figures 4.5-4.6 D-F). 
Consistent with the raw data, the percent contribution of intermediate branches in control 
IHBD casts was the greatest of all the branch diameters and remained consistent with age 
(Figure 4.5 D). The percent contribution of each diameter in RBP KO IHBD casts did not 
change with age, indicating that RBP KO IHBD casts are losing intermediate and main 
branch diameters at the same rate (Figure 4.5 E). NICD IHBD casts demonstrated a shift in 
contribution towards main branches at P120, which could be attributed to the inability to 
resolve individual intermediate branches with increased cast density at later time points with 
the current scanning resolution (branch separation <20 um) (Figure 4.5 F).  
 For RBP KO IHBD casts, a reduction in the frequency of a specific diameter could be 
due to (1) branch shortening and/or (2) branch loss (Figure 4.7 A). In order to ascertain 
which possibility is more likely, I determined the total number of segments within the IHBD 
casts. A segment is defined as the portion between two branch points. The total number of 
segments in control IHBD casts was not significantly changed with age (Figure 4.7 B). In 
RBP KO IHBD casts, there was a significant reduction in segment number at P90 (P<0.05) 
that was further reduced by P120 (P<0.05) (Figure 4.7 B). NICD IHBD casts had a 
consistently, but not statistically significant increased number of segments compared to 
control (Figure 4.7 B). These data suggest that changes in branch diameter frequency in 
RBP KO are due, at least in part, to cast branch loss.  However, we cannot rule out that 
branch loss is due to excessive branch shortening. Resin casting and microCT analysis 
demonstrated that intact intermediate and main branches were not maintained with age in 
RBP KO mice. 
 
Reduction in 3D architecture is not due to structural loss of branches. 
 I hypothesize that Notch signaling might modulate maintenance of intact IHBD 
structure by (1) IHBD loss or gain, (2) functional blockage of the duct due to obstruction, or  
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Figure 4.7 Loss of RBP-J results in a reduction of segments due to total branch loss 
with age. (A) Schematic illustrating a model of branch reduction in RBP KO IHBD casts. 
Upper panel represents a portion of the IHBD at a younger time point. This portion contains 
one originating branch with two side branches emanating from it. In this simplified example, 
the younger time point has five segments (S) and an initial frequency of a given diameter of 
five counts (C). A reduction in branch diameters as observed in RBP KO mice might be due 
to branch shortening (Option #1) and/or branch loss (Option #2). In either case, the 
frequency of branch diameter is reduced to 4C. To elucidate the difference between these 
two options, the number of segments must be taken into account. In the instance of branch 
shortening, the number of segments would not be affected (5S); however, in the instance of 
branch loss, there would be a reduction in the number of segments (3S). (B) The average 
number of segments, where a segment is defined as the portion between branch points, is 
consistent with age in control IHBD casts. In RBP KO casts, there is a progressive loss of 
segments compared to control. Conversely, NICD IHBD casts show a consistent, but not 
significant, increase in segments with age. Error bars – standard error of the mean. *p<0.05. 
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(3) physical collapse of the IHBD structure. To address the underlying physiology leading to 
structural loss, I examined apoptosis and proliferation in the cytokeratin-positive 
cholangiocyte population. I found that cytokeratin-positive cells undergoing apoptosis are 
very rare regardless of genotype or age (Figure 4.8 C). 
 Cholangiocyte proliferation was assessed by BrdU administration for 4 days via the 
drinking water (Figure 4.8 A-B). In this analysis, peripheral branches refer collectively to the 
intermediate branches, as resolved by microCT, and small branches. In control mice, 
peripheral cytokeratin-positive cells show significantly reduced proliferation with age (P60 – 
8.9%, P90 – 5.7% [P<0.05 vs. P60] and P120 4.2% [P<0.01 vs. P60]; Figure 4.8 A), which 
corresponds to the reduction in growth rate in these mice (Figure 4.2). There are no 
significant changes in the proliferation of hilar cholangiocytes composing main branches 
(Figure 4.8 B). In RBP KO mice, there is a significant increase in the proliferation of 
peripheral cytokeratin-positive cells at P90 and P120 (P60 – 12.7%, P90 – 14.6%, P120 – 
13.1%) as compared to age-matched controls (P<0.05 and P<0.01, respectively) (Figure 4.8 
A). RBP KO hilar cytokeratin-positive cells showed significantly increased proliferation as 
compared to control at P120 (P<0.01) (Figure 4.8 B). Conversely, in NICD mice, there are 
no significant changes in proliferation rate at the hilum or the periphery as compared to 
control (Hilum/Periphery;  P60 – 9.0%/5.5%, P90 – 12.5%/5.5%, P120 – 5.5%/4.6%; Figure 
4.8 A-B).  
 It is important to note that there is no histological evidence of a ductular reaction (i.e. 
increased ductules (Roskams and Desmet, 1998)) in RBP KO mice, and all cytokeratin-
positive cells were incorporated into a ductal structure (Please refer to Chapter III). 
However, to confirm this observation, I took an unbiased approach of ARIOL analysis. 
ARIOL is an automated platform, which allows for the imaging and quantification of 
immunohistochemical or immunofluorescent staining area (For full details, please refer to  
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Figure 4.8 RBP KO mice have increased cholangiocyte proliferation without 
significant apoptosis.  (A-B) Mice at the indicated age were labeled for 4 days with BrdU 
administered via drinking water. Paraffin sections were stained for pan-cytokeratin to mark 
cholangiocytes, BrdU to mark DNA replication and bis-benzamide to mark DNA. Pan-
cytokeratin-positive and double pan-cytokeratin/BrdU-positive cells were counted from 
regions of the hilum and periphery. (A) In control mice, peripheral pan-cytokeratin-positive 
cells demonstrate a significant decrease in proliferation with age (n=4, 5 and 5 for P60, P90 
and P120, respectively). RBP KO mice has significantly increased proliferation at P90 and 
P120 compared to control (n=4, 4 and 3 for P60, P90 and P120, respectively. NICD mice 
show no significant changes in proliferation (n=2, 3 and 4 for P60, P90 and P120, 
respectively). (B) Hilar pan-cytokeratin-positive cells in control and NICD mice have no 
significant changes in proliferation. RBP KO mice have an increased proliferation at P120 
compared to control. (C) TUNEL-labeled cholangiocytes undergoing apoptosis in P120 RBP 
KO tissue (TUNEL – red, pan-cytokeratin – green, DNA – blue)). Cholangiocytes undergoing 
apoptosis are rare regardless of genotype or age.  Error bars – standard error of the mean. 
*p<0.05t, **p<0.01. 
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Chapter II: ARIOL analysis). Using this approach, I assessed the cytokeratin-positive area in 
regions adjacent to portal veins, and was able to determine that there was no change in the 
total cytokeratin-positive between control and RBP KO tissue in hilar or peripheral regions at 
P15, P60 and P120 (Figure 4.9). To validate this approach, I also analyzed NICD mice and 
demonstrated a significant increase in cytokeratin-positive area as compared to control in 
the periphery at P15, P60 and P120 (Figure 4.9 B).   
A further consequence of increased proliferation could be an expansion of liver size. 
However, analysis of the liver to body weight ratio of RBP KO mice, demonstrates that while 
this ratio is increased compared to control, it remains consistent at P60, P90 and P120 
(Figure 4.10). An increased liver to body weight ratio at P30 in RBP KO mice is posited to be 
a result of compensatory growth, or expansion of the liver mass, in response to the hepatic 
necrosis observed at this time period (Please refer to Chapter III, Figure 3.4). Taken 
together, these results suggest that alterations in proliferation and/or apoptosis are not 
sufficient to explain the 3D structural loss with age. 
 Changes in the proliferation and/or apoptotic status of individual cholangiocytes do 
not preclude the possibility that full ductal structures are being lost, which results in the 3D 
structural loss with age. While the ARIOL analysis suggests we are maintaining cytokeratin 
area per portal vein, this could also be attributed to ductal or cellular hypertrophy. Therefore, 
I assessed the number of bile ducts per portal vein (BD/PV) in control and RBP KO mice at 
P60 and P120. For counting purposes, bile ducts were defined as cytokeratin-positive 
structures containing a lumen. As expected, there was a reduction in the number of bile 
ducts per portal vein in P60 and P120 RBP KO mice as compared with age-matched 
controls (P<0.0001 and P<0.05, respectively) (Figure 4.11 A). However, the number of 
BD/PV did not change between P60 and P120 in RBP KO mice (Figure 4.11 A). It remains a 
possibility that portal veins are lost, thus reducing the overall number of ducts without  
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Figure 4.9 There is no change in cytokeratin19-positive area in RBP KO mice. Paraffin-
embedded tissue was immunostained for cytokeratin19 and subjected to ARIOL analysis. 
Three different mice were analyzed from control, RBP KO and NICD at P15, P60 and P120. 
Total cytokeratin19-positive area in hilar (A) or peripheral (B) regions was normalized to total 
nuclear area. (A) The cytokeratin19-positive area at hilar regions is unchanged regardless of 
age of genotype. (B) The cytokeratin19-positive area at peripheral regions in NICD mice is 
significantly increased as compared to control at P15, P60 and P120. There are no 
differences in cytokeratin19-positive area in RBP KO as compared to control. Error bars – 
standard error of the mean. *p<0.05. 
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Figure 4.10 RBP KO and NICD mice demonstrate an elevated liver to body weight ratio 
compared to control.  Liver to body weight ratios from P30, P60, P90 and P120 control 
(n=18, 15, 15 and 15, respectively), RBP KO (n=6, 16, 10 and 15, respectively) and NICD 
(n=6, 9, 7 and 11, respectively). Both RBP KO and NICD mice have an increased liver to 
body weight ratio as compared to control mice at P30, P60 and P90. Error bars – standard 
error of the mean. **p<0.01, ***p<0.001. 
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Figure 4.11 RBP KO mice have a reduction in bile ducts per portal vein and portal 
veins per area (mm) ratios at P60, which are not further reduced at P120. (A,B) Regions 
from the left or medial lobe were counted for peripheral bile ducts per portal vein and portal 
veins per mm. (A) RBP KO mice demonstrate significant reduction in bile ducts per portal 
vein at P60 (n=5) and P120 (n=4) compared with control (n=6 and 6, respectively). There is 
no difference in the number of bile ducts per portal vein in RBP KO mice at each age. (B) 
RBP KO mice demonstrate reduced portal veins per mm at P60 and P120 compared with 
age-matched controls. However, there is no difference in the number of portal veins per mm 
in RBP KO mice between P60 and P120. (C) A non-diffusible dye, CFDA, was injected into 
the portal vein to assess the number of portal veins with bile ducts associated. There is no 
significant difference in the number of portal veins with bile ducts associated at either time 
point (P60 or P120) between RBP KO and control. Error bars – standard error of the mean. 
*p<0.05, ****p<0.0001. 
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affecting the number of BD/PV. As there is a paucity of markers to distinguish portal from 
central veins, for this analysis, a portal vein was defined by having a bile duct associated. 
Consistent with the BD/PV analysis, there is an initially reduced number of PV/mm in P60 
RBP KO compared with control, but no further reduction at P120 (Figure 4.11 B). The 
reduction in PV/mm in RBP KO mice is surprising, as this phenotype has not been 
previously described. Therefore to validate these findings and rule out the possibility that 
portal veins remain without any bile ducts associated, I assessed the number of portal veins 
by an additional method. I injected CFDA, a non-diffusible dye, which penetrates one cell 
layer deep and is irreversibly cleaved to fluoresce and inhibit transport out of the cell, into 
the portal vein. Thus marking the portal veins as those vessels marked by dye incorporation. 
Using this method, I stained with cytokeratin19 and counted the number of dye-labeled 
vessels with or with/out a bile duct associated. This analysis reveals that equivalent 
numbers of portal veins with bile ducts associated are indentified in control and RBP KO 
mice at P60 and P120 (Figure 4.11 C). This analysis identified a portal vein as any dye-
incorporating area, thus only 50% of portal veins have bile ducts associated due to labeling 
of sinusoidal hepatocytes. Together, 3D and 2D analyses indicate that communicating 
branches are not maintained with age in RBP KO mice, however 2D ductal structures are 
maintained. Conversely, NICD mice maintain an excess of intermediate branches with age. 
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Discussion 
 
Notch signaling regulates the three-dimensional architecture of IHBDs with age 
 Mechanistically, Notch signaling is linked to the regulation of cell fate, proliferation 
and/or death, and progenitor cell maintenance (Chiba, 2006). Previous studies have 
demonstrated a requirement of Notch signaling in the specification and morphogenesis of 
the IHBD (Geisler et al., 2008; Lozier et al., 2008; Zong et al., 2009), but the post-natal 
consequence of this improper development has not been studied. To date, many studies 
have evaluated “ductal cells” in 2D following chronic or acute genetic manipulations (Mishra, 
2004), however these prior approaches have not revealed the 3D nature of the IHBD 
systems, which has limited our understanding of how intercellular and intracellular signals 
regulate the intact communicating IHBD structure. In this chapter, I describe the cell-
autonomous requirement of chronic Notch signaling in liver epithelial cells to maintain an 
intact IHBD structure. My results establish that Notch signaling is required to maintain an 
intact IHBD structure, however subsequent to the initial establishment of the IHBD system, 
Notch is not required for the maintenance of the number of ductal structures per portal vein. 
Thus, this work reveals a previously unappreciated role for Notch signaling in the 
maintenance of an intact communicating IHBD network and describes a model of evolving 
cholestasis. 
 Resin casting and microCT anslysis have allowed us to define a role for Notch 
signaling in the maintenance of intact communicating IHBDs. In this chapter, I’ve shown that 
constitutive activation of Notch1 in hepatoblasts results in a slight overall increase in cast 
volume compared with control at all ages (Figure 4.3 B). I speculate that the changes in 
volume would be significantly greater should we have the ability to resolve small branches 
(<20 um) within the context of the whole left lobe resin cast. Furthermore, my data indicate a 
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consistent increase in intermediate braches (20-220 um) and main branches (240-520 um) 
within the IHBD resin casts, which was confirmed by individual branch diameter analysis at 
P60, P90 and P120 (Figures 4.4-4.6). 
 By contrast, loss of Notch signaling in the hepatoblasts resulted in a loss of cast 
volume in P120 resin casts (Figure 4.3 B), as a result of a reduced frequency of 
intermediate and main branches (Figures 4.4-4.6). Reduced frequency of intermediate 
branches in RBP KO resin casts was due in part to branch loss, as demonstrated by a 
reduction in the number of segments in P120 casts, but I cannot rule out the contribution of 
branch shortening to the phenotype (Figure 4.7). Conversely, the reduced frequency of main 
branches in RBP KO mice (Figure 4.4 B) was due to shortening without branch loss. I infer 
this because the stereotypical main branch structure did not change in RBP KO resin casts 
compared with control (Figure 4.12). In summary, RBP KO resin casts demonstrate 
progressive reduction of peripheral branches with age, and thus an inability to maintain an 
intact IHBD network. 
 
Loss of the three-dimensional IHBD structure is not due to changes in proliferation, 
apoptosis or cytokeratin19-positive area.  
 To determine the underlying physiology of 3D branch loss and reduction in diameter, 
I first analyzed the potential contribution of proliferation and apoptosis (Figure 4.8). 
Peripheral RBP KO cholangiocytes have increased proliferation as compared to control at 
P90 and P120 (Figure 4.8 A), and hilar RBP KO cholangiocytes have increased proliferation 
at P120 as compared to control (Figure 4.8 B). The increased proliferation is due to a 
reduction in control proliferation levels, but maintenance of higher proliferation in RBP KO 
mice. I am unable to detect significant apoptosis within these cells (Figure 4.8 C). As no 
ductular reaction is observed, one possible explanation is an increase in the total ductal  
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Figure 4.12 A stereotypical main branch structure is maintained in RBP KO mice. Main 
branch determination was made by computerized removal of peripheral branches, and 
comparison of control casts at all ages (P60, P90 and P120). (A,A’) Representative image of 
a P120 control casts with peripheral branches faded to 50% transparency (A) and 100% 
transparency (A’). (B,B’) Representative image of a P120 RBP KO casts with peripheral 
branches faded to 50% transparency (B) and 100% transparency (B’). (C) Analysis of main 
branch patterning defined a stereotypical pattern, which is maintained in RBP KO mice. 
Scale bar = 1 mm. 
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area. To address this possibility, I used ARIOL analysis to determine the cytokeratin-positive 
area, specifically adjacent to portal veins. This analysis detected no difference in 
cytokeratin-positive area between control and RBP KO in peripheral or hilar regions at P15, 
P60 or P120 (Figure 4.9). Analysis of liver to body weight ratios suggests, that while the liver 
to body weight percentages are significantly higher in RBP KO mice than age-matched 
controls, the ratio does not increase in RBP KO mice with age (Figure 4.10), nor is there a 
difference in overall growth rate (Figure 4.2).  Together, these data indicate that RBP KO 
cholangiocytes are maintaining a higher level of proliferation without affect the cytokeratin-
positive area. While I am not able to detect apoptosis within the cholangiocytes, it has been 
hypothesized that when cholangiocytes initiate an apoptotic program, they are extruded 
from the duct and shed into the lumen (Strazzabosco et al., 2000). Thus I postulate RBP KO 
cholangiocytes increase their turnover with age, however these results are not sufficient to 
explain the 3D structural changes observed in the resins.  
While the total cytokeratin-positive area, as assessed by ARIOL analysis, is 
unchanged in RBP KO mice compared to control (Figure 4.9), this study was limited to 
cytokeratin-positive areas adjacent to portal veins and does not account for the number or 
size of ducts. Therefore these results do not preclude the possibility that entire ducts are 
being lost and consequently I analyzed the number of BD/PV. I found that the number of 
BD/PV was reduced in RBP KO mice at P60 compared with control, but there was no further 
reduction at P120 (Figure 4.11 A). The initial reduction in BD/PV can be attributed to the 
reduced number of ductal cells specified early in development, as described in Chapter III 
(Please refer to Chapter III, Figure 3.5). Thus, duct loss cannot explain the loss of 3D 
structural in RBP KO resin casts from P60 to P120. However, these results do not preclude 
that loss of entire portal veins could contribute to the 3D phenotype. Yet I have 
demonstrated that this is not the case as the number of PV/mm is maintained from P60 to 
P120 in RBP KO mice (Figure 4.11 B). An initial reduction in PV/mm in RBP KO mice at P60 
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and P120 was observed compared with age-matched controls (Figure 4.11 B). In the 
PV/mm analysis, a portal vein was defined as having a bile duct associated. However, it is 
possible that the portal vein remained intact, but no longer had a bile duct associated. The 
lack of markers to distinguish portal and central veins necessitated that I use an alternative 
approach; I injected a non-diffusible dye, CFDA, into the portal vein to mark these vessels 
specifically. Analysis of the number of portal veins, as marked by dye incorporation, with bile 
ducts associated is unchanged between control and RBP KO at P60 or P120 (Figure 4.11 
C). Together these results describe a mouse model in which there is a reduction in the 
number of portal veins per millimeter of tissue.  
To my knowledge, a defect in portal vein number has not been described in AGS 
patient biopsies or in any mouse model. The reduction in PV/mm could be due to a 
feedback requirement of the biliary system from proper venous development, portal vein 
destruction, or an inability of the portal vein to expand with post-natal growth. As a wave of 
necrosis is observed in RBP KO mice at P30 (Please refer to Chapter III, Figure 4C), and 
the consequence of this necrosis is not understood, it is possible that portal tracts containing 
portal veins are lost during this period. However, at P15, an age that precedes the necrotic 
period, the increased liver to body weight ratio and reduction in PV/mm was already 
observed in peripheral tissue (Figure 4.13). Thus these results suggest the reduction in 
PV/mm in peripheral tissue is not due to destruction of portal veins nor an inability to expand 
with post-natal growth. Instead, these results suggest a developmental defect, however, the 
mechanism of this reduction remains to be understood. Together, my 3D and 2D results 
demonstrate a failure to maintain an intact 3D biliary system without concomitant loss of 
ductal structures.  
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Figure 4.13 RBP KO mice have a reduction in bile ducts per portal vein and portal 
veins per area (mm) ratios at P15. (A,B) Regions from the left or medial lobe were counted 
for peripheral bile ducts per portal vein and portal veins per mm. (A) RBP KO mice 
demonstrate a reduction in bile ducts per portal vein at P15 (n=3) compared with control 
(n=2). (B) RBP KO mice demonstrate reduced portal veins per mm at P15 compared with 
age-matched controls. Error bars – standard error of the mean. 
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Loss of three-dimensional architecture without concomitant ductal loss suggests progressive 
IHBD obstruction in RBP KO mice. 
 A reduction of intact structure with age in RBP KO mice without 2D ductal loss 
suggests an obstruction or physical collapse within the IHBD. In the periphery of RBP KO  
casts, the resin changes from a completely filled structure to fine tenuous branches (Figure 
4.1 F). I postulate that this fill pattern is indicative of a blockage at the point of transition 
between complete structure and tenuous branches, where the resin can only pass in fine, 
high velocity streams. An alternative explanation for the apparently contradictory 2D and 3D 
observations is non-productive compensatory sprouting. This phenomenon has been noted 
in tumor angiogenesis after Delta-like-4, a Notch ligand, blockade resulting in reduced Notch 
signaling (Noguera-Troise et al., 2006). If this were the case, we would expect to see an 
increase in ductal structures with progressive 3D loss; however, in our model the number of 
BD/PV was unchanged with age. Therefore, this model is not as likely to explain my results. 
Instead, I hypothesize that loss of intact structure is due to a progressive obstruction of the 
intact IHBD, which prevents resin from completely filling the distal tips. This hypothesis will 
be investigated further in Chapter V. 
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CHAPTER V 
 
LOSS OF HEPATIC NOTCH SIGNALING LEADS TO INTRALUMINAL OBSTRUCTION OF 
THE INTRAHEPATIC BILE DUCT SYSTEM  
 
Introduction 
Alagille syndrome (AGS) is a pleiotropic developmental disorder that is highly 
associated with Notch pathway mutations (McDaniell et al., 2006; Warthen et al., 2006). 
AGS is characterized, in the majority of cases, by neonatal jaundice, cholestasis and paucity 
of intrahepatic bile ducts (IHBDs). However, there is a lack of understanding how specific 
mutations correlate with the severity and pleiotropy of the disease, suggesting 
environmental or other genetic factors are involved (Kamath et al., 2003). A study assessing 
the outcome of 163 children diagnosed with AGS, revealed that cholestasis usually worsens 
until school age, and then in some children will improve (Lykavieris et al., 2001). However, 
there are no known radiological or genetic markers to predict which children will progress to 
liver failure and which will improve.  
 Studies into the role of Notch signaling in bile duct development have been well 
described (McCright et al., 2002; Loomes et al., 2007; Geisler et al., 2008; Zong et al., 
2009), however the long-term consequence of improper development is not well understood. 
In the previous chapter, I described a mouse model in which loss of Notch signaling results 
in an acquired post-natal obstruction of the IHBD. This is particularly intriguing as a subset 
of AGS patients demonstrate an inability to transport bile, based on failure to excrete biliary 
tracer upon hepatobiliary scintigraphy, suggesting an obstruction of the IHBD (Emerick et 
al., 1999). Unfortunately, these patients are often misdiagnosed as biliary atresia patients as 
a result of these tests and undergo a Kasai procedure, which replaces the extrahepatic bile 
duct with a portion of the intestine in an attempt to alleviate extrahepatic biliary obstruction. 
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AGS patients who undergo a Kasai procedure due to misdiagnosis are highly likely to 
proceed to liver failure and require transplant (Kaye et al., 2010). While Kaye et al. suggest 
that the Kasai procedure itself leads to increased mortality by interfering with liver function in 
AGS patients, it is not clear whether these patients had an IHBD obstruction due to 
irresolvable cholestasis which correlated with the severity of disease.  
In this chapter, I investigate the underlying mechanism of IHBD obstruction in RBP 
KO mice, and assess the role of Notch signaling in the maintenance of proper liver function 
in the adult. My results provide evidence that obstruction is due to inspissated material 
accumulation within the ductal lumen. However, this obstruction cannot be attributed to 
alterations in the bile acid content or dysregulation of bile acid metabolism within the liver, 
gallbladder or intestine. Further, my preliminary results suggest that the acquired post-natal 
defects are independent of Notch signaling, and support a model in which post-natal defects 
are secondary to ductal malformations. Current models of cholestasis are achieved by acute 
surgical or chemical obstruction, therefore this model would provide a non-surgical, non-
chemical model to study the progression of cholestatic liver disease. 
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Results 
 
Intrahepatic bile duct blockage is due to intraluminal obstruction  
 In Chapter IV, I demonstrated that loss of Notch signaling within the hepatoblast 
population (Alb-Cre;RBP-Jflox/flox [RBP KO]) results in an age-dependent loss of intact IHBD 
structure without concomitant loss of ductal structures. Three possible models can 
substantiate these findings; the first model is that at focal points within the ductal structure, 
the bile ducts are constricted and do not allow resin to pass, one possible cause for this is 
benign stricturing of the duct. A second model provides that focal cellular loss results in 
disconnection of the communicating structure. A third, and final model, suggests that 
intraluminal obstruction prevents the resin from completely filling the distal branches of the 
IHBD.  
Benign biliary stricturing as a result of excessive inflammation and subsequent 
fibrosis has been described previously in a dog model of biliary trauma (Geng et al., 2005). 
As RBP KO mice have inflammation at hilar ducts (Please refer to Chapter III, Figure 
3.6H,K). I assessed the levels of collagen deposition by Sirius Red staining in RBP KO 
mice. I qualitatively observed that there was no substantial difference in the amount of 
fibrosis in hilar regions P120 RBP KO mice compared to control (Figure 5.1). 
To isolate the point of obstruction and narrow down the possible models, I added a 
fluorescent dye, Nile Red, to the methyl methacrylate resin for casting.  Surface images of 
Nile Red resin injected P120 control and RBP KO liver lobes confirmed that the resin is not 
filling distal structures in RBP KO mice (Figure 5.2). Specifically, control resin casts 
demonstrate fluorescent resin filling the surface vessels (Figure 5.2 A), whereas RBP KO 
resin casts demonstrate surface vessels void of fluorescent resin (Figure 5.2 B). As 
demonstrated by the surface images of fluoresecently-labeled resin injections, visualization 
below the cell surface with conventional microscopy is not feasible. Therefore,  
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Figure 5.1 RBP KO mice do not have increased collagen deposition. Paraffin-
embedded tissue was stained for Collagen with Sirius Red. Analysis of collagen deposition 
at hilar ducts in control (A) and RBP KO (B) mice at P120 reveals no obvious defects. Scale 
bar = 50 µm. 
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Figure 5.2 Fluorescently-labeled resin does not reach the liver surface in RBP KO 
mice. Nile red was added to the methyl methacrylate resin to a final concentration of 0.05 
mg/ml, and injected in p120 control (A) and RBP KO (B) mice. Surface images of whole liver 
from (A) control mice, demonstrate that the fluorescent resin is visible at the surface of the 
liver lobe. (B) RBP KO mice demonstrate no fluorescent resin visible at the surface of the 
liver lobe, though vessels remain identifiable. Arrows – surface vessels.  
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in order to isolate the blockage, liver lobes were cleared with benzyl alcohol/benzyl 
benzoate (BABB) (Figure 5.3 A-B), and then sliced into 1mm sections (Figure 5.3 C-D). RBP 
KO slices were screened for those that incorporated the transition from completely filled 
resin to the fine tenuous structures (please refer to Discussion Chapter IV: Loss of three-
dimensional architecture without concomitant ductal loss suggests progressive IHBD 
obstruction in RBP KO mice). These slices were then paraffin processed and serial 
sectioned. Sections were counterstained with hematoxylin (Figure 5.4) and examined for the 
point where fluorescent resin was no longer visible within the bile duct. In control resin casts, 
the fluorescent resin completely fills the bile duct and can be traced indefinitely through the 
tissue (Figure 5.4 A). Conversely, in the RBP KO mice, the resin initially completely fills the 
bile ducts in hilar regions (Figure 5.4 B), but progressively disappears as the sections 
proceed peripherally into the tissue (Figure 5.4 C-E). These data support a model of 
intraluminal obstruction (Figure 5.5). Indeed, at the point where the resin stopped filling the 
bile duct, inspissated material is observed in the lumen (Figure 5.5 B).  
 
RBP KO mice do not have a leaky epithelium 
 In the Nile Red resin cast sections, I observed resin in the periportal space and while 
this was mild in control mice, the periportal resin was quite prevalent in RBP KO mice 
(Figure 5.4). This extra-ductular resin could be due to two different reasons; first, that the 
RBP KO mice have a leaky biliary epithelium or second, the pressure of the resin after 
encountering the blockages breaks apart the epithelium. To investigate the possibility of a 
leaky epithelium, I injected into the common bile duct, CFDA, a non-diffusible dye that 
incorporates into a cell and is irreversibly cleaved to fluoresce and render itself unable to be 
exported from the cell.  Thus, if RBP KO mice had a leaky epithelium, I would expect to see 
dye incorporation into the cell layer next to the epithelium. However, this is not the case as 
the only cells incorporating CFDA are either bile duct epithelia or hepatocytes at the canals  
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Figure 5.3 Fluorescently-labeled resin in conjunction with clearing the tissue allows 
visualization of cast structure and isolation of obstruction.  (A-B) Nile red was added to 
the methyl methacrylate resin to a final concentration of 0.05 mg/ml, and injected into P120 
control (A) and RBP KO (B) mice. Tissue was cleared using Benzyl-Alcohol/Benzyl-
Benzoate (BABB). Red boxes indicate regions in A’ and B’. (C-D) After injection, left liver 
lobes were sliced into 1 mm segments and screened for blockage. (C) A 1 mm slice from a 
control resin cast demonstrates resin filled to the periphery. (D) A 1 mm slice from a RBP 
KO resin cast demonstrates a potential obstruction, as defined by the transition from filled 
structure to fine tenuous branches.  
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Figure 5.4 Serial sections of fluorescently-labeled resin injection reveals nature of 
obstruction in RBP KO mice. Nile red was added to the methyl methacrylate resin to a 
final concentration of 0.05 mg/ml, and injected into P120 control and RBP KO mice. Tissue 
was sliced into 1 mm segments, cleared with BABB and screened for obstruction. Paraffin-
embedded slices were serial sectioned, counterstained with Mayer’s hematoxylin and 
screened for the resin to vacate the bile duct. (A-E) Mayer’s hematoxylin counterstain. (A’-
E’) Flourescent resin. (A”-E”) Overlay of Mayer’s hematoxylin and fluorescent resin. (A-A”) 
Control resin casts demonstrate complete fill of the ductal structure with minimal resin 
observed outside of the duct. (B-B”) In RBP KO resin casts, at an arbitrary distance of 0 µm, 
the resin completely fills the ductal structure. Extra-ductal resin is observable at this 
distance. (C-C”) At 48 µm after the initial image, the resin still mostly fills the ductal 
structure, but regions void of resin start to be observed. (D-D”) At 72 µm after the initial 
image, the resin is filling only the outer edges of the bile duct. (E-E”) At 144 µm after the 
initial image, the resin is completely absent from the ductal structure, however the extra-
ductal resin becomes even more apparent at this point.  An intraluminal obstruction is the 
reason for a reduction in the intact communicating IHBD in RBP KO mice. Scale bar = 100 
µm. 
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Figure 5.5 Model of IHBD obstruction in RBP KO mice. Isolation of the obstruction in 
RBP KO mice via fluorescent resin tracing revealed an intraluminal obstruction as the 
source. (A) Dotted black line indicates the ductal structure, as observed in section. Red line 
indicates where resin fills. Blue box indicates region in A’. (A’) At the point where the resin 
stops filling the IHBD system, a blockage is observed (green). The source of this blockage 
remains to be defined. (C) Inspissated material is observable within the duct of RBP KO 
mice at the point of obstruction (arrow). 
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of Herring (Figure 5.6). Surprisingly, even the most distal bile ducts in RBP KO mice 
incorporate CFDA, suggesting that a less viscous liquid is able to pass the biliary 
obstruction.  
 CFDA incorporation suggests that epithelial integrity is not compromised when it 
comes to passive diffusion, however cell junctions may not be well-established in RBP KO 
mice. To further assess the integrity of the epithelium, I looked for membrane localization of 
beta-catenin in bile ducts. Consistent with the CFDA results, beta-catenin is properly 
localized at cell junctions in both control (Figure 5.7 A-D) and RPB KO mice (Figure 5.7 M-
P) at P30 and P120. To confirm broadly that modulations in Notch signaling do not affect 
beta-catenin localization, P30 and P120 N2 KO (Figure 5.7 E-H), N1/N2 DKO (Figure 5.7 I-
L) and NICD (Figure 5.7 Q-T) liver tissue was analyzed. As expected, beta-catenin is 
properly localized, although the epithelium looks qualitatively different, regardless of the 
levels of Notch signaling. Therefore, my results suggest that the resin leakage observed in 
RBP KO mice is not due to epithelial integrity problems, but rather a result of increased 
pressure due to luminal obstruction.  
 
Biliary obstruction is not due to changes in bile composition.  
 To identify the source of obstruction in RBP KO mice, I investigated the hypothesis 
that improper bile formation leads to obstruction. First, it is important to note that Hall’s 
Bilirubin Stain, which detects bilirubin, the pigment of bile, in RBP KO tissue did not identify 
any bile plugs or bile lakes within the tissue. However, to my knowledge, no study has 
described bile plugs in mice, thus this maybe a phenomenon specific to human liver.  
To investigate the hypothesis that bile composition is altered, I analyzed the 
concentration of bile acids, the major component of bile, from four different sources: the 
liver, gallbladder, serum and feces using UPLC-MS/MS. During normal bile acid  
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Figure 5.6 RBP KO mice do not have leaky epithelium. A non-diffusible dye, CFDA, was 
injected into the common bile duct of P120 control (A,C) and RBP KO (B,D) mice. Dye was 
allowed to incorporate for 1-hour before fixation and paraffin embedding. Sections were 
stained for cytokeratin19 to mark cholangiocytes. (A-B) Small bile ducts demonstrate 
cytokeratin19-positivity (Red) and CFDA incorporation (Green). (C-D) Intermediate ducts 
also demonstrate cytokeratin19-positivity and CFDA incorporation. A leaky epithelium would 
result in hepatocytes around ducts incorporating CFDA, however that is not observed. In 
some instances, hepatocytes surrounding the canals of Hering do incorporate dye (Arrow). 
Arrowheads – double-positive ducts. Scale bar = 50 µm.  
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Figure 5.7 Beta-catenin is properly localized to cell junctions at P30 and P120 in all 
modulations of Notch signaling. An additional assessment of epithelial integrity is the 
proper localization of cell adhesion proteins. Paraffin-embedded sections from control, N2 
KO, N1/N2 DKO, RBP KO and NICD mice at P30 and P120 were stained for beta-catenin. 
Hilar (A,B,E,F,I,J,M,N,Q,R) and peripheral (C,D,G,H,K,L,O,P,S,T) regions were analyzed. 
(A-D) Control tissue at P30 and P120 demonstrate normal localizations of beta-catenin in 
hilar and peripheral regions. (E-H) N2 KO tissue demonstrates proper localization of beta-
catenin, even in un-remodeled cells, the cell contacts localized beta-catenin. (I-L) N1/N2 KO 
tissue also demonstrates proper localization of beta-catenin. (M-P) RBP KO tissue has 
proper localization of beta-catenin in hilar and peripheral ducts at P30 and P120. (Q-T) 
NICD mice demonstrate that the excess ductal cells properly localize beta-catenin. Scale 
bar = 100 µm. 
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metabolism, bile is produced within the liver, stored in the gallbladder, and excreted via the 
feces. Bile acids within the circulation are a result of the enterohepatic circulation recycling 
bile acids back to the liver. Thus analysis of bile acids within these pools lends insight into 
the potential misregulation of the bile acid metabolism pathway and of bile transporters or 
proteins involved in cholesterol metabolism.  UPLC-MS/MS analysis was performed in 
collaboration with Dr. Grace Guo, an expert in bile acid metabolism, at the University of 
Kansas Medical Center. Interestingly, there is no change in the concentration of un-
conjugated, taurine-conjugated, glycine-conjugated or total bile acids in liver, gallbladder or 
feces at P120 between control and RPB KO samples (Figures 5.8-5.10). However, in the 
serum analysis, all types of bile acids were increased in RBP KO samples compared to 
control (Figure 5.11 A), suggesting a failure of the enterohepatic circulation. 
A failure of the enterohepatic circulation, and thus elevated serum bile acids, can be 
the result of defects in hepatocyte function or defects in hepatic sinusoids. To investigate if a 
failure of the enterohepatic circulation in RBP KO mice is due to hepatocyte defects, I took a 
candidate approach to analyze the mRNA expression of different components of the bile 
acid metabolism pathway. Specifically, I analyzed two nuclear receptors, Liver X Receptor 
(LxR) and Farnesoid X Receptor (FxR), which act as receptors for bile acids and regulate 
bile acid metabolism at a transcriptional level. At P120, both nuclear receptors were 
elevated, however only FxR transcript levels achieved statistical significance (Figure 5.12). 
A downstream target of FxR is the bile salt exporter protein (BSEP), which also has 
significantly increased transcript levels compared to control (Figure 5.12). Increases in these 
components would correlate with a cholestatic phenotype by decreasing bile acid production 
and increasing bile acid export. However, I also analyzed other transporters, specifically the 
multi-drug resistance-2 (MDR2), multi-drug resistance protein-2 (MRP2), multi-drug 
resistance protein-3 (MRP3) and organic anion transporting polypeptide-1 (OatP1). MDR2  
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Figure 5.8 Liver bile acids are unchanged in P120 RBP KO mice. Bile acids were 
isolated from liver and analyzed by UPLC/MS. (A) Total levels of Taurine-conjugated (T-
conj), Glycine-conjugated (G-conj), Un-conjugated (Un-Conj) and total bile acids are 
unchanged between control and RBP KO. (B) Individual Taurine-conjugated bile acids 
demonstrate no difference between control and RBP KO. (C) Individual Glycine-conjugated 
bile acids demonstrate no difference between control and RBP KO. (D) Un-conjugated bile 
acids demonstrate no difference between control and RBP KO. Error bars – standard error 
of the mean. 
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Figure 5.9 Gallbladder bile acids are unchanged in P120 RBP KO mice. Bile acids were 
isolated from the gallbladder and analyzed by UPLC/MS. (A) Total levels of Taurine-
conjugated (T-conj), Glycine-conjugated (G-conj), Un-conjugated (Un-Conj) and total bile 
acids are unchanged between control and RBP KO. (B) Individual Taurine-conjugated bile 
acids demonstrate a significant reduction in only TDCA in RBP KO compared to control. (C) 
Individual Glycine-conjugated bile acids demonstrate no difference between control and 
RBP KO. (D) Un-conjugated bile acids demonstrate a significant reduction in aMCA in RBP 
KO compared to control. Error bars – standard error of the mean. *p<0.05, **p<0.01. 
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Figure 5.10 Fecal bile acids are unchanged in P120 RBP KO mice. Bile acids were 
isolated from feces and analyzed by UPLC/MS. (A) Total levels of Taurine-conjugated (T-
conj), Glycine-conjugated (G-conj), Un-conjugated (Un-Conj) and total bile acids are 
unchanged between control and RBP KO. (B) Individual Taurine-conjugated bile acids 
demonstrate a significant reduction in only TMDCA in RBP KO compared to control. (C) 
Individual Glycine-conjugated bile acids demonstrate no difference between control and 
RBP KO. (D) Un-conjugated bile acids demonstrate a significant reduction in HDCA and an 
increase in UDCA in RBP KO compared to control. Error bars – standard error of the mean. 
*p<0.05. 
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Figure 5.11 Conjugated and unconjugated bile acids are elevated in the serum of P120 
RBP KO mice. Bile acids were isolated from serum and analyzed by UPLC/MS. (A) Total 
levels of Taurine-conjugated (T-conj), Glycine-conjugated (G-conj), Un-conjugated (Un-
Conj) and total bile acids are significantly increased in RBP KO mice compared to control. 
(B) Individual Taurine-conjugated bile acids demonstrate a significant increase in all 
analyzed, except TLCA in RBP KO compared to control. (C) Individual Glycine-conjugated 
bile acids demonstrate a significant increase in all analyzed in RBP KO compared to control. 
(D) Un-conjugated bile acids demonstrate a significant in bMCA, aMCA, CA, CDCA, and 7-
oxoDCA in RBP KO compared to control. Error bars – standard error of the mean. *p<0.05, 
**p<0.01, ****p<0.0001. 
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Figure 5.12 Bile acid metabolism components mRNA expression increase in P120 
RBP KO total liver as compared to control.  The relative expression ratio of bile acid 
metabolism components was calculated using real-time PCR efficiency and the deviation in 
cycle threshold (Ct) of RBP KO versus control samples, expressed in comparison to GAPDH 
mRNA levels. At P120, FxR, MDR2, BSEP and OatP1 are elevated in RBP KO compared to 
control. Horizontal line represents control value. *p<0.05, **p<0.01. 
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and OatP1 transcript levels were significantly increased in RBP KO mice at P120 (Figure 
5.12). Increases in OatP1 would not necessarily correlate with a cholestatic phenotype, as 
increased OatP1 would result in increased bile acid uptake. MDR2 is involved in broad 
substrate export, and is not specific to bile acid regulation. Interestingly, these results 
suggest that a failure of enterohepatic circulation in RBP KO mice is not due to hepatocytes 
defects. Further, these results correlate with the bile acid analysis and demonstrate a 
general increase in bile acid production, both uptake and export, which would result in an 
increase in both conjugated and un-conjugated bile acids. Taken together, these results 
suggest a failure of the enterohepatic circulation, but are not indicative of hepatocyte 
defects. 
 
RBP KO mice have an increase in mucin-producing peribiliary glands 
 Another documented, although rare, source of biliary obstruction has been attributed 
to mucinous masses (Smith and Matzen, 1985). During homeostasis, cytokeratin-positive 
peribiliary glands, preferentially located around hilar bile ducts, produce mucus. Mucus 
secretion is proposed to play a dual role; both in the protection of the epithelium from toxic 
bile and in the defense against infection by enterogeous micro-organisms (Nakanuma et al., 
1994b). However, during liver injury, peribiliary glands have been documented to increase 
mucosal secretion as a non-specific reactive process. Seromucinous hypersecretion can 
lead to retardation of bile flow, alteration of bile composition and/or increased bile viscosity 
(Nakanuma et al., 1994a). Therefore, I stained P60 and P120, control and RBP KO tissue 
with Alcian Blue at pH 1.0 and pH 2.5, to detect sulfated acid and acid mucins respectively. 
Nakanuma et al. had described peribiliary glands to only secrete neutral and acid mucins 
(Nakanuma et al., 1994b); consistent with this, I observed no ducts regardless of age or 
genotype, which expressed sulfated acid mucins.  In contrast, I detected a significant 
increase in the number of acid mucin-producing ducts in P120 RBP KO compared to P120  
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Figure 5.13 RBP KO mice have an increase in mucinous ducts at P120. (A-B) Alcian 
blue pH 2.5 staining in control and RBP KO tissue demonstrates an increase in acid mucin-
producing ducts in RBP KO. (C-D) Serial sections stained with cytokeratin19, alcian blue pH 
2.5 and cytokeratin19 confirms the localization of mucin to ductal structures. (E) 
Quantification of the number of ducts containing mucinous cells in control, N1/N2 DKO, RBP 
KO and NICD mice. RBP KO mice have an increase in mucinous ducts at P120 compared 
to P120 control and P60 RBP KO. Error bars – standard error of the mean. *p<0.05, 
**p<0.01. 
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control and P60 RBP KO (Figure 5.13 E). Mucin-producing ducts were only observed in 
small bile ducts associated with hilar ducts or hilar ducts themselves, consistent with the 
location of peribiliary glands (Figure 5.13 A-B). Further, I confirmed that mucin-producing 
cells were cytokeratin-positive by staining serial sections (Fig 13 C-D). Interestingly, this 
phenomenon is specific to the RPB KO mice, as N1N2 DKO and NICD mice do not have an 
increase in mucin-producing ducts (Figure 5.13 E). Therefore, it remains a possibility that 
excess mucin production by peribiliary glands results in biliary obstruction. 
 
RBP KO mice have longer cilia 
 In addition to the possibility that mucous production alters bile content, cholangiocyte 
regulation of bile composition may also contribute to an obstructive phenotype. It has been 
established that cholangiocytes have a primary cilium radiating from their apical surface that 
acts as a mechano- and chemo-sensory organelle to detect and regulate bile composition 
and flow (Masyuk et al., 2008). As ductal defects have been described within the RBP KO 
mouse model (Please refer to Chapters III and IV), it remains possible that the 
cholangiocytes are unable to properly regulate bile composition and flow, thus contributing 
to an obstruction of the IHBD. Interestingly, in P120 RBP KO cholangiocytes, the cilia, as 
identified by Arl13b staining, appear longer (Figure 5.14). Thus alterations in bile 
consistency and/or flow as a result of irregular cholangiocyte cilia remain a possible source 
of obstruction. 
 
Post-natal cholangiocyte function may not require Notch signaling 
 An additional question that remains is the role of Notch signaling in adult phenotype. 
The progressive obstruction observed in mice with a chronic loss of Notch signaling (RBP 
KO) can be attributed to one of three models: 1. There is an additional requirement of Notch 
signaling for the adult function of cholangiocytes, 2. Notch signaling is required  
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Figure 5.14 RBP KO mice appear to have longer cholangiocyte cilia at P120 compared 
to control.  Paraffin-embedded tissue was immunostained for Arl13b to mark cilia. (A-B) 
Control sections demonstrate small cilia, with the longest indicated by the arrow. (C-D) In 
contrast, RBP KO sections demonstrate long cilia, as indicated by the arrow.  
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developmentally for the lineage restriction of properly functioning cholangiocytes, or 3. Post-
natal obstruction defects are secondary to the ductular malformations resulting from loss of 
Notch signaling. To investigate the requirement of Notch signaling in adult cholangiocytes, I 
utilized a mouse model which allows spatial and temporal deletion of RBP-J via a 
Cytokeratin19-CreERT2 (K19-CreERT2;RBP-Jflox/flox [RBPΔK19]) (Means et al., 2008). While 
the Cytokeratin19-CreERT2 is expressed in a multitude of tissues as assessed by ROSA26 
Reporter (R26R) expression, within the liver it is specifically expressed in cholangiocytes 
(data courtesy of Teagan Walter). To address the effects of deleting RBP-J in the adult 
mouse, Tamoxifen was administered every other day for 4 days at 4mg per injection to P30 
or P60 mice. This approach achieves <50% recombination as assessed by R26R 
expression (data courtesy of Teagan Walter).   
 At three months post-injection, RBPΔK19 mice were analyzed to determine if similar 
defects to RBP KO mice were observed. Initial analysis of liver function tests suggests no 
difference in ALT, TB or ALP levels between control (Tamoxifen-treated) and RBPΔK19 
mice (Table 5.1). Histological analysis of mice administered Tamoxifen at P30 and sacrificed 
at P120, revealed no overt ductal deformation or architectural defects (Figure 5.15). 
However, as noted in RBP KO mice, intra-luminal blockage may not be apparent in 
histological section, and the definitive experiment is resin casting.  At three months post-
Tamoxifen, with injections beginning at P60, resin casts from P150 RBPΔK19 mice are 
visually normal as compared to Tamoxifen injected littermate controls (Figure 5.16), 
however quantitative microCT analysis has not been performed, therefore subtle defects 
cannot be discounted. Unfortunately at 3 months post-Tamoxifen injection, RBPΔK19 mice 
develop keratinous cysts in the muzzle, paws and tail, and must be euthanized.  Thus, this 
mouse model can only demonstrate that within three-months at approximately 50% 
recombination, there are no obvious ductal differences noted in RBPΔK19 mice. 
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Genotype n ALT n TB n ALP 
Control (+TAM) 2 79.0 + 12.3 1 0.429 1 5.6 
RBP∆K19 (+TAM) 3 64.0 + 19.3 3 0.418 + 0.08 3 4.2 + 2.6 
 
Table 5.1 Serum chemistry analysis. Serum was obtained from control (Tamoxifen-
injected) and RBP∆K19 (Tamoxifen-injected) mice and analyzed for alanine 
aminotransferase (ALT), total bilirubin (TB), and alkaline phosphatase (ALP). Values are 
mean (IU/L) + standard error of the mean. P values are calculated by a student t-test.  
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Figure 5.15 RBP∆K19 mice have normal bile duct morphology. Control and RBP∆K19 
mice were administered Tamoxifen (TAM), 4 x 4 mg, every other day at P30, and analyzed 
at P120. Paraffin-embedded tissue was immunostained for cytokeratin19 to mark ductal 
cells. (A) The administration of TAM to control mice did not alter bile duct morphology. (B) 
The deletion of RBP-J within the adult cholangiocyte has no effect on bile duct morphology. 
PV – portal vein, BD – bile duct. Scale bar = 50 µm. 
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Figure 5.16 RBP∆K19 mice have no gross defects in IHBD architecture. Resin casts 
were BABB cleared and imaged. (A) P120 control resin casts demonstrate normal biliary 
architecture. (B) P120 RBP KO resin casts demonstrate the extreme paucity as described 
previously. (C-D) Control and RBP∆K19 mice were administered Tamoxifen (TAM), 4 x 4 
mg, every other day at P60, and analyzed at P150. (C) The administration of TAM to control 
mice does not appear to affect the gross IHBD structure. (D) RBP∆K19 do not demonstrate 
structural defects, as observed in RBP KO mice. Scale bar = 2 mm. 
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RBPΔK19 data suggests that Notch is not required for adult cholangiocyte function, however 
it does not distinguish between the other models as to the developmental requirement of 
Notch signaling. Therefore, I investigated the possibility that Notch signaling is required for 
cholangiocyte lineage restriction and thus required to specify functional cholangiocytes.  
Utilizing the same candidate approach for components of the bile acid metabolism pathway 
mentioned earlier in this chapter (Figure 5.12), I investigated the mRNA expression in P15 
control and RBP KO mice.  Interestingly, there is no detectable difference in gene 
expression between control and RBP KO mice at P15 (Figure 5.17).  This data suggests 
that the components of the bile acid metabolism pathway that are dysregulated in RBP KO 
mice at P120 are not due to improper lineage restriction. Together these data suggest a 
model in which an acquired post-natal obstruction is secondary to the ductular defects 
resulting from loss of Notch signaling. 
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Figure 5.17 Bile acid metabolism components mRNA expression is unchanged at P15 
in RBP KO total liver as compared to control. The relative expression ratio of bile acid 
metabolism components was calculated using real-time PCR efficiency and the deviation in 
cycle threshold (Ct) of RBP KO versus control samples, expressed in comparison to GAPDH 
mRNA levels. At P15, none of the bile acid metabolism components are elevated in RBP KO 
compared to control. Horizontal line represents control value. 
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Discussion 
 
Developmental loss of Notch signaling results in progressive obstructive cholestasis 
 A progressive obstructive phenotype, as observed in RBP KO mice can be explained 
by one of three models:  1. At focal points within the ductal structure, the bile ducts are 
constricted and do not allow resin to pass, potentially due to fibrotic constriction, 2. Focal 
cellular loss results in disconnection of the communicating structure or 3. Intraluminal 
obstruction prevents the resin from completely filling the distal branches of the IHBD. 
Analysis of collagen deposition in P120 RBP KO mice suggests that ductal constriction due 
to fibrosis is not a likely scenario (Figure 5.1). Therefore to identify what is occurring at the 
site of obstruction, I undertook a method of tracing flourescent resin through the tissue. 
Using this approach, I was able to provide evidence that the progressive obstruction of IHBD 
structure observed in RBP KO mice is due to an intraluminal impediment as observed by 
inspissated material accumulation at the point of cessation of luminal resin (Figure 5.4).  
It is surprising to note that the absence of resin is initially observed in the center of 
the duct, suggesting that the obstruction is more tightly associated with itself than the 
epithelium. This indicates that the obstructive material is likely not due solely to mucinous 
accumulation (Figure 5.13), which I would expect to be more closely associated with the 
biliary epithelium than itself. Further, a less viscous liquid, such as the dye CFDA, which is 
diluted in PBS, is able to pass the obstruction, suggesting this is not an impassable 
blockage depending on the viscosity of the liquid (Figure 5.6). While this analysis has lent 
insight into the character of the obstruction, the source remains to be determined.  
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Improper bile acid metabolism is not the source of obstruction.  
Bile acid analysis suggests that the composition of bile within the liver and 
gallbladder remain in the normal range. Further confirmation of this finding is observed with 
mRNA expression of bile acid metabolism components. Interestingly, components that 
increase both the uptake and export of bile acids are increased in RRB KO livers, 
suggesting an upregulation of genes to generally increase hepatocyte function.   
I was intrigued to note a general increase of bile acids, conjugated and un-
conjugated within the serum (Figure 5.11). A failure of the hepatocytes to uptake bile acids 
from the enterohepatic circulation would result in increased serum bile acids, which is 
consistent with no changes in other routes of excretion. However, it is surprising that the 
increase in total bile acids is due to increase in both conjugated and un-conjugated bile 
acids. If the increased bile acids were due to defects in hepatocyte function, either impaired 
uptake or release of bile acids, I would expect to see either conjugated or un-conjugated bile 
acids increase. I propose that one or two different mechanism may contribute to the 
increase in both conjugated and un-conjugated bile acids within the serum. The first 
contributing factor may be that RBP KO mice have a reduced number of portal veins per 
millimeter (Please Refer to Chapter IV, Figure 4.11 B), therefore I speculate that the 
reduction of portal veins results in a decreased enterohepatic circulation. A second 
contributing factor maybe defects in the sinusoids or bile canaliculi, which would allow bile 
acids to leak back into the circulation instead of being transported to the biliary tree. These 
data support the hypothesis that a reduction in the enterohepatic circulation accounts for the 
increased serum bile acids observed in the RBP KO mice, and I postulate that this is due to 
a two-fold process: reduction in portal veins and damage to sinusoids and/or canaliculi.  
 Analysis of bile acid levels does not preclude the possibility that bile is the source of 
obstruction. It remains feasible that the regulation of other bile components and/or regulation 
of bile flow contributes to the obstructive phenotype. In light of this, I observe an increase in 
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mucinous ducts (Figure 5.13), as well as longer cholangiocyte cilia in P120 RBP KO mice 
(Figure 5.13). As mentioned earlier in this discussion, mucous production alone is not 
sufficient to explain the obstructive phenotype, however it may contribute in the context of 
other defects. One of the other defects that may contribute is abnormal cilium (Figure 5.14).  
An alternative hypothesis is that the luminal obstruction is due to cellular debris. As 
documented in Chapter IV, RBP KO cholangiocytes have increased turnover at P120 
compared with control cholangiocyte (Please refer to Chapter IV, Figure 4.8). Since the 
accepted idea within the field is that apoptotic cells are shed into the lumen (Strazzabosco 
et al., 2000), I posit that an increase in cellular debris can also lead to the obstructive 
phenotype observed in RBP KO mice. However the exact nature of luminal obstruction in 
RBP KO mice remains to be determined. 
 
Notch signaling may not be required for adult cholangiocyte function 
 The requirement of chronic Notch signaling for the progressive obstruction observed 
adult RBP KO mice could be attributed to one of three models. The first model suggests 
there is a requirement of Notch signaling for the function of cholangiocytes in the adult. The 
second model posits that Notch signaling is required developmentally for the lineage 
restriction of properly functioning cholangiocytes and thus affects adult function. Finally, the 
third model suggests that post-natal obstruction defects are secondary to the ductular 
defects but independent of Notch signaling.  
To investigate the first model, that Notch signaling is required in the adult 
cholangiocyte for proper function, I used a mouse model that allowed temporal deletion 
within the adult cytokeratin19-positive population. Examination of ductal morphology at 3 
months post-Tamoxifen injection, revealed no obvious ductal defects by cytokeratin19 
immunohistochemical analysis and resin casting (Figure 5.15-5.16). However, I cannot rule 
out that observation over a longer time course would result in loss of the communicating 
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ductal structure. Unfortunately, this mouse model has limitations due to the formation of 
keratinous cysts on the muzzle, paws and tail, independent of a liver phenotype. Further Cre 
recombination efficiency is poor in the adult, presumably due to the quiescent nature of 
cholangiocytes (Please refer to Chapter IV, Figure 4.8). Therefore, while the definitive role of 
Notch signaling in the adult cholangiocytes remains to be fully defined, at this juncture, my 
results indicate that Notch signaling is dispensable for adult cholangiocyte function.  
 The second model of how Notch contributes to the adult phenotype is in the initial 
lineage restriction of cholangiocytes. This model suggests that loss of Notch signaling 
results in immature, improperly functioning cholangiocytes. To investigate this possibility, I 
examined the mRNA expression of the bile acid metabolism genes, which are up-regulated 
in the adult RBP KO liver (Figure 5.12). Interestingly, there are no detectable differences in 
gene expression at P15, suggesting that improper liver function is a product of an acquired 
defect, not improper lineage decision (Figure 5.17). However, it is important to note that the 
components of the bile acid metabolism pathway analyzed here are restricted to 
hepatocytes. At this time, I have not defined specific molecular defects within 
cholangiocytes, therefore I cannot directly assess defects associated with improper lineage 
restriction within the cholangiocyte population. These data make the assumption that if 
cholangiocyte defects result in liver dysfunction, and the cholangiocyte defects are due to 
improper lineage restriction, that at P15 the liver dysfunction would be observable. However, 
without definitive results as to the mechanism of biliary obstruction, it is difficult to fully 
define the requirement of Notch signaling in the adult obstructive phenotype.   
Within this chapter, I have begun to investigate the underlying mechanism of biliary 
obstruction as described in Chapter IV.  This investigation is two-fold; first in the discovery of 
the source of obstruction, and second into the precise requirement of Notch signaling in this 
phenotype. While at this juncture, I am unable to make irrefutable conclusions; I have 
outlined my future directions to further refine these conclusions in Chapter VI. 
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CHAPTER VI 
 
SUMMARY AND FUTURE DIRECTIONS  
 
 Hepatobiliary disease and in particular cholangiopathies are a prevalent health 
concern in the United States. While a variety of insults, both genetic and exogenous, can 
result in cholangiopathies, a common pathology is associated with all cholangiopathies. 
These pathologies include inflammation, cholestasis, fibrosis, and apoptosis (Strazzabosco 
et al., 2005). In particular, cholestasis, or the reduction in bile flow, is a very important 
clinical consideration. Cholestasis can result from impaired bile formation at the level of the 
hepatocytes, or defects in bile regulation or flow at the level of the cholangiocytes. As the 
diagnosis of cholangiopathies is the number one predictor of pediatric liver transplant and 
the number three predictor of adult liver transplant (Bogert and LaRusso, 2007), 
understanding the pathogenesis of the disease is critical for future therapeutics. 
 In particular, one genetic cholangiopathy to which much effort has been devoted is 
Alagille syndrome (AGS). Mutations in the Notch pathway are causative of AGS, thus 
providing a tool to study how bile duct morphogenesis is regulated. The bulk of my studies 
have been focused on defining the role of Notch signaling in the development and 
maintenance of biliary formation and structure.  
 Initially, I defined the cell-autonomous requirement of Notch signaling within the liver 
progenitor hepatoblast population for bile duct development and the formation of the biliary 
architecture. These results revealed the three-dimensional (3D) effect of genetic 
modulations in Notch signaling and demonstrated that the level of Notch signaling correlates 
with a dose-dependent reduction in peripheral branch density in IHBD resin casts. The 
underlying two-dimensional (2D) morphology suggests a threshold requirement for Notch 
signaling in cholangiocyte specification and bile duct formation; in the absence of all Notch 
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signaling, fewer cholangiocytes are specified, however when limited levels of Notch 
signaling remain, cholangiocytes are specified but cannot remodel. Together these results 
indicate that the level of Notch signaling contributes to the variable clinical severity of AGS 
patients. 
 To investigate the post-natal consequence of improper bile duct development, my 
studies transitioned into the examination of the adult phenotype as a result of chronic loss or 
gain of Notch signaling. The first observation of note was a reduction in the intact IHBD 
architecture with age in the complete absence of Notch signaling. These results were 
consistent with a progressive paucity described in AGS patients (Dahms et al., 1982), 
however I was surprised to determine that the loss of intact structure was not due to 
ductopenia. Instead, I have identified a progressive obstructive phenotype with the complete 
loss of Notch signaling. The source of this obstruction and the source of dysregulated 
signaling are the focus of my future investigations as discussed below. 
 Overall, the clinical outcome of AGS patients into adulthood has not been well 
described. Thus understanding the post-natal consequence of improper bile duct 
development is critical to predict the outcome of adult AGS patients. Further, my results 
suggest that the progressive obstructive phenotype is independent of a direct requirement 
for Notch signaling. Thus, I have defined a general model of acquired cholestasis that can 
be utilized to identify new therapeutics and test the effectiveness of current therapeutics. 
Currently, the most common model to study obstructive cholestasis is the bile duct ligation 
(BDL) model. This model is generated by the surgical constriction of the common bile duct, 
thus mechanically disrupting bile flow out of the liver. As this model utilizes a physically 
imposed constriction, it cannot be used to identify new therapeutics, as the obstruction could 
not be relieved by a therapeutic. Thus, the further characterization of the progressive 
obstructive mouse model is critical to define a non-surgical model of general cholestasis.  
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Future Directions 
 
Identification of Obstructive Material 
 The future directions of this work include first and foremost the identification of the 
source of obstruction. As outlined in Chapter V, I hypothesize that the obstructive material is 
either improperly formed bile or cellular debris. I have ruled out the possibility that 
hepatocyte defects contribute to improper bile formation. However, it remains possible that 
the cholangiocytes are unable to generate an osmotic gradient and control the water content 
of the bile. As this regulation is intimately tied to the presence and proper function of 
cholangiocyte cilia, I will examine the mutant cholangiocytes for cilia defects. This approach 
will be two fold; first I will quantitate the number and length of cholangiocyte cilia in control 
and RBP KO mice. Second, a collaborator in Australia, Alessandra Warren, is performing 
scanning electron microscopy (SEM) on control and RBP KO liver tissue. I anticipate being 
able to characterize any cilia defects by the coordinated effort of these two approaches. 
 The other potential source of obstructive material is cellular debris as a result of 
increased cholangiocyte turnover. To investigate this possibility, I plan to collect bile by 
fasting mice for four hours and collecting the bile accumulating in the gallbladder. I will then 
cytospin the bile and stain for DNA content. While bile collection by this method is not ideal, 
as I have no evidence that cellular debris would enter the gallbladder, the other method by 
which to collect bile requires a non-survival surgery, in which animals are under anesthesia 
for extended periods of time with a catheter attached to the common bile duct to collect bile, 
which we are not approved to perform at this time. 
 Together, I anticipate these experiments will reveal the source of the biliary 
obstruction. However, a third option is to perform imaging mass spectrometry on the 
obstruction as identified by tracing the fluorescent resin. Unfortunately due to the harsh 
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nature by which the tissue is treated to identify the obstruction, and the size of the 
obstruction, I am unsure how much information this approach will be able to provide. 
 
Acute Requirement of Notch Signaling 
 The second immediate future direction is to further define the role of Notch signaling 
within the adult cholangiocyte. My attempt to address this question in vivo by cholangiocyte-
specific deletion of RBP-J in the adult was disappointing due to off-target skin defects. Thus, 
to further refine the acute role of Notch signaling in vivo, I have undertaken the analysis of a 
mouse model that both activates and removes Notch signaling within the hepatoblast. By 
both activating and removing Notch signaling, this allows cholangiocytes to be specified and 
remodeled, but subsequently cannot utilize Notch signaling. My initial characterizations of 
this model are described in Appendix C. At this junction, I can confirm that bile ducts are 
formed, but in depth analysis remains to be completed.  
 To supplement the rather unconventional in vivo approach, I will also address the 
requirement of Notch signaling in vitro in cultured cholangiocytes. I have successfully 
implemented a cholangiocyte isolation technique in our laboratory (Please refer to Appendix 
F). This isolation technique allows me to culture, not only single cells, but also intrahepatic 
bile duct units (IHBUs) (Cho et al., 2001). I will culture adult RBPflox/flox cholangiocytes and 
IHBUs with or without exogenous Cre. An alternative approach is to culture isolated 
RBP∆K19 cholangiocytes with or without 4-Hydroxytestosterone (4-OHT) to induce 
recombination. In single cell cultures, I will analyze proliferation and apoptosis to determine 
the role of RBP-J in adult cholangiocyte turnover. In IHBU cultures, I will analyze the ability 
of cholangiocytes to respond to exogenous secretin; the response will be monitored by the 
luminal expansion after treatment as previously described (Cho et al., 2001). This approach 
assumes a functional defect in the ability of RBP KO cholangiocytes to regulate the aqueous 
content of the bile. 
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 Lastly, I plan to use these isolations to define global changes in gene expression 
within cholangiocytes. I will isolate cholangiocytes from P60 and P120 control and RBP KO 
mice, isolate the mRNA and perform RNA sequencing on the samples. This experiment will 
allow me to identify gene expression changes between control and RBP KO cholangiocytes, 
as well as any changes that may occur as the cholestatic phenotype progresses in RBP KO 
mice. I will also be able to use RNA sequencing to assess the gene expression changes in 
cultured adult cholangiocytes in which RBP-J has been acutely removed. The use of RNA 
sequencing allows characterization of all transcripts and avoids the limitations imposed by 
microarray technology which only asseses a subset of transcripts. Comparison of the 
expression profiles of P120 RBP KO cholangiocytes and P120 cultured cholangiocytes with 
acute loss of RBP-J will allow me to identify the acute changes in gene expression in 
cholangiocytes upon loss of Notch signaling. As mentioned in Chapter V, it remains possible 
that the progressive cholestatic phenotype due to chronic loss of Notch signaling results in 
improper lineage restriction of cholangiocytes. Thus RNA sequencing will allow me to 
globally address some of questions as to cholangiocyte identity and the acute requirement 
of Notch signaling by analyzing specific transcripts that are over- or under-represented in 
RBP KO cholangiocytes as compared to control. A caveat of this approach is that the 
heterogeneity of the cholangiocyte population, both in terms of hilar and peripheral cells as 
well as potential intra-ductal heterogeneity, is lost in this pooled analysis. Therefore, I may 
isolate cholangiocytes based on size or DBA-positivity to determine the difference in RNA 
profile within the heterogeneous population. 
 The coordination of these three approaches will allow me to determine the acute 
requirement of Notch signaling within adult cholangiocytes. If my preliminary results are 
correct, and the progressive obstruction is not due to an adult requirement of Notch 
signaling within cholangiocytes, then I will have defined a non-surgical model of progressive 
obstructive cholestasis. 
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Inflammatory-mediated Cholangiopathies 
 Another predominant finding in cholangiopathies is inflammation. In RBP KO mice, I 
observe hilar inflammation beginning at P15 and persisting throughout the life of the mice 
(Please refer to Appendix B). The inflammation is perplexing, as it is only observed at hilar 
ducts, which are completely formed, although tortuous (based on 2D analysis of 
cytokeratin19 expression), and patterned normally (based on 3D analysis of IHBD resin 
casts) in P120 RBP KO mice. Therefore, I am interested in pursuing the question of how 
inflammation contributes to cholestatic liver disease. Two future directions exist within this 
project; first to define the origin and identity of the inflammatory cells, and second to define 
the physiological consequence of inflammation. 
The origin and identity of the inflammatory cells has been the subject of some 
investigation by myself. As inflammation is observed early and persists, the source of the 
immune cells could be attributed to improper maintenance of a hematopoietic 
stem/progenitor cell niche or persistent homing of immune cells in response to cholestasis. 
To address the possibility that RBP KO mice improperly maintain a hematopoietic 
stem/progenitor cell niche, I isolated non-parenchymal cells and assessed their ability to 
form colonies in methylcellulose cultures. Colony formation in methylcellulose cultures 
indicates the presence of a myeloid stem/progenitor cell. In RBP KO methylcellulose 
cultures of non-parenchymal cells, there was no statistical difference in the number of 
colonies formed compared to control. This suggests that the observed inflammatory cells in 
tissue section are not due to the maintenance of a hematopoietic stem/progenitor cell niche. 
Thus, my results suggest that inflammatory cells observed in RBP KO mice are due to a 
homing of immune cells into the liver as a result of liver injury. To confirm this possibility, I 
have undertaken bone marrow transplants of GFP-labeled bone marrow cells into sub-lethal 
irradiated RBP KO mice. I will assess the ability of GFP-positive immune cells to home to 
the liver at 1 week and 4 weeks post-transplant.  
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The effect of inflammation on the progression of cholestatic liver disease has been 
minimally documented. For example, one study determined that inflammatory cells modulate 
the expression of hepatocyte transporters leading to improper bile formation and 
subsequent obstruction in a mouse model of biliary atresia (Yang et al., 2009). In this study, 
transporters were down-regulated as a consequence of inflammation. In contrast, RBP KO 
up-regulate hepatocyte transporter expression, suggesting the potential for an alternative 
influence of inflammation in cholestasis.  
To further address the role of inflammation in the RBP KO cholestatic phenotype, I 
plan to assess the levels of common inflammatory cytokines (i.e. TNF-alpha, IL6) in whole 
liver mRNA from control and RBP KO mice. Upon determination of the increase in an 
inflammatory cytokine, I will exogenously add that cytokine to cultures of wild-type 
cholangiocytes and assess the effects on proliferation, apoptosis, and secretion. 
Additionally, I will attempt to co-culture wild-type cholangiocytes with isolated wild-type or 
RBP KO non-parenchymal cells and assess the effects on proliferation, apoptosis and 
secretion.  
At this juncture, the specific identity of immune cells, whether macrophages, 
monocytes, etc., is unknown. I have examined markers of individual hematopoietic cell fates 
by immunohistochemistry, however the staining was either negative or did not work for 
technical reasons. Thus another future direction is to define the specific cell type, isolate by 
fluorescence-activated cell sorting (FACS) and co-culture specific immune cell types with the 
isolated cholangiocytes. Unfortunately a caveat of this study is that the majority of antibodies 
that recognize subsets of hematopoietic cells specifically recognize cells from the C57/B6 
strain background mice, and our mice are on a CD1 outbred strain background. Therefore 
identification of specific cell types requires back-crossing onto a C57/B6 strain background. I 
have performed cytospins of non-parenchymal liver cells and determined a general increase 
in all cell types based on morphology, however immunofluorescent confirmation of this has 
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been limited due to the specificity of antibodies. Therefore a future direction, and future 
project, is to define the role of inflammation in the RBP KO model of obstructive cholestasis. 
 
Therapeutic Screens 
 The RBP KO model provides many interesting future directions in terms of 
developing therapeutics. As mentioned in the introduction, the most prevalent treatment for 
cholestasis is the administration of bile acid binding resin or secondary bile acids. Therefore, 
an important next step is to administer cholestyramine (a bile acid binding resin) or UDCA (a 
secondary bile acid) to RBP KO mice and assess by resin casting whether these 
therapeutics relieve the obstruction. Interestingly, the mechanisms by which cholestyramine 
and UDCA alleviate cholestasis are not well understood. Thus a well-characterized model of 
progressive obstructive cholestatic liver disease such as the RBP KO will be useful not only 
to identify how current therapeutics are mediating therapeutic benefits, but also to identify 
similar or completely different drugs that may be used to alleviate biliary obstruction.  
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 APPENDIX A 
 
TIMING AND EXTENT OF GENE DELETION BY THE ALBUMIN-CRE TRANSGENE  
 
Introduction 
As discussed in the Introduction, there is a deficiency of Cre lines that mediate 
specific recombination of loxP sites within the liver (Please refer to Introduction: Molecular 
Cue for Bile Duct Development, Notch Signaling in Cholangiocyte Development: the Signal-
Receiving Cell). Thus the issue of timing and extent of gene deletion is very important for 
the interpretation of experimental results. I have made use of the Albumin-Cre (Alb-Cre) 
transgene to generate mice with chronic deletion or activation of Notch signaling. Alb-Cre 
was originally designed to facilitate gene recombination within the adult hepatocytes (Postic 
et al., 1999). The initial report investigating recombination of the glucokinase locus, revealed 
by Southern Blot analysis, to quantify gene recombination, that full recombination (90%) did 
not occur until 6 weeks of age, with 40% recombination at P1 (Postic and Magnuson, 2000). 
However as this analysis was performed on whole liver genomic DNA from C57/Bl6 strain 
background mice, it is impossible to determine the level of recombination specifically in the 
liver epithelial lineage. Thus my further characterization of this Cre line is discussed within 
this appendix. 
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Results 
 Timing and extent of deletion mediated by Alb-Cre was first assessed using the 
ROSA26-LacZ reporter (R26R). In this mouse model, the beta-galactosidase gene preceded 
by a floxed STOP cassette is knocked-in to the ROSA26 locus (Soriano, 1999). Upon Cre 
expression, the STOP cassette is deleted by permanent recombination of the genetic locus, 
and beta-galactosidase is expressed. This technique permanently labels cells expressing 
the Cre and their progeny. Using this approach, Alb-Cre is expressed in the majority of 
hepatoblasts at E16.5 (Figure  A.1 A). To further confirm the expression within hepatoblasts, 
I analyzed P30 tissue, and identified lineage labeled cells within the bile duct (Figure A.1 B). 
As Albumin is not expressed in cholangiocytes, recombination must have occurred in the 
hepatoblast for expression in the adult cholangiocytes. These results are in contrast to the 
original characterization that suggests gene recombination is occurring only in the 
hepatocyte. 
 While R26R expression serves as an indicator for the timing of Cre expression, the 
LacZ reporter expression is not necessarily directly correlative to other genetic loci. 
Therefore, I first analyzed the recombination of the Notch1 and Notch2 loci in P120 control 
and N1/N2 DKO cholangiocytes. I used laser capture microdissection (LCM) to capture hilar 
and peripheral ducts as identified by morphology (Figure A.2 A-D). DNA was isolated from 
the captured tissue and analyzed for the amplification product resulting from the recombined 
Notch1 or Notch2 genomic loci (quantitative PCR analysis performed by Kari Huppert). This 
analysis revealed that significantly more recombination of both the Notch1 and Notch2 loci 
in both hilar and peripheral regions as compared to control (Figure A.2 E-F). These data 
further support the expression of the Alb-Cre transgene in the hepatoblast population prior 
to the bi-potential decision to differentiate into cholangiocytes or hepatocytes. 
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Figure A.1 Alb-Cre-mediated recombination results in hepatoblast-specific 
recombination.  Panels demonstrate X-gal detection of Cre-inducted recombination of the 
ROSA26-LacZ reporter allele in frozen sections with a nuclear fast red counterstain. (A) At 
E16, hepatoblasts (arrow) stain blue indicating recombination of the reporter. Cells that are 
not X-gal positive are hematopoietic cells, as the liver is the major site of hematopoiesis at 
this age. (B) At P30, the two derivatives of the hepatoblast lineage, hepatocytes (arrow) and 
cholangiocytes (indicated as BD), are X-gal positive. Cells that are not X-gal positive are 
non-hepatoblast-derived, forming hepatic arteries, portal veins, mesenchymal cells 
surrounding the portal triad or the endothelial and stellate cells in the parenchyma. PV – 
portal vein, BD – bile duct. Scale bars = 50 µm. 
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Figure A.2 Laser capture microdissection of P120 liver. Paraffin sections from the left 
lobe of control (Notch1flox/flox ;Notch2flox/flox, A,C) and N1/N2 DKO (Alb-Cre;Notch1flox/flox 
;Notch2flox/flox, B,D) were rehydrated, hematoxylin and eosin stained, and dehydrated. Bile 
ducts, identified by morphology from hilum (A-B) and periphery (C-D) were dissected. (A-D) 
Representative tissue regions before and (A’-D’) after capture. Dotted lines indicated 
specific region of capture. DNA was isolated from capture tissue using the Picopure kit. 
Three slides of two mice per genotype were captured. (E-F) Quantiative genomic PCR 
results of Notch1 (E) and Notch2 (F) deletion at the hilum and periphery demonstrate 
significant deletion at both regions. Statistical analysis was performed using a one-way 
ANOVE with Tukey’s Multiple Comparison test. Error bars – standard error of the mean. 
*p<0.05, **p<0.01. 
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 LCM analysis could not be used to assess the recombination of the RBP-J locus, as 
peripheral ducts are too few. Instead, genomic recombination of the RBP-J was assessed 
by whole liver analysis.  Genomic DNA was isolated from at least three different mice per 
genotype (control [RBP-Jflox/flox] and RBP KO [Alb-Cre;RBP-Jflox/flox]) at E14, E15, and E16. 
Quantitiative PCR analysis was used to determine the amount of genomic recombination at 
the RBP-J locus compared to control (Figure A.3 A). Surprisingly, as early as E14, I can 
detect a significant level of recombination. The amount of recombination is progressively 
increased with age, however as this analysis was performed on whole liver DNA, the 
increase in recombination with age could be attributed to an decreased ratio of non-
epithelial cells in the liver. However, these results suggest that Albumin promoter-driven Cre 
is expressed even earlier than previously supposed. 
 To assess whether the adult cholangiocytes that compose patent bile ducts in RBP 
KO mice have experienced Cre expression, I crossed the RBP KO mice to the R26R-YFP 
reporter mice (Srinivas et al., 2001), and examined reporter expression at P60 and P120 
(Figure A.3 B-E). The lineage-traced YFP expression is observed in peripheral ducts at P60 
and P120 (Figure A.3 B,D). Interestingly in hilar ducts, a few cells have escaped 
recombination, however these cells are found at P60 and P120, and do not appear to 
preferentially expand with age (Figure A.3 B’,D’). Thus these results suggest that cells, 
which have expressed Cre in their lineage, compose the majority of adult cholangiocytes 
both in the peripheral and hilar ducts. 
 For NICD mice, the Notch1 intracellular domain preceded by a floxed STOP cassette 
and followed by an internal ribosomal entry site (IRES) GFP was knocked into the ROSA26 
locus (Murtaugh et al., 2003).  Monitoring the expression of the Notch1 intracellular domain 
in NICD mice was achieved by analyzing expression of the IRES-GFP. In NICD mice, GFP 
expression is observed at E16.5 at various levels in the majority of hepatoblasts (Figure A.4 
C). At P3, the expression of GFP can be detected in both ductal and parenchymal cells,  
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Figure A.3 Alb-Cre-mediated recombination of the RBP-J conditional allele. (A) 
Quantitative PCR analysis of genomic DNA isolated from whole liver at E14, E15 and E16. 
Whole liver analysis demonstrates that Cre-mediated recombination of the RBP-J locus 
begins at E14. (B-E) Co-immunfluorescence for GFP and cytokeratin19 in P60 and P120 
livers. (B,D) RBP KO mice without R26R-YFP reporter activity demonstrate no reactivity with 
the GFP antibody. (C,E) RBP KO mice with R26R-YFP demonstrate reporter expression in 
peripheral and hilar ducts. At P60 and P120, a small number of cells do not express reporter 
in hilar ducts, suggesting that these cells have escaped recombination (arrowhead). Non-
GFP-positive cells have not been observed in peripheral cytokeratin19-positive ductal calls. 
Scale bar = 50 µm. *p<0.05, **p<0.01. 
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Figure A.4 Alb-Cre-mediated recombination of the ROSA26Notch1 conditional allele. 
Immunofluorescent staining for GFP expression expressed from the ROSA26Notch1 internal 
ribosomal entry site. (A) E16.5 and (B) P3 control liver tissue demonstrates no GFP 
expression. (C) E16.5 and (D) P3 NICD liver tissue shows expression of GFP. Scale bar = 
100 µm. 
 
 
	   152	   	  
based on morphology (Figure A.4 D). Thus, in NICD mice, GFP-expression can be 
extrapolated to infer NICD expression by Alb-Cre-mediated recombination of the ROSA26 
locus, and can be identified as early as E16.5.  
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Discussion 
 Analysis of both reporter expression and specific loci recombination by Alb-Cre 
suggests efficient recombination by E16.5.  Thus timing of genomic recombination can be 
determined by these approaches. Unfortunately, I have not been able to examine the extent 
of specific recombination at early time points. Further, while I can demonstrate genomic 
recombination of the RBP-J locus as early as E14, the half-life of RBP-J messenger RNA 
and protein is currently unknown. The lack of antibodies for immunohistochemical analysis 
has hindered my ability to identify protein expression in the RBP KO mice. Therefore, the 
timing at which RBP-J protein is no longer present is currently unknown.  
 An additional caveat of these results is contribution of non-epithelial liver cells, which 
have not recombined the genetic loci, to expression levels. While LCM allowed me to focus 
more specifically on ductal regions, I cannot obtain single cell resolution due to the limits of 
the LCM equipment and the highly fibrous nature of the liver. Thus, I made various attempts 
to use fluorescence activated cell sorting (FACS) to isolate cholangiocytes. Unfortunately, a 
poor cholangiocyte cell yield (<0.3% in control) and poor cell quality after sorting has made 
FACS unfeasible. I have recently learned a cholangiocyte cell isolation technique based on 
magnetic cell sorting, which allows for a good cell yield and the ability to culture after 
isolation (Please refer to Appendix F). For future experiments, I plan to isolate ductal cells 
and analyze both the recombination of the genetic loci as well as culture and troubleshoot 
antibodies. 
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Materials and Methods 
 
Beta-Galactosidase Activity and Immunofluorescence 
 Liver tissue was fixed for 4 to 6 hours at 4ºC in 4% formaldehyde. To detect 
ROSA26-LacZ reporter activity, tissue was washed in PBS, equilibrated in 30% sucrose, 
and embedded in optimal cutting temperature (OCT) compound. Frozen, 10 µm sections 
were incubated with 2 mM MgCl2, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 0.1% Triton-X 100, and 1 mg/ml X-gal in PBS, and color development was 
monitored. Sections were post-fixed and counterstained with nuclear fast red. 
 For the detection of the ROSA26-YFP reporter in RBP KO mice, tissue was fixed at 
4ºC overnight in 4% paraformaldehyde. Paraffin-embedded tissue was sectioned at 6 µm, 
and subjected to antigen retrieval with 100 mM Tris, pH 10 at 60ºC overnight. Slides were 
incubated overnight at 4ºC with rat-anti-cytokeratin19 (1:250; DSHB) and rabbit-anti-GFP 
(1:500; Novus) in a 1% BSA, 0.2% nonfat dry milk, and 0.3% Triton-X 100 in PBS. Slides 
were incubated overnight in the appropriate secondaries and incubated in bis-benzamide to 
label DNA.  
 For the detection of the IRES GFP expression in NICD mice, tissue was fixed at 4ºC 
overnight in 4% formaldehyde, equilibrated in 30% sucrose and embedded in OCT. Frozen, 
10 µm sections were incubated overnight at 4ºC in chicken-anti-GFP (1:500; Abcam) in 1% 
BSA. Slides were then incubated overnight at 4ºC in anti-chicken-biotin secondary (1:500; 
Jackson Immunoresearch), followed by a 1 hour incubation with avidin-Cy3 (1:500; Jackson 
Immuno). Bis-benzamide was used to label DNA. Images were acquired using a Zeiss 
Axioplan2 microscope and QImaging RETIGA EXi camera. 
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Laser Capture Microdissection 
 Paraffin sections from the left lobe of control (Notch1flox/flox;Notch2flox/flox) and N1/N2 
DKO (Alb-Cre;Notch1flox/flox;Notch2flox/flox) mice were sectioned, placed on non-charged glass 
slides and allowed to air dry overnight. Slides were hematoxylin and eosin (H&E) stained; 
slides were rehydrated (2 x 5’ xylene, 2 x 5’ 100% ethanol, 1 x 5’ 95% ethanol), stained (3 
quick washes in distilled water, 5 dips in hematoxylin, 3 quick washes in distilled water, 5 
dips in eosin), and dehydrated (1 x 5’ 95% ethanol, 2 x 5’ 100% ethanol, 2 x 5’ xylene). 
Slides were placed in a vacuum bell jar until capture.  An average of 84 hilar and 164 
peripheral regions were captured per mouse and pooled for quantitative PCR analysis. 
Average capture area was 33.3 µm and 36.2 µm for hilum and periphery, respectively.  
 
Quantitative PCR analysis 
For laser capture microdissection (LCM; Veritas Microdissection System, CapSure 
Macro LCM Cap) hilar and peripheral ducts were dissected from three slides per mouse and 
two mice per genotype.  DNA was isolated using the Picopure kit (Arcturus). For detection of 
RBP-J deletion, I isolated genomic DNA from whole liver. 25ng of total DNA was used for 
quantitative PCR analysis using ABI Prism 7900. Primers used to detect deletion are 
identified in Table A.1. 
 
Statistical Analysis 
 Genomic recombination in the N1/N2 DKO mice was subjected to a one-way ANOVA 
with Tukey’s Multiple Comparison Test. Genomic recombination in the RBP KO mice was 
subjected a Students t-test. In both instances, a P-value of <0.05 was considered significant. 
	   156	   	  
 
Primer Forward (5’ to 3’) Reverse (5’ to 3’) 
Notch1 Del TGG CCT GCC TGT CTG GAA CAA CAG TTC AGG ACC CTT GCC TCA GTT CAA ACA CAA GAT ACG 
Notch2 Del TCA TCA CGC TCA GCT AGA GTG TTG TTC TTC ATA ACG CTA AAC GTG CAC TGG AG 
RBP-J Del GAG ATA GAC CTT GGT TTG TTG CCA CTG TTG TGA ACT GGC GT 
RBP-J Ref GCC ACT CCA TGT CCA AAA GA GCA AGT TAT AGC TCA GAA CAG CAA 
Beta-actin TTC CTT CTT GGG TAT GGA AT GAG CAA TGA TCT TGA TCT TC 
 
Table A.1 Primers for quantitative genomic PCR. Primers used within this appendix are 
described. 
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APPENDIX B 
 
CHARACTERIZATION OF THE IMMUNE RESPONSE IN RBP KO MICE 
 
Introduction 
 The liver can be considered an important component of the immune system, as it 
hosts the largest population of tissue macrophages (Kupffer cells), dendritic cells, T 
lymphocytes, natural killer and natural killer T cells in the body (Szabo et al., 2007). All of 
these components, with the exception of T lymphocytes, are components of the innate 
immune system, and recognize invading pathogens. In cholangiopathies, a primary 
pathology and indicator for the progression of cholestasis is the presence of inflammation. 
 Understanding how inflammation contributes to the progression of cholestasis is an 
area of much study. The majority of work to determine the contribution of inflammation to 
cholestasis has focused on models with defective hepatocellular transport mechanisms or 
biliary atresia (Yang et al., 2009; Kosters and Karpen, 2010). Specifically, it has been well 
defined in both types of cholangiopathies that inflammation leads to the down-regulation of 
hepatocyte-specific bile acid metabolism pathway components, and subsequently a 
reduction in bile formation (Yang et al., 2009; Kosters and Karpen, 2010). Despite these 
recent advances, the effect of inflammation on cholangiocytes has not been investigated.   
 In the instance of chronic loss of Notch signaling (RBP KO), I observe an 
inflammatory response beginning at P15 and persisting through the lifespan of the mice. 
Interestingly, this inflammation is concentrated around hilar ducts, which have no significant 
alterations in IHBD patterning (Please refer to Chapter IV, Figure 4.12). Thus in this 
Appendix, I will describe my attempts to characterize the inflammatory response and 
consequence in RBP KO mice. 
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Results 
 RBP KO mice demonstrate an increase in non-hepatocyte, non-ductal cells at hilar 
portal triads visible at P15 and persisting until P120 (Figure B.1). At P15, the extra cells in 
RBP KO mice are concentrated within the confines of the portal triad (Figure B.1 B), yet by 
P120, they have also extended out into the parenchyma (Figure B.1 D). The identity of these 
cells could be either mesenchymal or immune in nature.  
To investigate the possibility that these cells are an expansion of the mesenchymal 
cell compartment, I stained control and RBP KO tissue at P15 and P30 for desmin (Figure 
B.2). In the liver, desmin has been demonstrated to label three populations of fetal 
mesenchymal cells: hepatic stellate cells in the parenchyma, perivascular mesenchymal 
cells and submesothelial cells (Asahina et al., 2009). In control tissue, I can detect 
perivascular desmin-positive cells, however parenchymal hepatic stellate cells are only 
weakly visualized (Figure B.2 A-B). In RBP KO tissue, there is an increase in desmin-
positive cells, however they are still concentrated periportally and reveal an increase in 
hepatic artery formation at P30 (Figure B.2 C-D). Therefore, an increase in the 
mesenchymal cell compartment is not sufficient to account for the increased non-
hepatocyte, non-ductal cells in RBP KO mice. This result is consistent with the observation 
that RBP KO mice do not demonstrate an increase in fibrosis compared to control (Please 
refer to Chapter V, Figure 5.1). 
To investigate the hypothesis that the increased non-hepatocyte, non-ductal cells in 
RBP KO mice are due to immune cells, I stained P15 control and RBP KO mice tissue with 
for CD45 (Figure B.3). CD45 is a protein tyrosine kinase found in all nucleated 
hematopoietic cells, therefore, not erythrocytes or platelets. In control tissue at P15, there 
are a few CD45-positive cells adjacent to the hilar bile ducts (Figure B.3 A) as expected due 
to the liver’s general role in immunity. In contrast, in P15 RBP KO tissue, there is an  
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Figure B.1 RBP KO mice have an increase in cells with a high nucleo-cytoplasmic 
ratio at the portal vein visible at P15 and persisting until P120. Paraffin-embedded 
tissue from control and RPB KO mice at P15 and P120 was hematoxylin and eosin stained. 
(A-B) At P15, control tissue demonstrates a small amount of non-hepatocyte, non-ductal 
cells within the mesenchymal space. Conversely, RBP KO mice demonstrate an expansion 
of these cells. Area denoted by yellow dotted line. (C-D) at P120, there is still minimal non-
hepatocyte, non-ductal cells within the control tissue, however these cells have persisted in 
RBP KO mice and now extend into the parenchyma (Arrows). PV – portal vein, BD – bile 
duct, HA – hepatic artery. Scale bar = 50 µm. 
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Figure B.2 Increased cells with a high nucleo-cytoplasmic ratio in RBP KO mice are 
not due to an expansion of mesenchymal cells. Paraffin-embedded tissue from control 
and RBP KO mice at P15 and P30 was immunostained for desmin to mark mesenchymal 
cells. (A-B) Desmin-positive cells, brown, in control at P15 and P30 specifically surround the 
hepatic artery (HA). (C-D) In RBP KO mice, despite the expansion of non-hepatocyte, non-
ductal cells, there is not an increase in desmin-positive cells. PV – portal vein, BD – bile 
duct, HA – hepatic artery. Arrows – desmin-positive cells surrounding hepatic arteries. Scale 
bar = 50 µm. 
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Figure B.3 Increased cells with a high nucleo-cytoplasmic ratio in RBP KO mice are 
due to immune cells. Paraffin-embedded tissue from control and RBP KO mice at P15 was 
immunostained for CD45 to generally mark cells from the hematopoietic lineage. (A) Control 
tissue demonstrates a few immune cells. (B) RBP KO tissue demonstrates a significant 
expansion in CD45-positive cells. PV – portal vein, BD – bile duct. Arrows – CD45-positive 
cells. Scale bar = 50 µm. 
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qualitative increase in the number of CD45-positive cells in the regions adjacent to hilar bile 
ducts (Figure B.3 B). These results suggest the increase in non-hepatocyte, non-ductal cells 
at the hilum in RBP KO mice is due to immune cells. 
To characterize the immune response as innate or adaptive immunity, I undertook a 
series of approaches. First, I attempted to identify the specific type of immune cells by 
immunofluorescent techniques. I stained P30 control and RBP KO tissue with B220 to 
identify B cells, a component of adaptive immunity (Figure B.4). While B220-positive cells 
were readily identifiable in both control and RBP KO livers, there was no apparent increase 
in the number of B220-positive cells in RBP KO mice. Thus an increase in B cells is not 
sufficient to explain the increase in immune cells. In an attempt to further identify the 
immune cells with immunofluescence, I stained for markers of T-cells (CD4), monocytes 
(CD11b) and macrophages (F4/80). Unfortunately, I have been unable to work out staining 
conditions for these antibodies. A caveat of this approach is that most antibodies that have 
been raised against hematopoietic cells from C57/B6 strain background mice and may not 
cross-react with CD1 strain background mice. 
A different approach that I used to identify the type of immune cells was to isolate 
cells <70 µm in size, cytospin and count the cells based on morphology (Figure B.5). Using 
this approach I can identify lymphocytes, neutrophils, eosinophils, monocytes, macrophages 
and promonocytes. Analysis of P9 control (n=2) and RBP KO (n=2) mice revealed that there 
was no change in the contribution of each cell type (Figure B.5 A), but instead there was an 
overall increase in the number of immune cells identified (Figure B.5 B). These results 
suggest that the immune infiltrate is composed of cells types from all lineages. A caveat of 
this approach is that I preformed analysis on P9 mice, and the immune response is more 
obvious later in development. 
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Figure B.4 RBP KO immune infiltration is not due to increased B cells. Paraffin-
embedded tissue from control and RBP KO mice at P30 was immunostained for B220 to 
mark B cells. (A) Control liver tissue demonstrates a few B220-positive cells (Red). (B) RBP 
KO mice demonstrate a few B220-positive cells, but not enough to account for the total 
increase in immune cells. (C) Spleen was stained for B220 as a positive control (Red – 
B220, Green – red blood cell autofluorescence). PV – portal vein, BD – bile duct. Dotted line 
– boundary of non-hepatocyte tissue. Arrows – B220-positive cells. Scale bar = 50 µm. 
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Figure B.5 Cytospin analysis of P9 RBP KO mice reveals a general increase in 
immune cells. Non-parenchymal cells were isolated from P9 control and RBP KO livers, 
cytospun and analyzed for morphology.  (A) This technique allows identification of 
macrophages, monocytes, eosinophils, neutrophils, lymphocytes and promonocytes. The 
distribution of cells between control and RBP KO mice was not altered drastically. (B) The 
total number of immune cells was increased in RBP KO mice compared to control.  
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While it was originally presumed that the excess cells in RBP KO mice were a 
consequence of homing of immune cells to the liver, it remains possible that these cells are 
the result of improper maintenance of a hematopoietic stem/progenitor cell niche in the liver.  
The cytospin results suggesting a general increase in all types of immune cells supported 
this hypothesis. Therefore, to investigate the possibility that the immune cells are due to 
improper maintenance of a hematopoietic stem/progenitor cell niche, I isolated cells <70 µm 
in size from P15 control (n=5) and RBP KO (n=7) mice, and cultured the cells in 
methylcellulose to promote colony formation (Figure B.6). Using this approach, there was no 
significant difference in the number of colonies formed between control and RBP KO mice, 
thus suggesting the immune cells observed in RBP KO mice are not due to improper 
maintenance of a hematopoietic stem/progenitor cell niche. 
Finally, I wanted to address whether the immune response was local or systemic. A 
systemic immune response would be identifiable by peripheral blood analysis. Therefore, I 
analyzed peripheral blood from P120 control (n= 9) and RBP KO (n=9) mice (Figure B.7). At 
P120, there is no difference in the amount of white blood cells (WBCs), suggesting that RBP 
KO mice do not have a systemic response. Lack of a systemic response, confirms localized 
inflammation, and an absence of infection.  
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Figure B.6 RBP KO immune cells are not hematopoietic stem/progenitor cells. Non-
parenchymal cells were isolated from P15 control and RBP KO livers and cultured in 
methylcellulose to promote colony formation. Analysis of the number of colonies after 13 
days of culture reveals no difference in the number of colonies formed. Horizonal black line 
– average number of colonies. 
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Figure B.7 The increased inflammatory cells in RBP KO mice do not result in a 
systemic response. Complete blood count (CBC) analysis of peripheral blood from P120 
control and RBP KO mice reveals no difference in the number of while blood cells (WBC).  
 
	   168	   	  
Discussion 
 At this juncture, I have determined that the increased non-hepatocyte, non-ductal 
cells in RBP KO mice are due to the presence of immune cells.  In investigating the identity 
of these immune cells, I have determined that there is an increase in CD45-positive 
hematopoietic cells, but not due to improper maintenance of hematopoietic stem/progenitor 
cells. Interestingly, in cytospin analysis, it appears that all types of immune cells are 
increased in RBP KO mice compared with control (Figure B.5), however it is important to 
note that this analysis was done at P9 and merits being done again at later time points.  
Antibody identification of specific types of immune cells has proven difficult, as the 
antibodies are more often used for flow cytometry, and raised against C57/Bl6 strain 
background mice.   
 To determine if cells are continually homing to the liver in response to injury, I have 
performed bone marrow transplants of GFP-labeled bone marrow into sub-lethal irradiated 
P120 RBP KO mice. The results of this experiment are pending, but will reveal the nature of 
the immune response, whether a continual homing from the bone marrow, or a tissue-
specific response. Further, chronic inflammation usually results in the transition from innate 
immune to adaptive immune responses (i.e. B and T cells) and the simultaneous destruction 
and healing of the offending tissue. Interestingly, I cannot observe the shift to adaptive 
immune, as assessed by the presence of B cells, and the consequence of inflammation on 
the ductal cells is not clear. I have, previously in this dissertation, suggested that RBP KO 
cholangiocytes increase their turnover with age (Please refer to Chapter IV, Figure 4.8), and 
I hypothesize that inflammation contributes to this phenotype. Therefore, in the future, I will 
analyze the inflammatory response and consequence on ductal cells in depth (Please refer 
to Chapter VI, Future Directions: Inflammatory-mediated Cholangiopathies). 
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Materials and Methods 
 
Histology, Immunohistochemistry and Immunofluorescence 
 Liver tissue was fixed in 4% paraformaldehyde overnight at 4ºC. Paraffin-embedded 
tissue was sectioned at 6 µm. Hematoxylin and eosin staining was performed by standard 
histotechnology techniques (Carson, 1990).  
 For Desmin antibody staining, slides were subjected to antigen retrieval with 100 mM 
Tris, pH 10, overnight at 60ºC. Sections were incubated in primary antibody, goat-anti-
desmin (1:100; Santa Cruz Biotechnology) overnight at 4ºC. Sections were incubated at 
room temperature for 4 hours in anti-goat-biotin secondary (1:1000; Jackson 
Immunoresearch), followed by incubation in Vectashield ABC reagent and developed with 
DAB substrate. 
 For CD45 antibody staining, freshly cut slides were subjected to antigen retrieval with 
10 mM sodium citrate, pH 6 for 20 min in a rice cooker. Slides were incubated in primary 
antibody, anti-CD45-biotin (1:200; Biolegend) overnight at 4ºC. Slides were incubated at 
room temperature for 4 hours in streptavidin-Cy3 (1:300; Jackson Immunoresearch), 
followed by incubated in bis-benzamide.  
 For B220 antibody staining, freshly cut slides were incubated in primary antibody, 
anti-B220-biotin (1:50; aliquot courtesy of Dr. Sandra Zinkel) at room temperature for 1 hour. 
Slides were incubated at room temperature for 4 hours in streptavidin-Cy3, and then 
incubated in bis-benzamide. 
 
Cytospins 
 For cytospin analysis, livers were removed from P9 mice and chopped coarsely in 
PBS with a razor blade. Livers were subsequently passed 6 times through a 21-gauge 
needle, and filtered through 70 µm cell strainers. Dissociated liver was placed in a 1.7 ml 
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Eppendorf tube and centrifuged for 5 min at 12000 rpm to pellet cells. Supernatant was 
discarded and cells were resuspended in 1 ml of red blood cell lysis buffer (Qiagen EL 
Buffer). After 5 min, total volume was brought up to 15 ml with water, and samples 
centrifuged at 12000 rpm for 5 min.  Approximately 25,000 cells were resuspended in 1 ml 
of water and loaded into cytospin chambers. Cells were spun at 800 rpm for 5 mins. Slides 
were stained using a Hema3 Stat Pack (Fisher), and counted using the Atlas of Mouse 
Hematopathology as a reference guide (Fredrickson and Harris, 2000). 
 
Methylcellulose Cultures 
 Non-parenchymal cells were isolated as described for cytospins. After counting, cells 
were resuspended in Dulbecco’s Modified Eagle Medium (DMEM). Cells were mixed with 
1.5 ml of methylcellulose optimized for the detection and quantification of erythroid 
progenitors, granulocyte-monocyte progenitors, and multi-potent granulocyte, erythroid, 
macrophage, megakaryocyte progenitors (MethoCult GF Stem Cell Technologies), and 
plated in triplicate. Colonies were counted at 13 day after beginning culture, and a colony 
was considered to be greater than 32 cells. 
 
Complete Blood Count (CBC) 
 Blood was collected postmortem using a cardiac stick method. Whole blood was 
placed in tubes containing EDTA to prevent coagulation (Microtainer Tubes, Becton 
Dickinson). Samples were loaded into a Hemavet 950 CBC machine for complete blood 
analysis. 
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APPENDIX C 
 
CHARACTERIZATION OF MICE WITH CHRONIC ACTIVATION AND DELETION OF 
NOTCH SIGNALING 
 
Introduction 
 To address the requirement of Notch signaling subsequent to bile duct specification 
and remodeling, I analyzed a Cre line that allowed for gene recombination within the adult 
cholangiocytes (RBP∆K19). Unfortunately, analysis of this mouse line was limited due to the 
development of keratinous cysts (Please refer to Chapter V: Post-natal cholangiocyte 
function does not require Notch signaling).  
An alternative approach to analyze the requirement of Notch signaling subsequent to 
the initial developmental requirement is to use the developmental Alb-Cre to both activate 
and delete Notch signaling (NICD/RBP). This mouse model was recently described in a 
model of osteogenesis, where it was used to determine that the effects of activating Notch 
signaling were solely dependent on RBP-J-mediated gene transcription (Tao et al., 2010). 
As Alb-Cre mediates deletion after the initial cholangiocyte specification and remodeling at 
the hilum, this provides a time period during which the Notch1 intracellular domain (NICD) is 
expressed and latent messenger RNA (mRNA) and protein expression of RBP-J allow for 
Notch signaling to be propagated (Figure C.1). When RBP-J transcript and protein turnover 
is complete, the ability for the NICD to signal via the canonical pathway is removed. Thus 
subsequent to the initial specification and remodeling of bile ducts, Notch signaling is 
removed.  
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Figure C.1 NICD/RBP mice experience a period of Notch activation followed by an 
inability to signal. This schematic represents the predicted expression period of 
mRNA/protein in NICD/RBP mice. As Alb-Cre mediates gene recombination after the initial 
cell fate decisions, the hepatoblasts will experience Normal Notch Signaling until the Cre is 
expressed. After Cre expression (vertical red dotted line), the RBP-J mRNA and protein 
levels will slowly taper off (green line), dependent on the half-life of the transcript and 
protein. Conversely, at the time of recombination, the NICD mRNA and protein levels wills 
slowly increase as the gene is expressed (red line). Thus for a period of time, the NICD/RBP 
mice have an increase in Notch signaling, followed by an inability to signal once the RBP-J 
transcript and protein levels cease, No Canonical Notch Signaling. 
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Results 
 To assess the effects of both activating and deleting Notch signaling within the 
hepatoblasts, I analyzed the alterations in morphology of cytokeratin19-positive cells in 
NICD/RBP mice at P15, P30, P60 and P120 (Figure C.2-C.3). At P15 there is an increase in 
the number of cytokeratin-positive cells at the periphery (Figure C.2 E), however the excess 
cells are limited as compared to NICD tissue (Please refer to Chapter III, Figure 3.5). 
Interestingly, the excess ductal cells are maintained at P30, P60 and P120 and form luminal 
structures (Figure C.2 F-H). Conversely, at all ages hilar ducts demonstrate little change 
compared to control, with a few excess cytokeratin-positive cells noted (Figure C.3), but 
again significantly less than in NICD tissue (Please refer to Chapter III, Figure 3.6). While 
the excess of cholangiocytes does not change with age in the NICD/RBP mice, I have not 
performed quantitative analysis, either ductal counts or cytokeratin19-positive area by 
ARIOL analysis, to fully confirm this observation.  
Of note, is a significant level of focal inflammation in the periphery of NICD/RBP mice 
at P60 (Figure C.2 G-inset). The origin and consequence of this inflammation is not 
understood at this time. Also, it is not clear whether the inflammation is occurring at portal or 
central veins. Inflammation is usually noted at portal veins, however the lack of bile ducts in 
the region of inflammation suggests either central vein inflammation or immune-mediated 
destruction of bile ducts. Therefore further analysis is required to define this model. 
 Interestingly, liver function tests from 2-month to 4-month old mice reveal that 
NICD/RBP mice have a statistically significant increase in ALT and ALP levels as compared 
to control (Table C.1). However, it is important to note that the levels of ALT in the 
NICD/RBP mice are significantly lower than those in RBP KO (P<0.01), further supporting a 
reduced severity of phenotype. As more cholangiocytes are specified and bile ducts formed 
in the NICD/RBP mice as compared to RBP KO mice, the increased ALT levels in  
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Figure C.2 Morphological defects in cytokeratin19-positive cells in peripheral liver 
tissue with hepatoblast-specific deletion of RBP-J and activation of Notch1. Paraffin-
embedded sections from control (A-D) and NICD/RBP (E-H) tissue over a developmental 
time course was immunostained for cytokeratin19 to mark cholangiocytes and 
counterstained with Mayer’s hematoxylin. (A,E) At P15, NICD/RBP peripheral 
cholangiocytes are scattered within the parenchyma, and extra cells are observed. (B,F) At 
P30, there is an even more apparent increase in peripheral ductal cells, limited to regions 
directly surrounding the portal vein. (C,G) At P60, the excess ducts are maintained, however 
areas of severe inflammation are observed (G, inset). (D,H) At P120, the extra ducts are 
also maintained, but appear cystic and dilated. Scale bar = 50 µm. 
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Figure C.3 Morphological defects in cytokeratin19-positive cells in hilar liver tissue 
with hepatoblast-specific deletion of RBP-J and activation of Notch1. Paraffin-
embedded sections from control (A-D) and NICD/RBP (E-H) tissue over a developmental 
time course was immunostained for cytokeratin19 to mark cholangiocytes and 
counterstained with Mayer’s hematoxylin. (A,E) At P15, NICD/RBP hilar cholangiocytes are 
all incorporated into a ductal structure. (B,F) At P30, there a few excess cytokeratin19-
positive cells are observed in hilar regions. (C,G) At P60, the few excess cells are 
maintained. (D,H) At P120, the few extra ducts are maintained. Scale bar = 50 µm.  
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Table C.1 Serum chemistry analysis. Serum was obtained from control and NICD/RBP 
mice between 2-months and 4-months, and analyzed for alanine aminotransferase (ALT), 
total bilirubin (TB), and alkaline phosphatase (ALP). Values are mean (IU/L) + standard error 
of the mean. P values are calculated by a student t-test. *p<0.05, **p<0.01. 
 
 
 
Genotype n ALT n TB n ALP 
Control 40  57.5 + 5.5 37  1.2 + 0.1 29 8.421+1.197 
NICD/RBP 20 86.07 + 9.1 ** 16 0.6 + 0.1 16 17.30 + 4.8 * 
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NICD/RBP mice suggest a requirement for Notch signaling subsequent to the initial 
development.  
 To determine the effects on three-dimensional structure, and whether a progressive 
obstruction, as defined in the RBP KO mice, is also observed in NICD/RBP mice, I analyzed 
resin casts from P60 and P120 control and NICD/RBP mice (Figure C.4). At P60, NICD/RBP 
resin casts are reminiscent of NICD casts with an excess of branches (Figure C.4 A-C). 
Interestingly, the NICD/RBP casts do appear to lose branches at P120 (Figure C.4 D-F), 
however these resin casts have not been quantified by microCT.  
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Figure C.4 Three-dimensional resin casting of the biliary system reveals a role for 
Notch signaling to maintain the intact communicating IHBD (A-F) Representative 
images of the ventral surface of left lobe resin casts are shown at P60 and P120. (A,D) 
Control resin casts (n=2 and 7). (B,E) NICD resin casts demonstrate a duplication of the 
main branches and a general increase in branches (n=6 and 5). (C,F) NICD/RBP mice 
demontrate a duplication of the main branches and a general increase in branches at P60 
(n=1), however the branches are attenuated at P120 (n=2), suggesting an acute 
requirement for Notch signaling in the maintenance of IHBD structure. Scale bar = 2 mm. 
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Discussion 
 Initial characterization of the NICD/RBP mice reveals ductal morphology consistent 
with a window of Notch signaling in which specification and remodeling occur, albeit to a 
lesser extent than the NICD alone mice (Figure C.2-C.3). Excess ductal structures are 
limited to peripheral tissue, and do not visually alter morphology with age (Figure C.2-C.3). 
Thus two-dimensional analysis doesn’t reveal any alterations after the initial specification 
and remodeling of the ductal system.  
Conversely, an increase in ALT and ALP levels in NICD/RBP mice suggest that 
despite having formed ducts NICD/RBP mice have liver damage (Table C.1). As ALP levels 
are increased in NICD alone mice, this particular readout of liver function does not suggest 
much. In contrast, the increase in ALT, albeit less than in the RBP KO, suggests that despite 
the formation of ductal structures, liver damage is still occurring without acute Notch 
signaling in the adult. Further, three-dimensional analysis revealed an initially expanded 
structure, similar to the NICD, which appeared to lose branches with age (Figure C.3). 
Together, these results suggest that the progressive obstructive phenotype, as observed in 
RBP KO mice, is due, in part to an acute post-natal requirement of Notch signaling. 
However, more careful analysis of this model is required for definite conclusions. While this 
approach is unconventional and remains to be validated, it will augment the finding in 
cultured cholangiocytes (See Appendix F). 
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Materials and Methods 
 
Mouse Lines 
 CD1 mice carrying the Albumin-Cre (Alb-Cre) were crossed with the conditional 
deletion allele for RBP-J and the conditional activation allele for Notch1 (Alb-Cre;RBP-
Jflox/flox;ROSANotch1). Genotyping was performed by polymerase chain reaction (PCR) 
analysis using previously published primer pairs. 
 
Immunohistochemistry, resin casting and serum chemistry was performed as 
described in Chapter II, Materials and Methods. 
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APPENDIX D 
 
ANALYSIS OF RBP FLOX/NULL MICE 
 
Introduction 
 As discussed, gene deletion by Alb-Cre occurs around E16.5 (Please refer to 
Appendix A), thus in an attempt to facilitate deletion, we generated an Alb-Cre;RBP-Jflox/null 
(RBP fl/null) mouse line. We anticipated a more severe ductal phenotype than the RBP KO, 
as Cre was only required to mediate deletion of one allele, as all cells are null for RBP-J at 
the other allele. Interestingly, the phenotype of the RBP fl/null mice has been quite 
perplexing, and appears to be a hybrid between the RBP KO and the N1/N2 DKO mice. 
Further, the previous characterization of the role of RBP-J in ductal specification used RBP 
fl/null mice, which developmentally appear identical to RBP KO mice, however the authors 
did not analyze the post-natal phenotype (Zong et al., 2009). The initial characterization of 
the post-natal phenotype is described within this Appendix. 
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Results 
 RBP fl/null tissue at P15, P30, P60 and P120 was analyzed for cytokeratin19-
positive expression to assess the morphological changes (Figure D.1-D.2). At P15 in RBP 
fl/null mice, there are un-remodeled cytokeratin-positive cells within the peripheral liver 
tissue (Figure D.1 E). Surprisingly, these un-remodeled cells are resolved at P30, and form 
tortuous ducts (Figure D.1 F), which are then further reduced with age, at P60 and P120 
(Figure D.1 G-H). Consistent with the observation in N1/N2 DKO and RBP KO mice at P30, 
necrosis is detectable in RBP fl/null mice (Figure D.1 F-inset). In contrast, hilar ducts appear 
normal, with mild inflammation at all ages (Figure D.2 E-G) and expansion of large cystic 
structures with age (Figure D.2 H). The cysts are not cytokeratin positive, suggesting they 
are not due to ductal expansion. I postulate that these cysts are lymphatic in origin, but the 
nature of these cysts is not understood at this point. These results suggest that RBP fl/null 
mice have un-remodeled peripheral ducts in early post-natal periods, but are unable to 
maintain them.  
Assessment of the three-dimensional architecture of the IHBD revealed mild defects 
in biliary structure at P60 (Figure D.3 C). At P120, RBP fl/null resin casts appear to have a 
reduction in the intact communicating IHBD (Figure D.3 F), similar to that observed in the 
RBP KO mice. Thus, the acquired post-natal defects observed in RBP KO mice, appear to 
occur similarly in RBP fl/null mice.  
To further address the severity of the RBP fl/null phenotype, I assessed liver function 
in 2-month to 4-month old RBP fl/null mice (Table D.1). RBP fl/null mice have elevated ALT 
and ALP levels as compared to control, however the values are not statistically significantly 
different than the RBP KO mice. Thus together these data suggest that while the underlying 
histology in RBP fl/null mice is quite different from RBP KO mice, the effects on liver function 
and IHBD architectural defects are equivalent. 
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Figure D.1 Morphological defects in cytokeratin19-positive cells in peripheral liver 
tissue with hepatoblast-specific deletion of one allele of RBP-J and global inactivation 
of the other allele. Paraffin-embedded sections from control (A-D) and RBP fl/null (E-H) 
tissue over a developmental time course was immunostained for cytokeratin19 to mark 
cholangiocytes and counterstained with Mayer’s hematoxylin. (A,E) At P15, RBP fl/null 
peripheral cholangiocytes are un-remodeled and resemble the N1/N2 DKO. (B,F) At P30, 
the un-remodeled cells are resolved into tortuous ductal structures. As with other mouse 
models in which Notch signaling is removed, RBP fl/null mice demonstrate hepatic necrosis 
at P30. (C,G) At P60, the peripheral ducts appear grossly normal. (D,H) At P120, the early 
phenotype of RBP fl/null is completely resolved. Scale bar = 50 µm. 
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Figure D.2 Morphological defects in cytokeratin19-positive cells in hilar liver tissue 
with hepatoblast-specific deletion of one allele of RBP-J and global inactivation of the 
other allele. Paraffin-embedded sections from control (A-D) and RBP fl/null (E-H) tissue 
over a developmental time course was immunostained for cytokeratin19 to mark 
cholangiocytes and counterstained with Mayer’s hematoxylin. (A,E) At P15, RBP fl/null hilar 
ducts are well formed, with mild inflammation. (B,F) At P30, the hilar ducts are unaltered in 
RBP fl/null mice. (C,G) At P60, the hilar ducts are unaltered compared to P15 and P30. 
(D,H) At P120, the hilar ducts in RBP fl/null mice are grossly normal, however large cystic 
dilations become evident at this age. Scale bar = 50 µm. 
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Figure D.3 Three-dimensional resin casts of the RBP fl/null biliary system are grossly 
indistinguishable from RBP KO casts. (A-F) Representative images of the ventral surface 
of left lobe resin casts are shown at P60 and P120. (A,D) Control resin casts (n=2 and 7). 
(B,E) RBP KO resin casts demonstrate the loss of branches from P60 (n=6) to P120 (n=5), 
as previously quantified. (C,F) RBP fl/null mice also demonstrate a progressive paucity of 
IHBD architecture with age (n=3 and 4). Scale bar = 2 mm 
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Table D.1 Serum chemistry analysis. Serum was obtained from control and RBP fl/null 
mice between 2-months and 4-months, and analyzed for alanine aminotransferase (ALT), 
total bilirubin (TB), and alkaline phosphatase (ALP). RBP fl/null values are not statistically 
significantly different than RBP KO values. Values are mean (IU/L) + standard error of the 
mean. P values are calculated by a student t-test. ***p<0.001. 
 
Genotype n ALT n TB n ALP 
Control 40  57.5 + 5.5 37  1.2 + 0.1 29 8.42 + 1.1 
RBPfl/null 19 105.0 + 8.7 *** 16 0.7 + 0.1 19 29.21 + 4.6 *** 
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Discussion 
 While we originally set out to utilize the RBP fl/null mouse as the most severe loss of 
Notch signaling, the analysis of this model has been quite confusing. Specifically, the two-
dimensional ductal morphology appears less severe at the periphery in early post-natal time 
points (P15, Figure D.1 E) resembling a N2 KO or N1/N2 DKO instead of the RBP KO. 
Subsequently RBP fl/null mice undergo a period of ductal hypertrophy (P30, Figure D.1 F), 
and become visually equivalent to the RBP KO at later post-natal time points (P60 and 
P120, Figure D.1 G-H). Thus, RBP fl/null mice are unable to maintain the un-remodeled 
cytokeratin19-positive cells in the periphery. The mechanism of differential histology in RBP 
KO and RBP fl/null mice is currently not understood. One approach we have undertaken to 
further characterize the severity of the RBP fl/null, is to cross it into the background of the 
activated Notch, thus producing Alb-Cre;RBP-Jflox/null;ROSA26Notch1 mice. We anticipate that 
these mice will help to address the question of severity in this model. 
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Materials and Methods 
 
Mouse Models 
 Alb-Cre and RBP-Jflox/flox have been described in Chapter II: Materials and Methods. 
RBP null mice (Oka et al., 1995), which are heterozygous viable, were crossed into the RBP 
KO line. Genotyping was performed by PCR analysis using previously described primers. 
 
Immunohistochemistry, resin casting and serum chemistry was performed as 
described in Chapter II, Materials and Methods. 
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APPENDIX E 
 
INTRAHEPATIC BILE DUCT STRUCTURAL ALTERATIONS DURING LIVER 
REGENERATION 
 
Introduction 
 Liver regeneration is generally divided into two types: proliferation of normally 
quiescent hepatocytes and activation of a liver progenitor cell. Thus, regeneration studies 
have mainly focused on the role of hepatocytes or progenitors respectively, with little focus 
on the response of cholangiocytes. To study regeneration due to the proliferation of normally 
quiescent hepatocytes, the common experimental approach is the 70% partial hepatectomy 
(PHx). A common method to study liver progenitors in mice is the administration of 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC) to induce a progenitor “oval cell” response. In 
this Appendix, I use both PHx and DDC feeding, in conjunction with resin casting to address 
the structural changes in the intrahepatic bile duct (IHBD) network during liver regeneration.  
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Results 
 To address the alterations in IHBD architecture after 70% PHx, I resin cast mice at 3, 
7, 10 and 14 days post-PHx (Figure E.1). PHx surgeries were performed at Washington 
University St. Louis School of Medicine, in the laboratory of Dr. David Rudnick. It is 
important to note that the liver to body weight ratio is not fully recovered until 14 days post-
PHx (Figure E.2). Analysis of biliary resin casts after PHx reveal that the IHBD structure 
expands in concert with the growing size of the regenerating lobes. While further analysis is 
required to determine how proliferation and/or cell elongation plays into the expansion of the 
ductal system, I have demonstrated that the IHBD maintains a normal distribution 
throughout regeneration. It remains possible that earlier than 3 days post-PHx, the IHBD will 
not have expanded with the lobes, but this remains to be determined. 
 To address the alterations in the IHBD ductal architecture during progenitor cell-
mediated regeneration, I administered DDC to P120 control mice for 10 days and then resin 
cast (Figure E.3). The administration of DDC is considered to induce cholestais, due to 
IHBD obstruction by porphyrin plaque accumulation. Therefore, I hypothesized that DDC 
administration would lead to an obstruction of the IHBD reminiscent of obstruction observed 
in RBP KO mice. Instead, analysis of resin casts after 10 days of feeding DDC reveals no 
alterations in IHBD architecture (Figure E.3 A). Further I assessed the effect of feeding DDC 
on the IHBD structure in P120 RBP KO and NICD mice (Figure E.3 B-C). Surprisingly, no 
obvious defects are detected in these genetic backgrounds either. Analysis of mice who 
have been fed DDC longer is currently in progress, however these results suggest minimal 
alterations to the biliary structure during early progenitor cell-mediated injury responses. 
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Figure E.1 Three-dimensional resin casting of control mice after 70% partial 
hepatectomy. Representative images of right lobe resin casts at 3, 7, 10 and 14 days post-
partial hepatectomy (PHx) on a CD1 strain background. (A-B) Sham operated mice 
demonstrate the normal IHBD structure in the two left lobes (n=8). (C-D) Resin casts at 3 
days post-PHx (n=5). (E-F) Resin casts at 7 days post-PHx (n=5). (G-H) Resin casts at 10 
days post-PHx (n=5). (I-J) Resin casts at 14 days post-PHx (n=5). Resin casts after PHx 
reveal no obvious alterations in structure and suggest a general expansion of the IHBD 
coincident with the growth of the lobe. Scale bar = 2 mm. 
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Figure E.2 The liver to body weight ratio in CD1 strain background mice is recovered 
at 14 days post-partial hepatectomy.  Liver to body weight ratios from sham (n=8), 3 days 
post-PHx (n=5), 7 days post-PHx (n=5), 10 days post-PHx (n=5) and 14 days post-PHx 
(n=5) were calculated. Mice demonstrate a liver to body weight recovery to sham levels at 
14 days post-PHx. Error bars – standard error of the mean. **p<0.01, ***p<0.001. 
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Figure E.3 Three-dimensional resin casting of control, RBP KO and NICD mice during 
oval cell activation. Control, RBP KO and NICD mice were administered a diet of 0.1% 
DDC for 10 days prior to resin injection. (A-C) Representative images of left lobe resin casts. 
(A) Control (n=4), (B) RBP KO (n=4) and (C) NICD (n=5) mice demonstrate no obvious 
changes to the IHBD structure after 10 days of DDC. Scale bar = 2 mm. 
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Discussion 
 Thus far, analysis of IHBD structural changes during liver regeneration has not 
revealed striking qualitative changes. Instead, in the 70% PHx model, the IHBD appears to 
gradually expand with the regenerating lobes (Figure E.1). Further, in the DDC oval cell 
model, no structural affects on the IHBD are evident after 10 days of feeding DDC (Figure 
E.3). Further examination of the two-dimensional ductal cholangiocyte changes are required 
to fully interpret this data. 
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Materials and Methods 
 
Partial Hepatectomy 
 Partial hepatectomy procedures were completed at Washington University St. Louis 
School of Medicine in Dr. David Rudnick’s laboratory. In brief, mice were anesthetized, and 
an incision was made in the abdomen. Medial and left lobes were tied off at the hilum and 
excised. Mice were sutured and allowed to come out of anesthesia.  
 
DDC Injury 
Mice were fed a diet containing 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) for 10 days prior to resin casting. 
 
Resin casting was performed as described in Chapter II, Materials and Methods. 
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APPENDIX F 
 
CHOLANGIOCYTE ISOLATION 
 
Introduction 
 The isolation and culturing of cholangiocytes to assess function in vitro is critical to 
overcome the deficiencies of the in vivo analysis, and to augment the mouse genetic 
analysis. Further, the establishment of cholangiocyte cultures will allow me to use molecular 
analysis in a pure cholangiocyte population to answer questions such as the acute 
requirement of Notch signaling for cholangiocyte function, and the role of immune-mediate 
destruction in the phenotypes observed in RBP KO mice (Please refer to Chapter VI, Future 
Directions for a full description of experiments). Thus, I recently traveled to Yale University 
to the laboratory of Dr. Mario Strazzabosco to learn a cholangiocyte cell isolation technique. 
The isolation technique is outlined within this Appendix and the initial cholangiocyte images 
are displayed. 
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Results 
 The successful isolation of cholangiocytes is demonstrated by cytokeratin19-positive 
staining (Figure F.1). Epithelial cell adhesion molecule (EpCAM), a cholangiocyte-specific 
marker within the liver was used for Immuno-magnetic isolation. EpCAM isolated cells 
demonstrate a specific isolation of cytokeratin19-positive cells (Figure F.1 A-B), which was 
confirmed by a no-primary control (Figure F.1 C). However, plating and staining of cells that 
were not pulled-down with the magnet reveals that the efficiency of isolation is poor (Figure 
F.1 D). 
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Figure F.1 Cholangiocyte cultures. Representative images of immuno-magnetic EpCAM-
positive isolated cholangiocytes, stained with cytokeratin19 (green). (A-B) Successful 
isolation of cytokeratin19-positive cells. (C) No primary (cytokeratin19) control demonstrates 
cytokeratin19-positivity. (D) Cells not isolated by immuno-magnetic selection, reveals an 
inefficient isolation. Scale bar = 50 µm. 
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Discussion 
 The isolation and culture of cholangiocytes will be used for many aspects of my 
future research. While initial indications suggest that cholangiocyte isolation and culture is 
feasible, optimization of the protocol remains to be completed.  Increasing the concentration 
of primary antibody will be the first step in this optimization. The amount of secondary 
conjugated beads is currently in excess, and the suitable amount for the isolation of 2.5 
million cells, which is far greater than the expected number of cholangiocytes to be isolated 
by this method. 
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Materials and Methods 
 
Immunomagnetic Isolation of Cholangiocytes 
 Hanks A and Hanks B buffers were prepared fresh and incubated at 37ºC in 5% CO2 
for one half hour prior to use. Per mouse, 30 ml of each solution was prepared. To the 
Hanks B buffer, 25mg of Collagenase XI (Sigma) was added per 30 ml. 
 Mice were sacrificed by CO2 asphyxiation and the portal vein was cannulated with 
polyethylene (PE) 50 tubes and secured with a ligature of 5.0 silk. The inferior vena cava 
was cut to release blood and perfusate. Mice were perfused by hand with 30 ml of Hanks A 
followed by 30 ml of Hanks B with collagenase. Livers were incubated for 5-10 mins until the 
liver became malleable.  
 Livers were removed from the body, placed in L15 media and the capsule was 
manually removed using forceps.  Livers were shaken to release the majority of 
hepatocytes. The remaining structure was placed in a solution containing Pronase (50ml 
alpha-MEM, 1 ml Penicillin/Streptomycin, 1.5 ml fetal bovine serum, 1% bovine serum 
albumin, 0.06% Collagenase IV, 0.06% DNase and 0.33% Pronase [Sigma]). The structure 
was manually shredded using scissors, then allowed to shake at 37ºC for 30 min. Digested 
cells were filtered sequentially through a 100 µm and 30 µm filter. Cells that did not pass 
through the filters were subsequently incubated in a solution containing Hyaluronidase (50ml 
alpha-MEM, 1 ml Penicillin/Streptomycin, 1.5 ml fetal bovine serum, 1% bovine serum 
albumin, 0.06% Collagenase IV, 0.06% DNase and 0.33% Hyaluronidase [Sigma]) at 37ºC 
for 30 min, shaking. Cells were filtered through a 30 µm filter and cells <30 µm in size were 
combined, and centrifuged at 1600 rpm for 10 min, resuspended in 6% DNase in RPMI.  
 Cells were resuspended in primary antibody (rat-anti-EpCAM, 1:50; DSHB) and 
incubated on ice for 30 min. Cells were centrifuged at 1600 rpm for 10 min, and 
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resuspended in secondary-conjugated magnetic beads (anti-rat IgG, 25 µl per 2,500,000 
target cells, Invitrogen) to incubate for 30 min on ice. After incubation, tubes were placed on 
the magnet (Dynamag-Spin, Invitrogen) for 1 min. Non-magnetized cells were removed and 
plated to determine efficiency of isolation. Cells were washed using the magnet, 10 times for 
1 min each. Cells were resuspended in 100 µ l of fetal bovine serum and plated on 
coverslips. 
 Cells were allowed to attach for 5 hours, then fixed in 100% methanol for 10 min at -
20ºC. Cells were incubated in primary antibody (rat-anti-CK19, 1:100; DSHB) overnight at 
4ºC. The following day, cells were incubated in secondary antibody (anti-rat-Alexa488, 
1:300; Invitrogen), and mounted using a DAPI mounting media (Prolong Gold with DAPI; 
Invitrogen). 
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